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1 INTRODUCTION 
1.1 Cellular players of adaptive and innate immunity - An Overview 
When we talk about the immune system, (Latin, immunis, English, unaffected, free, pure), we 
refer to the biological defense system of higher organisms, which prevents tissue damage by 
pathogens. It protects the body from invading microorganisms and foreign substances and is 
also able to destroy defective endogenous cells.  
The immune system is a complex network of various organs, cell types and molecules and is the 
central subject of research in immunology. The immune system is of paramount importance for 
the physical health of living beings, since all organisms are constantly exposed to the influences 
and potential threats by the environment. If for example harmful microorganisms enter the body, 
they can lead to malfunctions and diseases. Characteristic pathogens are bacteria, viruses, 
fungi, and unicellular (e.g. protozoa such as Plasmodium) or multicellular parasites (e. g. 
Tapeworms). Even changes inside the own body can pose potential threats for the existence of 
a living being. The cells of the body that lose their proper function usually die via two distinct 
pathways. They have to be dismantled (necrosis) or undergo controlled death, apoptosis. In rare 
cases, they can also pathologically degenerate and lead to the development of cancer. 
Fortunately, all living beings harbor protective functions. Even simple organisms have such a 
defense mechanism, which is called the non-specific (innate) immune response.  
Innate immunity has emerged very early in the evolutionary history of organisms and since its 
basic mechanisms remained largely unchanged. In addition to these defense mechanisms, 
vertebrates developed a complex, adaptable, so-called adaptive immune system, which protects 
more effectively against pathogens. Both innate and the adaptive immune response depend 
upon the activities of white blood cells or leukocytes. These cells originate from the bone marrow 
and many of them also mature there. The innate immune system is based on the detection of 
certain types of molecules that are common to many pathogens, but are absent in the host. 
Those so called pathogen associated molecular patterns (PAMPs) are molecular signatures of 
pathogens that are recognized by the host germ-line encoded pattern recognition receptors 
(PRRs). These comprise soluble receptors in the blood (components of the complement system) 
and membrane-bound receptors on the surface of host cells like macrophages and neutrophils. 
They display a variety of cell-surface receptors that enable them to recognize and engulf 
pathogens. These include PRRs such as the toll like receptors (TLRs). Additionally, they have 
cell-surface receptors for the fragment crystallizable region (FcγR) of antibodies produced by the 
adaptive immune system, as well as for the C3b component of complement system1,2. The 
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activation of cell-surface receptors is usually quickly followed by its engulfment by phagocytic 
macrophages and neutrophils. The activation of an array of biochemical reactions, leads to the 
activation of transcription factors such as nuclear factor kappa B (NFκB) and interferon (IFN) 
regulatory factors (IRFs) for induction of inflammatory cytokine and type-I IFNs, respectively3. 
The released signaling molecules trigger an inflammatory response and begin to marshal the 
forces of the adaptive immune system via dendritic cells (DCs), B (B cells) and T lymphocytes (T 
cells). Both of these reactions can occur quickly, even if the host has never been exposed to a 
particular pathogen4,5. Unlike the innate immune system, the first formation of the specific 
(adaptive) part of the immune system only occurs after birth: The adaptive immune system of an 
organism evolves in the course of its life time by direct examination of various pathogens. Since 
the responses to recognized pathogens or associated molecules are destructive, it is crucial that 
they gain activity only in response to molecules that are foreign to the host while sparing host-
derived molecules. The ability to distinguish foreign molecules from the hosts’ endogenous 
molecules is a fundamental feature of the adaptive immune system. Whenever the system fails 
to make this distinction it will react destructively against the molecules of the host. Such 
dysregulations known as autoimmune disorders can be disastrous.  
However, when the adaptive immune responses are carried out correctly they can be divided in 
two different groups, the antibody responses and the cell-mediated immune responses. Adaptive 
immunity elicits very specific and strong immune responses, but is slower as it requires antigen 
presentation by antigen presenting cells (APCs), as well as selection and clonal expansion of its 
highly-specialized effector cells, namely the B cells and T cells. In antibody responses, B cells 
are activated to secrete specific antibodies, proteins which are called immunoglobulins. The 
antibodies circulate in the bloodstream and other body fluids, where they bind specifically to the 
foreign antigen that initially induced their production. The binding of an antibody can then lead to 
inactivation of viruses and microbial toxins by blocking their ability to bind to receptors on host 
cells and also marks invading pathogens for destruction, mainly by ingestion of phagocytic cells 
of the innate immune system5.  
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1.2 Atherosclerosis – a chronic inflammatory disease 
The term atherosclerosis was first introduced by Johan Lobestein in 1829 and the first theories 
regarding the pathogenesis of atherosclerosis followed in the middle of the 19th century6. Since 
then a broad range of theories has been employed to describe the development of 
atherosclerosis. Atherosclerosis was previously considered merely a lipid deposit-driven 
narrowing of the vessel lumen. Nowadays, it is recognized that both the innate and adaptive 
immune system engage in disease onset and progression7. Despite the long history of 
atherosclerosis research, the main clinical manifestations of the disease including coronary 
artery disease, stroke, and peripheral arterial disease, still represent the leading causes of death 
in Europe and North America8,9. Atherosclerosis, as a chronic inflammation elicited by 
hyperlipidemia and perpetuated by a dysbalanced immune response, is characterized by the 
development of lipid-rich lesions, or plaques, which preferentially arise at the sites of disturbed 
blood flow in medium- to large-sized arteries10. The origin of those plaques lies in an initial local 
dysfunction and activation of the endothelium, as lipoproteins and lipids in the vessel wall 
accumulate to a degree exceeding the capacity of clearance and are retained in the extracellular 
matrix of the vessel wall11. Specifically, a shear stress-responsive element, identified in the 
regulatory region of several genes, has been show to promote a local platelet-induced activation 
of the endothelium, which triggers an initial leukocyte-endothelial cell (EC) interaction and the 
activation of ECs12. Activated ECs entail the expression of adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), 
leading to the adherence of circulating leukocytes and their subsequent migration into the sub-
endothelial space along a chemokine gradient produced by the inflamed intima, establishing the 
nascent atherosclerotic lesion (Figure 1)13,14. The local inflammation and concomitant persistent 
hyperlipidemia, together contribute further to an enhanced endothelial dysfunction resulting in 
the infiltration and retention of lipoprotein particles in the sub-endothelial space15. The retained 
lipoprotein particles such as low-density lipoprotein (LDL) then may undergo chemical 
modifications. Assumingly, oxidation of LDL-cholesterol is induced by free radicals produced by 
macrophages, ECs, or smooth-muscle cells (SMCs). Whereas native LDL is not ingested by 
phagocytic cells, oxidized LDL (oxLDL) can be taken up by macrophages through  scavenger 
receptors16. This increased uptake of lipid particles by macrophages leads to a cytosolic 
accumulation of those particles and these macrophages gain a “foamy” appearance, thus their 
designation as foam cells, and become one of the primary components of the fatty streak, the 
earliest visible manifestation of atherosclerosis. Due to the massive cholesterol scavenging, 
foam cells will undergo different ways of cell death (i.e. apoptosis, necroptosis, and necrosis) 
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forming the necrotic core of the plaque17. The necrotic core and the increased apoptosis of 
invaded macrophages are elaborate sources of inflammatory cytokines, which fuel the immune 
reaction by recruiting more leukocytes including lymphocytes to the lesion site.18 The recruited 
immune cells within the atherosclerotic lesion will release further proteases and cytokines which 
reduce the survival and proliferation of SMCs and the degradation or impaired synthesis, 
respectively, of matrix proteins (e.g. collagen) which could compromise the stability of the fibrous 
cap.  
 
Figure 1. Immune components of the atherosclerotic plaque. The atheroma builds up in the intima, the innermost 
layer of the artery. The atheroma has a core of lipids, including cholesterol crystals, living and apoptotic cells and a 
fibrous cap with smooth muscle cells and collagen. Plasma lipoproteins accumulate in the sub-endothelial region. 
Several types of cells of the immune response are present throughout the atheroma including macrophages, T cells, 
mast cells and DCs. Outside the intima, the media contains smooth muscle cells that regulate blood pressure and 
regional perfusion, and further abluminal, the adventitia continues into the surrounding connective tissue. Here, cells 
of the immune response accumulate outside advanced atheroma and may develop into tertiary lymphoid structures 
with germinal centers, APC, antigen-presenting cell; DC, dendritic cell; oxLDL, oxidized LDL. Modified from Hansson 
et al and Spitz et al10,19. 
Ultimately, the rupture of the destabilized plaque leads to a release of highly-coagulant 
substances into the blood stream causing rapid thrombus formation, an acute occlusion of the 
vessel ceasing blood supply to vital organs and thereby to its life-threatening clinical 
manifestations, namely myocardial infarction and stroke7 . 
Introduction 
 
5 
 
1.3 Use of mouse models in atherosclerosis research 
Atherosclerosis and its pathogenesis may be studied in a variety of mammalian species, as the 
basic mechanisms for this pathology are similar in most of organisms. Animal models used for 
the investigation of atherosclerosis have included rabbits, pigs, and nonhuman primates. Yet, 
the greatest part of the mechanistic insight into the evolution of the plaque derives from the 
study of mouse models20.  
One of the most common models used for investigation of atherosclerosis is the LDL receptor-
deficient (Ldlr-/-) mouse, which is a murine model for familial hypercholesterolemia. The LDL 
receptor is a widely expressed plasma membrane protein that is responsible for the clearance of 
plasma lipoproteins containing either apoliprotein (Apo) B100 or E. These mice have elevated 
plasma cholesterol levels when compared to wild type mice but do not exhibit profound 
atherosclerosis while maintained on a regular chow diet. However, when feeding a cholesterol-
enriched, atherogenic diet atherosclerotic plaques occur throughout the arterial vasculature21.  
The apolipoprotein E-deficient (Apoe-/-) mouse is the other highly popular hypercholesterolemic 
mouse model that, in contrast to wild type and Ldlr-/- mice, develops atherosclerosis on a regular 
chow diet while aging22,23. ApoE is carried on plasma lipoproteins, mostly chylomicron remnants, 
very low-density lipoprotein (VLDL) and large high-density lipoprotein (HDL). It serves as a 
ligand for the hepatic uptake of non-HDL lipoproteins by members of the LDL receptor 
superfamily of receptors24. Accordingly, mice that are deficient for ApoE develop severe 
hypercholesterolemia and their total cholesterol can reach levels ~10 times higher than those in 
wildtype C57BL/6 mice23. Among available models, the Apoe-/- mouse is particular popular 
because of its propensity to spontaneously develop atherosclerotic lesions. In addition, the 
disease pattern can be aggravated by feeding the fat- and cholesterol-enriched Western-type 
diet (WD)25. Since hypercholesterolemia is exaggerated by administration of a WD, the innate 
immune system overrides effects caused by adaptive immune cells26. Several studies also 
demonstrated the importance of cholesterol levels, when studying the adaptive immune 
responses in experimental atherosclerosis27–30. In fact it is essential to avoid exaggerated 
hypercholesterolemic conditions (e.g., WD in Apoe-/- mice) as innate immune cells dominate the 
inflammatory response under such conditions and adaptive immunity becomes increasingly 
irrelevant for the disease progression26,28. Therefore the use of either the  
Ldlr-/- -or the Apoe-/- model in atherosclerosis research depends on whether the involvement of 
specific cells, products of the immune system or hypercholesterolemia in general, should be 
addressed. 
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1.4 Dendritic cells in atherosclerosis 
DCs are characterized by their capability to engulf and process antigens for presentation to 
naïve T cells and are therefore members of the group of the so called APCs31.  
They originate from precursors, that reside in the bone marrow, or from monocytes and can be 
found in both lymphoid and non-lymphoid tissues throughout the body32. DCs to some point 
share similar features with macrophages. Parallel to macrophages, DCs can engulf lipids to 
adopt a foam cell-like appearance thereby constitute the earliest stages of plaque initiation and 
formation but nevertheless they represent a unique and potent subset of professional APCs 
capable of activating naive lymphocytes33,34. Mature DCs are typically characterized by the 
surface expression of CD11c, their ability to strongly upregulate and express high levels of the 
major histocompatibility complex (MHC) II, the costimulatory molecules CD80 and CD86 and 
various members of tumor necrosis factor receptor (TNFR) superfamily, such as CD40. 
Additionally they hold a distinct morphologically feature, the dendrites, which give them their 
name (δένδρον or déndron being Greek for "tree"). The murine DC population can be divided 
into four main categories, conventional DCs (cDCs), plasmacytoid (pDCs), monocyte-derived 
DCs and Langerhans cells a special population of yolk sac-derived DCs3536. Here, I will mainly 
but not exclusively, focus on murine cDCs and pDCs. 
Although splenic DCs were first discovered in 1973 by Steinman and colleagues, it took nearly 
25 years before DCs were discovered in the arteries of mice and man37,38. Only few DCs are 
found in arterial vessels of healthy mice and humans but an accumulation of DCs was observed 
in atherosclerosis. Moreover, an increased abundance of DCs seems to correlate with signs of 
increased plaque vulnerability in humans39. Two of the four subtypes of DC were identified in 
atherosclerotic lesions, cDCs which mainly recognize bacterial signatures and pDCs which 
specialize in sensing viral fragments and have the unique potential of producing large amounts 
of type-I IFN. DCs play a central role in atherogenesis as they are directly implicated in 
cholesterol homeostasis and the immune response40. Lipid-loaded CD11c+ DCs can already be 
detected in the aorta of Ldlr-/- mice which consumed a high fat diet for a few days 40 . 
In atherosclerotic plaques T cells and DCs are found in close proximity and several studies imply 
that antigen-presentation by DCs fosters atherosclerosis progression41–44. The uptake of lipids by 
DCs leads to the induction of maturation markers and enhances antigen presentation to T cells 
and facilitates CD40- and TLR-induced DC maturation. Their enhanced maturation and 
activation status consecutively leads to an increased ability to stimulate T cells via costimulatory 
molecules45,46. These findings were underpinned by Buono et al, who demonstrated that the lack 
of the costimulatory molecules CD80 and CD86, which are known to be involved in 
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immunological synapse formation and activation of T cells, reduces atherosclerotic plaque size 
in Ldlr-/- mice47. Interestingly, mice lacking CD74 (MHCII-associated protein invariant chain, 
which regulates antigen processing and inhibits DC motility in vivo) also demonstrate marked 
reduction of atherosclerosis48,49. Further studies using the transfer, depletion or modulation of 
DCs indicated that DCs are capable of skewing immune responses in atherosclerosis towards 
either an athero-protective or promoting profile40,50–52. Under atherosclerotic conditions, some 
subtypes of DCs may take up atherosclerosis-specific antigens, become locally activated, and 
migrate to draining lymph nodes, where they then present the antigen to naïve T cells and 
leading to T cell activation and proliferation51. During progression of atherosclerosis, the 
emigration rate of DCs from aorta to secondary lymphoid organs decreases, which could lead to 
accumulation of antigen-loaded DCs in the plaque area53. These DCs in turn may then stimulate 
T cells and propagate a local, antigen-specific immune response. Finally these processes 
perpetuate local inflammation and increased plaque progression. Besides their ability to take up 
lipids and antigens, DCs can also produce various amounts of anti- and pro-inflammatory 
cytokines. The engagement of TLR for example, can result in the production of pro-inflammatory 
and pro-atherogenic cytokines including TNFα, interleukin (IL)-6 and IL-12, but also to the 
production of the anti-atherogenic cytokine IL-1054–57. IL-12 affects atherosclerosis by driving the 
presumably pro-inflammatory helper cell 1 (Th1) polarization and T cell recruitment (Figure 2). 
IL-12p40 deficient Apoe-/- mice have smaller lesions, whereas the injection of IL-12 increases the 
atherosclerotic lesion size58. 
As a prototypic anti-inflammatory cytokine, IL-10 down-regulates Th1 cytokines such as IL-12 
and IL-18 leading to inhibition of Th1-biased immune response and polarization of the Th1/Th2 
balances toward Th259,60. Induction of a regulatory T cell type 1 response attenuates the 
development of atherosclerosis in Apoe-/- mice by decreasing the Th1 response, decreasing the 
production of IFNγ and increasing IL-10 production61.  
In conclusion, DCs can influence atherosclerosis through different mechanisms such as 
production of cytokines, antigen presentation and lipid uptake, which either promote 
inflammation or induce tolerance. However, the exact role of DCs in directing different T and B 
cell subsets during atherosclerosis is not fully understood. 
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1.5 T cells in atherosclerosis 
Although cells of the innate immune system dominate the inflammatory response and are the 
most abundant immune cells in the atherosclerotic plaque, several studies have proven a pivotal 
role for T cells in the pathogenesis of atherosclerosis62. Elhage and colleagues demonstrated 
the importance of various T lymphocyte subsets in atherosclerosis by investigating Apoe-/- mice 
which were genetically deficient in specific lymphocyte subpopulation63. Whereas TCRαβ+ T 
lymphocytes appeared to play a modest role, absence of TCRαβ+ T lymphocytes significantly 
prevented early and late atherosclerosis at all arterial sites. Interestingly, the lack of CD4+ T cells 
led to a dramatic increase in early lesion abundance63. This emphasizes the pro-inflammatory 
role of CD4+ T cells, which are the most abundant T cell subset within human atherosclerotic 
lesions63,64. Moreover, the adoptive transfer of CD4+ T cells into scid/scid Apoe-/- mice, lacking a 
functional adaptive immune system, clearly demonstrates the pro-atherogenic role of CD4+ T 
cells in immune-deficient conditions27. Further studies with mice deficient for the recombinase 
activating gene 2 (RAG-2), which do not harbor any T- or B cells, because the gene re-
arrangement of immunoglobulins (Ig)- and T cell receptor (TCR) depends on RAG-2, were 
performed. The atherosclerosis-prone Rag2-/- mice developed reduced atherosclerosis under 
mildly-elevated hypercholesterolemia underlining the importance of those cells for plaque 
progression28. Despite of the increasing understanding of the role of different subsets of CD4+ 
cells in disease pathology it still remains a topic of controversial and sometimes contradictory 
results.  
Although T cell activation accelerates early progression of atherosclerosis, it is not required for 
its initiation, as shown using conditional ablation of dividing T cells in Apoe-/- mice65. Several 
subsets of CD4+Tcells (Th1, Th2, Th17, T follicular helper (TFH) and regulatory T cells (Tregs)) 
are found in the arterial wall and play a major role in atherosclerosis  
(Figure 2)18. The commitment of naïve T cells to a certain subpopulation is regulated for the 
most part by the cytokine milieu and the network of transcription factors that are induced 
downstream of cytokine signaling. The presence of IL-12 and IL-18 initiate Th1 skewing, IL-4 
leads to a Th2 commitment of naïve CD4+ T cells, the differentiation towards the Th17 lineage 
requires several cytokines including IL-6, TGFβ, IL-23 and IL-1β and the presence of IL-10 and 
TGFβ are required for Treg commitment66,67. APCs including B cells, DCs and macrophages 
express MHC II on their surface displaying antigen to CD4+ T cells, a process usually occurring 
in secondary lymphoid organs. The antigen leading to T cell activation in atherosclerosis are not 
known with certainty, but appear to involve epitopes of oxLDL and possibly heat shock protein 
60/65 (HSP60/65)68–70. Upon recognition of cognate antigen presented by APCs, naïve CD4+ T 
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cells undergo differentiation during their activation in response to TCR ligation and costimulatory 
signals via CD28 which binds to costimulatory molecules CD80/CD86 provided by the APCs71. 
 
Figure 2. The effects of T-cell subsets on atherosclerosis. 
Pro-atherogenic: Th1 (red). The presence of IL-12 and IL-18 causes Th1 skewing. IL-12 results in activation of the 
downstream transcription factor, T-bet. T-bet activation results in pro-inflammatory cytokine production, including IFN-
γ and TNF-α. Athero-protective: Treg (blue). IL-10 and TGFβ are required for Treg commitment. Tregs express the 
transcription factor Foxp3 and can produce IL-10 and/or TGFβ. Controversial: Th2 (orange, top) and Th17 (orange, 
bottom). Naive CD4+ T cells commit to a Th2 lineage under the influence of IL-4. In a positive feedback loop, IL-4 
increases expression of the transcription factor GATA3, which produces additional IL-4 and inhibits IFNγ production. 
Th17 differentiation requires a combination of several cytokines, including IL-6, TGFβ, IL-21, IL-23 and IL-1β. These 
cells express the transcription factor RORγT, and produce IL-17A/F and IL-22. Unknown: Follicular helper T cells 
(yellow). These are CD4+ T cells found in the B cell follicles of secondary lymphoid organs. They secrete IL-21 and 
express the transcription factor Bcl6. Modified from Tse et al62.  
 
The activation induces the production of IL-2 which leads to an IL-2- dependent activation of 
signal transducer and activator of transduction 5 (STAT5) and the entry into the cell cycle72. 
Thereafter their development is initiated by STAT1, which is activated in response to IFNγ and 
IL-27 that are produced by natural killer (NK) cells and APCs, respectively. STAT1 activation 
induces the transcription of the T-box transcription factor (T-bet), which in turn fosters the 
production of IFNγ and suppression of IL-4 thus promoting Th1 differentiation whilst inhibiting 
Th2 differentiation73,74. Th1 cells exceed the number of Th2 cells in atherosclerotic lesions and 
are considered the prototypical pro-inflammatory and pro-atherogenic T cells75. Additionally 
atherosclerotic lesions contain a substantial amount of IFNγ , supporting the idea that the 
predominant T cells in the lesion are IFNγ-releasing Th1 cells76. IFNγ enhances recruitment of T 
cells and macrophages to the plaque, inhibits SMC function and proliferation, reduces collagen 
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production and increases the synthesis of extracellular matrix-degrading proteins leading to 
compromised plaque stability77. Deficiency of T-bet decreases atherosclerotic burden in mice 
accompanied by reduced IFNγ levels and an enhanced, athero-protective Th2-mediated 
antibody response78. Additional cytokine associated with Th1 cells are IL-12 and  
IL-1866,67. IL-12 is typically produced by DC, macrophages, neutrophils and a subset of T cells. 
IL-12 stabilizes the Th1 subset by promoting the production of the IFNγ. Il12-/- mice exhibit 
impaired IFNγ production and increased levels of IL-4 indicating an dysfunctional Th1 response 
leading to reduced plaque development56. Furthermore, IL-12 increases expression of MHCII, 
CD80, and CD86 on APCs thereby enabling an efficient immune response. IL-18 synergizes 
with IL-12 to favor the differentiation of naïve T cells towards the Th1 lineage and to induce the 
production of IFNγ in T cells, natural killer cells, in certain macrophages, and even in SMC67,79–81. 
Mallat and colleagues suggested a role for the Th1 response in plaque destabilization by IL-18-
mediated mechanisms82. Overall the IFNγ, IL-12, IL-18 axis of cytokines is strongly inflammatory 
and promotes and accelerates lesion development. IL-4, IL-5, and IL-13 are Th2-associated 
hallmark cytokines. Th2 commitment occurs in presence of IL-4 which increases expression of 
the transcription factor GATA-binding protein 3 (GATA3), which through a positive feedback loop 
potentiates IL-4 expression and inhibits IFNγ expression83. IL-4 counteracts the production of 
IFNγ and lack of IL-4 leads to increased athero-progression. Since IL-4 inhibits Th1 
differentiation, yet its deficiency leads to mildly enhanced atherosclerotic lesion formation in 
Apoe-/- mice the role of the Th2 pathway in the development of atherosclerosis remains 
controversial56. Contrasting effects were also observed in Ldlr-/- mice where the lack of IL-4 led 
to decreased lesion formation 84. Furthermore, IL-4 can mediate numerous effects on non-T cell 
populations in the lesion leading to increased lipid oxidation in the arterial wall, enhanced 
leukocyte adhesion and attraction, increased uptake of modified lipoproteins and foam-cell 
formation, and promotes an M2-like macrophage phenotype85,86. Moreover, IL-4 activates mast 
cells which secrete mediators (e.g. serine proteases) promoting apoptosis of SMCs, reducing 
collagen production, and increasing production of proteases thereby potentially destabilizing the 
plaque87. Bone marrow transplant studies using IL-13-deficient donors demonstrated reduced 
macrophage content in lesions of Apoe-/- mice and limited recruitment of monocytes into the 
plaque by decreasing VCAM-1 expression. Furthermore, in vitro experiments revealed an IL-13-
mediated switch towards M2 macrophages which show a higher capacity in clearing oxLDL88. In 
sum, different studies show reduced and unaltered atherogenesis in hypercholesterolemic mice 
deficient for Th2 hallmark cytokines, the role of Th2 cells remains unclear and requires further 
evaluation. Overall, the Th2 response appears not to play a pivotal role in atherosclerosis, in 
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particular in murine models of atherosclerosis which are mainly performed in mice of the C57Bl/6 
strain which inherently displays a weak Th2 response56,89,90. 
The role of the rather recently discovered Th17 cells in atherosclerosis is also still 
controversial91,92. Naïve CD4+ T cells differentiate into Th17 cells by signaling cues requiring 
TGFβ and either IL-6 or IL-21, IL-1β, and IL-23 which influences the expression of the 
transcription factor STAT3, RORγT and RORα93. Th17 cells secrete IL-17A, IL-17F, and  
IL-2394,95. A recent study illustrated the presence of T cells producing IL-17 and IFNγ in 
atherosclerosis, but opposing effects of IL-17 in atherogenesis are reported 96,97. Th17 cells 
infiltrate coronary plaques, subsequently inducing vascular SMCs to produce pro-inflammatory 
cytokines and chemokines. Several studies demonstrated a pro-atherogenic role for Th17 cells 
in hyperlipidemic mice, whereas others suggested a protective role of IL-17 in 
atherosclerosis96,98–102. Madhut and colleagues, however, employing a genetically deficient 
mouse model showed that IL-17A is involved in systemic and vascular inflammation, but did not 
alter plaque burden in experimental atherosclerosis 103. Th17 and Treg development both 
depend on TGFβ. In addition, the cytokine milieu and fatty acid metabolism are critical in shifting 
the balance towards the of one of these cell type polarizations93,104,105. 
Since the first descriptions in the year 2000, TFH cells only recently became established as a 
distinct CD4 T cell type, and one of great importance for protective immunity. TFH cells depend 
on the expression of the master regulator transcription factor B cell lymphoma 6 (Bcl6). 
Distinguishing features of TFH cells are the expression of CXC- chemokine receptor type 5 
(CXCR5), Programmed cell death protein 1 (PD-1), IL-21, and Inducible T cell costimulator 
(ICOS), and the absence of PR domain zinc finger protein 1 (Blimp-1)106–108. TFH cells are 
important for the formation of germinal centers and antibody production109. Due to its rather 
recent research history the role of TFH cells in atherosclerosis has not been investigated yet110. 
Tregs are generally characterized as CD4+CD25 (IL2R)+ cells co-expressing the Forkhead box 
P3 (Foxp3) transcription factor111,112. Treg commitment is mainly driven by the presence of TGFβ 
and IL-10. Recently it has been shown commitment to this lineage is influenced by activated 
DCs that appear to have a supportive role in Treg differentiation113–115. Tregs are characterized 
as negative key regulators of immune effector cells. Foxp3+ Tregs suppress the proliferation of 
tissue-specific T cells and their differentiation into the Th1, Th2, and Th17 lineage. Moreover, 
they inhibit polyclonal T cell activation and the function of other immune cells including B cells, 
macrophages, and DCs116. They are further separated according to their functional phenotype in 
natural Tregs (nTregs) and inducible Tregs (iTregs). Both groups harbor a powerful anti-
inflammatory arsenal and are versatile in the modes of action by which they prevent 
autoimmunity or tissue damage by host-derived immune cells. Tregs constantly express 
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Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a co-inhibitory molecule which binds to 
CD80/CD86. Thus, Tregs prevent the activation of naïve T cells117. Furthermore, engagement of 
CTLA-4 with CD80/CD86 leads to their internalization further reducing their surface abundance 
and rendering the APC tolerogenic118. In parallel the high expression of CD25 enables Tregs to 
deprive the micro milieu from the T cell autocrine growth and activation factor IL-2, thus limiting 
survival and proliferation of effector T cells. Furthermore, Tregs are potent sources of the anti-
inflammatory cytokines IL-10, IL-35, and TGFβ which modulate and reduce the activation of 
APCs and other cells. Additionally, similar to CD8+ T cells, Tregs are equipped with the 
molecular machinery to produce and release granzyme B and perforin, which can negatively 
modulate function and survival of conventional T cells, B cells, and NK cells119.  
With the help of mouse models, the importance of Tregs in atherosclerosis became apparent 
within the past decade. Mouse models which employed genetic deficiencies or cell depletion 
clearly demonstrated a protective role for Tregs in atherosclerosis with studies demonstrating 
decreased Treg numbers in conditions of hypercholesterolemia and atherosclerosis120–122. In 
2006 Ait-Oufella and colleagues demonstrated that Tregs conferred atheroprotection in 
hyperlipidemic mice. The authors observed decreased Treg development and abundance in  
Ldlr-/- mice after reconstitution with CD80/CD86- or CD28-deficient bone marrow accompanied 
by an increased atherosclerotic burden. Furthermore they showed that the injection of an anti-
CD25 antibody in hyperlipidemic mice reduced abundance of Tregs and concomitantly increased 
lesion size and infiltration of macrophages and conventional T cells123. Vice versa, the adoptive 
transfer of Tregs in Apoe-/-  mice protected them from the development of atherosclerosis 124. In 
addition, Lievens and colleagues provided evidence that the interaction of the costimulatory 
molecule CD40 with CD40 Ligand (L) on platelets mediates the numbers of Tregs leading to 
accelerated atherosclerosis by rendering the Treg/T effector cell homeostasis125. Conversely, a 
treatment with anti-CD25 antibody in Apoe-/- mice completely prevented the observed protective 
effects of platelet CD40L deficiency on atherosclerosis. However, the presence of CD25 is not 
sufficient to characterize Tregs reliably as it is also present on activated T cells, NK cells, and 
myeloid DCs, leaving CD25+ cell populations contaminated and only enriched for natural Tregs. 
Accordingly, experiments employing CD25-depleting antibodies should be interpreted with 
caution and do not provide final evidence for a Treg-mediated phenotype. Klingenberg et al. 
confirmed the anti-atherogenic propensities of Treg directly. Hyperlipidemic Ldlr-/- mice were 
transplanted with bone marrow from transgenic mice expressing the diphtheria toxin receptor 
(DTR) under control of the Foxp3 promotor. Treatment of the resulting chimeric bone marrow 
mice with diphtheria toxin (DT) induced cell death of all Foxp3+ Tregs resulting in their systemic 
ablation. Depletion of Foxp3+ Tregs in these chimeric mice led to increased atherosclerosis but 
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also aggravated hypercholesterolemia ascribing Tregs an additional regulatory function in 
lipoprotein metabolism126. Although these findings provide yet further steps in understanding the 
athero-protective functions of Tregs in cardiovascular diseases it remains challenging to 
distinguish effects of a lesion-specific or systemic function/depletion of Tregs as the latter may 
indirectly affect local inflammatory response in the atherosclerotic vasculature. 
The role of CD8+ T cells in atherosclerosis is a topic of controversial debate. Although infiltration 
of CD8+ T cells in human atherosclerotic lesions were described 30 years ago, the role of these 
cells in lesion development has long remained inscrutable127. In murine models of 
atherosclerosis, CD8+ T cells are found in atherosclerotic lesions by immunohistochemistry in 
Apoe-/- mice or by flow cytometric analyses of vascular tissue in Ldlr-/- animals128,129 . In the past 
years, however, more refined research models have proposed both athero-protective and pro-
atherogenic functions for CD8+ T cells. A number of studies have focused on CD8+ T cells in 
atherosclerosis, and suggested that, similar to CD4+ T cells, the role of CD8+ T cells in 
atherogenesis is complex and subset-dependent. To explore the role of CD8+ T cells in 
atherosclerosis, Elhage and colleagues analyzed atherosclerotic lesion development in CD8+ T 
cell-deficient Apoe-/-Cd8-/- mice. In these mice, cytotoxic T cell responses were dramatically 
decreased, whereas B- as well as CD4+ T lymphocyte populations and function were described 
to be unaltered63. The Apoe-/- mice lacking CD8+ T cells did not show any significant changes in 
atherosclerotic lesion size in the aortic root and descending aorta, suggesting that CD8+ T cells 
do not play a major role in atherosclerosis. In contrast to that, the adoptive transfer of 
CD8+CD25+ T cells, a CD8+ subset that is considered anti-inflammatory and exerting 
suppressive effects, decreased atherosclerotic burden in Apoe-/- mice130. A recent report showed 
that depletion of CD8+ T cells in Apoe−/− mice reduced atherosclerotic lesion development, 
lesional inflammation, and cell death and that perforin/granzyme B-mediated cytotoxicity was 
key to the pro-atherogenic effect of transferred CD8+ T cells131. Overall, the data on CD8+ T cells 
in atherosclerosis indicate that CD8+ T cells are pro-atherogenic, but their contribution to 
atherogenesis seems to depend on timing and the subset. 
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1.6 B cells and Immunoglobulins in atherosclerosis 
B cells originate from the bone marrow and play an important role in humoral immune response. 
They are characterized by the presence of a B cell receptor (BCR) and are classically known for 
their ability to produce antibodies important for the clearance of antigens. Like DCs, B cells 
possess antigen presenting capacities, activating CD4+ and CD8+ T cells. In addition, they can 
produce a broad number of cytokines (e.g. IFNγ, IL-2, IL-12, IL-4, IL-6 and IL-10). B cells can be 
categorized into two developmentally-distinct lineages, B-1 and conventional B-2 cells.  
B-1 B cells include the B-1a and B-1b B cell subsets and conventional B-2 B cells include 
follicular B cells and marginal zone B cells132–134. Upon antigen recognition all mature B cell 
subtypes are capable of differentiating into plasma cells and produce natural antibodies like 
Immunoglobulin (Ig) M and IgA. Conventional follicular B-2 B cells undergo isotype switching in 
the spleen and lymph nodes in response to T cell-dependent antigens to either become plasma 
cells that secrete large amounts of antibody (adaptive IgM, followed by IgG (IgG1, IgG2a/c, IgG3), 
IgA, or IgE antibodies), or become memory B cells with the ability to produce specific antibodies 
upon re-exposure to the same antigen135–138. Unlike the follicular B-2 B cells of the adaptive 
immune system, marginal zone B cells are considered to be part of the innate immune 
system139,140. They reside in the spleen and are positioned to immediately respond to antigens in 
the blood that are filtering through the spleen. In contrast to follicular B cells they do not have the 
ability to become memory B cells139,140. 
In contrast to the role of T cells, which has been extensively studied for decades, the role of B 
cells only recently has gained attention. New studies have identified differential effects of 
different B cell-subsets and helped to clarify the still poorly understood mechanisms by which B 
cells act. Only low B cells numbers can be detected in atherosclerotic lesions141. Galkina et al 
were able to show that B cells participate in lymphocyte infiltrates of the adventitia surrounding 
arteries and in tertiary lymphoid organs.142. Although only a few were detected occasionally in 
the intima of atherosclerotic lesions, early lesions contain considerable amounts of IgG, IgM, and 
IgG antibodies143.  
Various studies reviewed by Perry et al and Kyaw et al have recently pointed out an important 
role for B cells in atherogenesis144,145. B cells may affect atherosclerosis potentially through 
mechanisms like the production of immunoglobulins and the subsequent formation of immune 
complexes with their cognate antigens. The first evidence for a functional role of B cells in 
experimental atherosclerosis came from studies, which demonstrated that the removal of the 
spleen, as a large B cell reservoir, resulted in aggravated atherosclerosis in Apoe−/− mice and 
that this effect could be reversed through the adoptive transfer of unfractionated splenic B 
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cells146. In agreement, Major et al demonstrated that the transfer of with B cell–deficient bone 
marrow from µMT mice into cholesterol-fed Ldlr−/− mice resulted in an increased plaque 
formation compared with mice reconstituted with wild-type bone marrow147. Although the results 
from the different studies indicated an overall protective role of B cells, some studies also 
reported pro-atherogenic effects for B cells. Anti-CD20–mediated B-cell depletion in 
atherosclerotic Apoe−/− and Ldlr−/− mice results in a significant reduction of lesion size148,149. 
Furthermore, the deficiency or adoptive transfer of B2 B cells revealed a pro-atherogenic role of 
this B cell subtype149. These contradictory findings do not only exclusively imply that B cells have 
both pro and anti-atherogenic roles in atherosclerosis, but also indicate that B cell subtypes are 
differently involved in atherosclerosis progression.  
A spate of studies has pointed toward a differential role of B1 and B2 cells in atherogenesis and 
there is conflicting evidence concerning the role of B2 cells in atherogenesis. Although the role 
of B2 cells in atherosclerosis is controversial, the role for B1 cells, which represent a much 
smaller subset of B cells, particularly B1a cells, seems clearer. B1a cells clearly prevent 
atherosclerosis in mice150. An intact spleen is required for B1a cell maintenance, because 
splenectomized or genetically modified asplenic mice have significantly lower B1 cell numbers in 
the circulation and peritoneal cavity151. Moreover, it has been shown that the splenic 
microenvironment enhances the antibody production capacity of B1 cells and a splenectomy 
therefore may result in the loss of this potentially athero-protective B-cell subset152. Indeed, 
Kyaw et al demonstrated that the number of peritoneal B1a cells of splenectomized Apoe−/− mice 
was reduced by 50% and that the transfer of peritoneal B1a cells but not splenic B2 cells into 
splenectomized Apoe−/− mice resulted in higher concentrations of IgM and an amelioration of the 
splenectomy-induced accelerated atherosclerosis153. It is currently not known whether B1b cells 
have the same athero-protective potential as B1a cells.  
Secretion of natural IgM antibodies is one of the major functions of B1 cells. Accordingly, it has 
been hypothesized that the athero-protective effect of B1 cells depends on the secretion of IgM 
antibodies153150. Splenectomy of Apoe−/− mice is associated with decreased IgM levels, and 
patients subjected to splenectomy after trauma have been reported to have significantly lower 
serum IgM titers154. Of note, unlike transfer of wild-type B1a cells, those isolated from sIgM−/− 
donor mice, which express but do not secrete IgM, failed to attenuate the accelerated 
atherosclerosis in splenectomized mice, demonstrating that the IgM conferred the 
atheroprotection153.The class of IgM antibodies comprises both, natural IgM antibodies and 
adaptive IgM antibodies. 
Natural antibodies are primarily derived from B1 cells that spontaneously secrete antibodies 
independently from T cells, whereas adaptive IgMs are secreted by B2 cells in a T cell–
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dependent manner. In naïve mice, up to 90% of the total IgM pool is derived from B1 cells155. 
Natural IgM antibodies are pre-existing germline-encoded products that do not require 
exogenous antigen stimulation for their generation30,144,156,157. Due to their specificity for microbial 
antigens, they play an important role in the first-line defense against infections with bacteria, 
viruses, and fungi. Natural antibodies also exhibit specificity for certain self-antigens, and in 
addition to their antimicrobial properties, possess so called “housekeeping functions” by 
regulating the safe disposal of apoptotic cells and self-antigens158. Natural antibodies facilitate 
the removal of cellular debris, because their repertoire includes specificities for highly conserved 
structures on apoptotic cells and other self-antigens, such as oxidation specific epitopes (OSE) 
that are found on apoptotic cells and on the highly immunogenic oxLDL159. Several studies could 
demonstrate that OSEs are a major target of natural IgM antibodies and that IgG and IgM 
autoantibodies to oxLDL can be easily detected in both humans and animal models of 
atherosclerosis160–163. OxLDL-specific antibody IgM titers associate with athero-protection, while 
oxLDL- specific IgGs correlate with atherosclerosis progression164,165. OxLDL generates various 
oxidation-specific neoepitopes, such as malondialdehyde-modified (MDA-modified) LDL (MDA-
LDL) or the phosphatidylcholine (PC) headgroup of oxidized phospholipids (oxPLs)164. Shaw et 
al isolated a panel of oxLDL-specific B cell lines that secrete IgM antibodies which specifically 
bind to the PC headgroup of oxPLs164. Of considerable interest is the fact that all of these PC-
specific autoantibodies recognized the lipid moiety of oxLDL, as well as the delipidated modified 
apoB (the protein moiety of oxLDL), but not native LDL164. The antibodies were found structurally 
and functionally identical to classic "natural" T15 anti-PC antibodies that are of B-1 cell origin 
and are reported to provide optimal protection from virulent pneumococcal infection164. 
Accordingly, Binder et al showed that pneumococcal vaccination of Ldlr-/- mice reduced 
atherosclerosis by expanding T15 natural antibodies166. The group also performed vaccination 
studies by immunization with MDA-LDL. They indicated that the athero-protective effect seen 
after the immunization was due to an increase in T15 antibody titers that resulted from IL-5 
production of Th2 T cells166. In addition they confirmed their theory by using a bone marrow 
transplantation model and showed that the deficiency in bone marrow IL-5, a cytokine which is 
important for maturation and Ig secretion of B1 cells, reduces the levels of oxLDL-reactive IgM 
and lead to an acceleration of atherosclerosis167. Taken together these data and supporting 
results from animal and clinical studies underline the athero-protective properties of IgM168,169.  
In contrast to IgM, antigen-driven IgG response are considered pro- atherogenic. IgG is the main 
immunoglobulin subtype in the circulation of humans. The IgG consists of 4 different subclasses 
in both humans (IgG1, IgG2, IgG3, and IgG4) and in mice (IgG1, IgG2a/c, IgG2b, and IgG3) and 
each of the IgG subtypes exhibits different fragment crystallizable gamma receptor (FcγR) 
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affinity and harbors different capacities to activate the complement system170,171. As already 
mentioned above oxLDL-specific IgG antibodies are detected in atherosclerotic lesions and the 
depletion of B cells lowered atherosclerotic burden and concomitantly titers of oxLDL-specific 
IgG antibodies and to a lesser extent those of IgM antibodies149. There are several studies which 
document positive or negative correlation of anti-oxLDL IgG with manifestations of 
cardiovascular disease (CVD)172. The inconsistent results may lose their significance when 
analyzed in combination with other CVD risk factors or could be explained by the fact that a 
reproducible antigen to perform reliable measurements (e.g. MDA-LDL) was missing. Despite 
the discrepancy between the different studies IgG antibodies have often been suggested to be 
pro-atherogenic. However, there is little experimental evidence for the functional role of IgG 
antibodies in atherosclerosis. Most information about IgG antibodies in atherosclerosis were 
derived from immunization approaches with HSP65 or oxLDL. The immunization of 
normocholesterolemic rabbits with HSP65 for example, induced accelerated atherosclerosis on 
a cholesterol-enriched diet173.These effects were reproduced in studies using Ldlr−/− mice fed a 
regular chow diet, which developed high anti-HSP65 IgG antibodies and increased 
atherosclerotic lesions69. The pro-atherogenic effect of anti-HSP65 IgG was also demonstrated 
by George et al, who showed that injecting chow-fed Ldlr−/− mice with IgG preparations from 
Hsp65-immunized mice promoted fatty streak formation174. Taken together these data suggest a 
pro-atherogenic role of HSP65-specific IgGs. The immunization of hyperlipidemic mice with 
MDA-LDL resulted in increased amounts of specific antibodies and was atheroprotective175,176. 
Contradictory results were obtained in vitro, where plasma of mice with high MDA-LDL-IgG titers 
inhibited oxLDL uptake by macrophages whereas recombinant human athero-protective MDA-
LDL–specific IgG1 promoted uptake of oxLDL by macrophages177,178. In summary, there is still 
information missing to understand the biological roles and functions of oxLDL-specific IgGs in 
atherosclerosis.  
IgE antibodies have been extensively studied in allergy and asthma and their role was only 
indirectly tested in atherosclerosis. Although a few epidemiological studies exist that suggest a 
contribution for IgE immunoglobulins to atherosclerosis. Kovanen et al could show, that high IgE 
levels are a prognostic factor for myocardial infarction and cardiac death in dyslipidemic men179. 
The results were later confirmed by Wang et al and several others180. Thus, epidemiological data 
suggest a pro-atherogenic role for IgE antibodies. Even though the role of IgE antibodies in 
experimental atherosclerosis has not been directly investigated, additional indirect evidence 
came from studies in atherosclerosis-prone mice deficient in Fcε receptors and just recently from 
studies in mice with a deficiency of secreted IgM (sIGM)180,181. Apoe−/− mice deficient for the 
high-affinity FcεRI receptors contained smaller atherosclerotic lesions accompanied by reduced 
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macrophage and apoptotic cell. However, these effects were achieved with IgE concentrations 
that were 200-fold higher than the concentrations measured in vivo in atherosclerotic mice. 
Therefore, these effects may not entirely reflect an in vivo situation180. In the beginning of 2017 
Tsiantoulas et al identified a previously unsuspected mechanism by which sIgM deficiency 
aggravates atherosclerosis through strongly increased plasma IgE level181. Insights into a direct 
role of IgE in atherosclerosis are still missing. Moreover, it will be important to demonstrate 
whether such effects are dependent on certain antibody specificities for relevant antigens, or 
whether they are antigen independent. 
Another Ig subclass is represented by IgA which confers mucosal protection against pathogens. 
Substantial IgA amounts are found in the circulation of humans. Epidemiologic studies correlate 
circulating IgA titers with myocardial infarction, CVD, and cardiac death in hyperlipidemic 
humans182. However the mechanistic contribution of IgA to atherosclerosis is not resolved yet.  
Comparable to T cells, the B cell population also harbors B cell subsets which are capable of 
dampening immune responses. These regulatory B cells modulate the immune response 
through mechanisms similar to Tregs. They either produce cytokines like IL-10 and TGFβ or 
interact with other immune cells via antigen presentation and secretion of antibodies. With the 
help of those mechanisms regulatory B cells might be capable to interact with pathogenic T cells 
to dampen harmful immune responses183. But their functions and impact on atherosclerosis still 
remains elusive. 
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1.7 Platelets in atherosclerosis 
Platelets are anucleated cell fragments of cytoplasm that are derived from the megakaryocytes 
in the bone marrow, and enter the circulation. Megakaryocytes first undergo nuclear 
endomitosis, organelle synthesis, and dramatic cytoplasmic maturation and expansion. The 
entire megakaryocyte cytoplasm afterwards is converted into a mass of proplatelets, which are 
released from the cell184. The nucleus is eventually extruded from the mass of proplatelets, and 
individual platelets are released from proplatelet ends184. Therefore the most of functional 
proteins may derive from different origins and are delivered to the major storage compartment in 
platelets, the α-granules. Von Willebrand factor (vWF) is synthesized in the megakaryocyte, 
while fibrinogen (340 kDa), also a major component of α-granules, is not synthesized by the 
megakaryocytes, but is exclusively recruited from plasma185–188. The platelet α-granule therefore 
represents a unique storage compartment that stores both endogenously synthesized proteins, 
as well as proteins derived from endocytic origin.189 Endocytosis and incorporation of 
glycoproteins into the α-granules require surface binding, internalization, and proper intracellular 
targeting. Little is known about the intracellular trafficking of proteins in megakaryocytes and 
platelets, especially with regard to the intracellular routing of glycoproteins following 
internalization and delivery to α−granules. 
Although central role of platelets lies in the prevention of bleeding, platelets probably contribute 
to diverse processes that extend beyond hemostasis and thrombosis. The process of thrombus 
formation is site dependent. Thrombosis inside veins is associated with high coagulation activity 
and the production of large amounts of fibrin. Arterial thrombosis however, is connected to high 
platelet activation. Therefore the thrombi contain high amounts of platelets 190. In arteries the 
activation of platelets occurs at the sites of injury such as ruptured atherosclerotic lesions where 
platelets are exposed to plaque components like vWF and Tissue Factor (TF)191. There is a 
constantly growing recognition that platelets modulate immune responses since platelets are 
well-equipped to facilitate leukocyte recruitment to sites of vascular injury and inflammation192. 
While their hemostatic and thrombotic roles are already well-established, their function as potent 
immune cells emerged rather recently. These studies implicated platelets as essential effectors 
in inflammatory conditions like sepsis, experimental autoimmune encephalomyelitis (a model for 
multiple sclerosis), allergy, rheumatoid arthritis, host defense during bacterial infection and 
cancer193–197.  
Besides the cell types that are present in the atherosclerotic lesion, circulating platelets today 
are also known to be important contributors to atherosclerosis198. Activated platelets promote 
leukocyte arrest on the vascular endothelium, which is believed to be a key process in the 
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development of atherosclerosis199 and they seem to play a role in all relevant stages of 
atherosclerosis by initiating or sustaining the chronic inflammatory process. Platelets facilitate 
the recruitment of inflammatory cells to inflamed lesion sites and dysfunctional endothelium by 
interacting with endothelial cells (ECs) and a plethora of circulating leukocytes like monocytes, 
neutrophils, DCs, T cells and progenitor cells200–208. A range of molecules present on the platelet 
surface or stored in platelet granules such as glycoproteins, costimulatory molecules (CD40, 
CD40L), cell adhesion molecules (e.g. P-selectin), junctional adhesion molecules (e.g. JAM-A), 
TLRs, chemokine receptors, scavenger receptors and protease-activated receptors contributes 
to the cross-talk of platelets with other inflammatory cells during the vascular inflammation 
involved in the development and progression of atherosclerosis209–214.  
Over 30 years ago Fitzgerald et al were the first to detect activated platelets, as defined by P-
selectin surface expression, in peripheral blood of patients with unstable atherosclerotic 
disease215. Later circulating activated platelets were also detected in the blood of atherosclerotic 
patients with stable coronary disease 216,217. Activated platelets can contribute to atherosclerosis 
via different ways, through the interaction with the endothelium and through the interaction with 
leukocytes. Both interactions can occur via direct or indirect mechanisms. The ability of activated 
platelets to interact with the endothelium was shown in the postcapillary venules in mice with 
hypercholesterolemia and after stimulation with the calcium ionophore A23187218,219. Hoe et al. 
could show that this interaction was an exclusive property of activated but not resting 
platelets220. The observed platelet endothelium interactions were mainly characterized by 
transient tethering, rolling, and firm adhesion and an essential role was ascribed to P-selectin 
during the interaction of activated platelets with atherosclerotic arteries220. Employing a similar in 
vivo model Massberg et al showed that platelet GPIb and GPIIb/IIIa are crucial for platelet 
translocation and firm adhesion, respectively221. Later the VWF was identified as another 
important molecule for both resting and activated platelet recruitment to atherosclerosis-prone 
sites of arteries of rabbits with hypercholesterolemia222. In addition to these findings Huo and 
colleagues showed that circulating activated platelets promote monocyte recruitment to 
atherosclerotic arteries and accelerate atherosclerosis in Apoe-/- mice220,221. The increase in 
lesion size was halted when the activated platelets were P-selectin negative220,221. During the 
adhesion process to the endothelium, platelets become activated and release an arsenal of 
potent inflammatory and mitogenic substances into the local microenvironment, thereby altering 
chemotactic, adhesive, and proteolytic properties of ECs. The engagement of GP IIb/IIIa 
receptor during platelet adhesion induces upregulation of P-Selectin and CD40L on platelets, 
resulting in CD40L-dependent endothelial activation210,223 
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Besides their direct interaction with the endothelium platelets also induce inflammation through 
their indirect interaction with other cell types of the immune system. The recruitment from, and 
the interaction with leukocytes requires multistep adhesive and signaling events, including 
selectin-mediated attachment and rolling, leukocyte activation, integrin-mediated firm adhesion, 
and diapedesis, which result in the infiltration of inflammatory cells into the blood vessel wall224. 
When adhered to the endothelium, platelets can attract leukocytes by secretion and deposit of 
chemokines and then provide a surface for their adhesion to the vessel wall213. During these 
interactions platelets, leukocytes, and the endothelium, become activated in a cascade-like 
manner. Upon activation, platelets release different adhesive and pro-inflammatory substances. 
The main organelles which are involved in this release are the α-granules, the most important 
storage compartments within the platelets. The released molecules contain chemokines like 
Platelet factor 4 (PF4, CXCL4), Regulated on activation, normal T cell expressed and secreted 
(RANTES, CCL5) or the Macrophage inflammatory protein 1α  (MIP1α)225. PF4 a member of the 
C-X-C subfamily of chemokines, is derived by limited proteolysis from platelet basic protein. PF4 
causes chemotaxis of monocytes and other leukocytes and enhances the binding of oxLDL to 
vascular wall cells, including endothelial cells and smooth muscle cells225. PF4 when co-
localized with oxLDL in atherosclerotic lesions, especially in macrophage-derived foam cells, is 
able to dramatically increase the oxLDL esterification by macrophages225. RANTES and MIP1α 
are members of the C-C chemokine subfamily. RANTES, first purified as a product of activated T 
cells, is a powerful chemoattractant for memory T lymphocytes and also monocytes226. MIP1α 
additionally causes chemotaxis of CD8+ T lymphocytes220. PF4, RANTES, and MIP1α deposition 
by platelets mainly promotes atherosclerosis by triggering monocyte arrest on the endothelium 
of atherosclerotic lesions202,220,225.  
Besides their direct effects, platelets induce inflammation also by indirect interactions with other 
cell types, especially EC and monocytes. They induce the expression of intercellular adhesion 
receptors (e.g. E-selectin or VCAM-1), the production of cytokines (IL-6, IL-8) and the production 
of matrix metalloproteinase (MMP) 9210,227,228. Although it is clear that platelets affect all phases 
of immune responses, further research is required to fully understand how platelets directly and 
indirectly affect atherosclerosis.  
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1.8 An introduction to the CD40/CD40L dyad 
To generate and mount a successful adaptive immune response, a variety of molecular signals 
is required. The initial signal is the binding of a cognate antigen to an antigen receptor (TCR or 
BCR) expressed by T or B cells. However, synergistic signaling by costimulatory molecules is 
also necessary to sustain and integrate TCR/BCR signaling and to stimulate optimal T or B cell 
proliferation and differentiation. Multiple secondary signals involve the engagement of 
costimulatory molecules expressed by T and B cells with their respective ligands. Due to its 
essential role in immunity, CD40 and its ligand CD40 ligand (CD40L) is one of the best 
characterized costimulatory molecule pair.  
Costimulatory molecules can be broadly divided into two groups based on their respective 
homologies. On one hand the CD28/B7 family includes CD28 and cytotoxic T lymphocyte 
antigen 4 (CTLA4) that binds to the ligands CD80 and CD86. On the other, the tumor necrosis 
factor receptor (TNFR) family, which includes CD40 in addition to the name-giving TNF isoforms 
and others229–232. Costimulatory molecules can be further subdivided based on their functions. 
For example, molecules containing positive costimulatory function, such as CD40L binding to 
CD40 can be grouped together while coinhibitory molecules such as CTLA-4 build another 
group233. 
CD40 was originally detected in immunohistochemical studies using an antibody recognizing  a 
50 kD protein on bladder cancer cells over three decades ago234,235. Those initial studies showed 
that with the status of B cell activation and proliferation, the expression level of a specific 
molecule originally named Bp50, varies234,235. Later studies showed that this activation of B cells 
required direct contact with T helper cells rather than soluble lymphokines236.This led to the 
hypothesis of the presence of an unknown ligand on T cells236. In further studies the identity of 
this antigen was elucidated by cloning of the murine and human ligand for CD40, termed CD40L 
or CD154 and cell surface tumor necrosis factor-related activation protein (TRAP), a 39 kD cell 
surface glycoprotein and member of the tumor necrosis factor (TNF) family, which originally 
thought to be restricted to activated CD4+ helper T cells237,238. The CD40L gene is located at X 
chromosome and is preferentially expressed by activated CD4+ T cells. Nowadays it is known 
that CD40L is also expressed by activated B cells and platelets, although it is variably induced 
on monocytic cells, natural killer cells, mast cells, and basophils under inflammatory 
conditions210,239. CD40 expression can be detected in DCs, B cells, monocytes, epithelial cells, 
fibroblasts and ECs, as well as in SMC under pro-inflammatory conditions240–243. This broad 
distribution of CD40 and CD40L points to the likely involvement of this receptor/ligand dyad in 
chronic inflammatory disease.  
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Initially, the importance of CD40 and CD40L and the crucial role of both, receptor and ligand, in 
T cell-dependent B cell differentiation and activation could be established. The performed 
studies provided evidence for the important impact of CD40 and CD40L, by using blocking 
antibodies which prevented an immune response to T cell-dependent antigens and affected the 
development of memory B lymphocytes and germinal centers244–246. The role of CD40/CD40L 
interaction in T cell-dependent B cell activation and differentiation nowadays can be best 
illustrated and understood by analyzing the consequences of certain genetic polymorphisms in 
the human CD40L gene. Several point mutations in the human CD40 ligand gene, interfering 
with receptor interactions, were identified as the cause of the X-linked immunodeficiency hyper 
IgM-syndrome (XHIGM), a disease associated with drastic or complete inhibition in the T cell-
dependent humoral immune response247. This disease is not exclusively characterized by 
elevated concentrations of serum IgM and decreased amounts of other immunoglobulin 
isotypes, but also by a reduced activation and proliferation of B cells248. Because CD40L is not 
only required in the functional maturation of T cells and B cells but also in the activity of DC and 
macrophages, patients with XHIGM also have a variable defect in T cell, DC, and macrophage 
effector function247. Patients with XHIGM have increased susceptibility to infections with a wide 
variety of bacteria, viruses, fungi, and parasites247. In addition, they have increased risk for 
developing autoimmune disorders and malignancies249. In consequence patients with this 
syndrome suffer from chronic infections of the upper respiratory tract as well as a number of 
opportunistic or viral infections250. Moreover, Th1-dependent inflammatory reactions are 
weakened indicating even more important functions of CD40/CD40L interactions in the 
regulation of the cellular immune response251. Apart from the importance of CD40/CD40L 
interaction for the mounting of an appropriate immune response, more recent studies associated 
this costimulatory pathway with the exaggerated reaction in various chronic inflammatory and 
autoimmune diseases, such as asthma, rheumatoid arthritis, psoriasis, type I diabetes and 
multiple sclerosis, to name a few, but also in atherosclerosis252. 
CD40 does not feature any intrinsic signaling activity and requires the help of adaptor molecules 
to relay its activation into subsequent signaling pathways. In accordance, the binding of CD40L 
to CD40 promotes the clustering of CD40 and induces the recruitment of adapter proteins 
(TNFR-associated factors (TRAFs)) to the cytoplasmic domain of CD40253. The TRAF family 
contains seven members (TRAF1-7) and five of them (TRAF1,2,3,5, and 6) are able to bind to 
CD40 via three different TRAF bindings domains254. The binding site for TRAF1, TRAF2, and 
TRAF3 are situated at the membrane distal domain of the intracellular tail of CD40 and is most 
often occupied by TRAF2 and TRAF3255. Recently a second alterative binding site for TRAF2 
was identified256. TRAF6 is recruited to the membrane proximal domain of CD40 which 
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exclusively binds to TRAF6257. Until now there is no consensus whether TRAF5 binds directly or 
indirectly to CD40257,258. After the binding to its domains the TRAF proteins activate different 
signaling pathways including the canonical and non-canonical nuclear factor κB (NFκB)-
signaling pathways, the mitogen-activated protein kinases (MAPKs), phosphoinositide 3-kinase 
(PI3K), as well as the phospholipase Cγ (PLCγ) pathway259. Accordingly, the activated signaling 
cascade depends on the TRAF family member expressed on the activated cell type and the 
surrounding conditions. In conclusion, CD40 primarily mediates signaling through TRAF 
proteins, which can activate or inhibit different signaling pathways dependent upon the cell type. 
TRAF proteins drive a wide range of cellular and immune processes and the complex pathways 
elicit the essential signals mediated by CD40 to support its diverse cellular processes. 
1.9 CD40/CD40L signaling in cell-mediated immunity 
Over time it has become evident that CD40 and CD40L are expressed on the majority of cell 
types involved in perpetuating and regulating proper immune responses in the body. To gain a 
better understanding of the importance of the CD40/CD40L dyad and to unravel its role in the 
different aspects of the immune system, it is necessary to understand CD40/CD40L signaling on 
the distinct cell types which play a role especially in the adaptive part of the immune response. 
APCs and particularly DCs, represent the central cell type of the immune system since they 
immediately sense pathogens and provide the first link to the adaptive immune response by 
activating T cells5,260. Their proper function relies crucially on the costimulatory signaling of CD40 
and CD40L. As already mentioned, the successful T cell priming depends on three individual 
signals, cognate TCR interaction, costimulation and instructing cytokines. Immature DCs have a 
low expression of costimulatory molecules on their surface and consequently have poor T cell 
priming capacity. However, upon specific antigen activation, DCs switch from an antigen 
capturing cell phenotype to that of a professional APC. The switch is accompanied by the 
upregulation of MHCII and costimulatory molecules expression. CD40 signaling has been shown 
to be an important step in this transition261. Notably, functional interactions between CD40 and 
CD40L are bidirectional. The interaction of CD40 on DCs with CD40L expressed on T cells leads 
to an activation of the DC enabling them to prime T cells and produce cytokines261. The 
interaction of CD40 with CD40L or, experimentally, an anti-CD40 antibody induces the 
upregulation of costimulatory molecules, adhesion molecules, and the Th1-polarizing cytokine 
IL-12 in both mouse and human DCs262–264. However, CD40-dependent maturation of DCs is far 
more complex than the simple upregulation of costimulatory molecules and cytokine production. 
The first Cd40−/− mice were generated by two different groups, one with the CD40 defect of all 
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hematopoietic cells and the other, with the defect restricted to lymphocytes and both groups 
showed that both types of CD40 deficient mice were impaired in the generation of a T cell 
dependent antibody responses265,266. With the help of these newly generated CD40 deficient 
mice, Mackey and others could show that CD40 signaling on DCs is important for the expression 
and increased stability of the MHC/alloantigen complex in the context of cardiac allograft 
rejection31,267. Indeed, the alloantigen-presenting, non-matured DCs induce abortive activation 
and anergy of the host alloreactive T cell pool31,267. Their increased life span after CD40L ligation 
is considered to be another major factor in the success of CD40-triggered DCs in driving  
cell-mediated immunity. CD40-mediated survival is based on the upregulation of the anti-
apoptotic factor B cell lymphoma extra-large (Bcl-XL) and is NFκB dependent268,269.  
Later, Wykes and MacPherson showed that the expression of CD40 on DCs and B cells is 
required for optimal proliferation of B cells in absence of any exogenous stimuli. CD40 deficient 
mice displayed a decreased number of proliferating B cells and a reduced survival of B cells26. 
While the mechanism of this interaction has not been established, they suggested that CD40 
expressed on DCs plays a direct role in regulating B cell proliferation and potentially more 
important in regulation of B cell homeostasis270. In addition, Litinskiy et al. could prove that DCs 
activated by CD40L induces the expression of the TNF family member cytokines B lymphocyte 
stimulator protein (BLyS, also known as B cell activating factor (BAFF)) and proliferation-
inducing ligand (APRIL)271. BAFF and APRIL promoted B cell survival, class switch 
recombination and secretion of IgG and IgA antibodies272. The addition of antibodies to 
neutralize DC-derived BAFF or APRIL abrogated antibody production and class switching, but 
was not observed after the addition of a CD40 neutralizing antibody. Accordingly, the authors 
concluded that B cell antibody responses are regulated by cytokines produced during CD40 
signaling on DCs, and not by DC-induced CD40 signaling on B cells272. Through its expression 
on B cells (CD40) as well as on T cells (CD40L) CD40-CD40L interactions play a crucial role in 
humoral adaptive immune responses273,274. Activated T helper cells express CD40L which binds 
to the constitutively expressed CD40 on the B cell surface. Together with cytokines produced by 
the T helper cell, this leads to the proliferation of B cells and finally to their differentiation into 
plasma cells273,274.The signal provided by the CD40-CD40L interactions also induces the Ig 
Isotype switch (IgM to IgG, IgE and IgA)236,274. In the absence of signals from T helper cells B 
cells will only produce IgM. An example for the consequence of the missing T helper cell signal 
constitutes the XHIGM syndrome which is characterized by low or absent levels of IgG, IgE and 
IgA in serum, but normal or elevated serum levels of IgM247,248. The constitutive expression of 
CD40 was first ascribed to B cells, and then extended to most APC (DC and macrophages); this 
property helped to decipher the APC function of activated/memory B cells and their use 
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alongside MHC molecules275. In their role as APC, B cells and DCs are tightly connected to T 
cells because they provide the antigen-specific (via TCR) and the antigen-unspecific signals 
(costimulatory molecules) which are essential for proper T cell activation. The ligation of T cell 
CD40L to CD40 on APCs leads to the upregulation of costimulatory activity (e.g. E-selectin, 
MHCII, CD40) and the production of pro-inflammatory cytokines like IL-1, IL-6, IL-12, and 
TNFα251. In lymphoid tissues, naïve T cells will be activated by APCs that present antigens 
leading to the differentiation and proliferation of the naïve T cell into an inflammatory T helper 
cell phenotype. Smook et al showed that CD40 signaling is crucial for the induction of Tregs by 
interacting with APCs276,277. They reported that the amount of Tregs was markedly reduced in 
Cd40−/
− mice since APCs lacking CD40 failed to induced Tregs and resulted in T cell 
autoreactivity277. An additional impact on T cell immunity can be achieved by the inhibition of 
CD40L. The blockade of CD40L leads to passive apoptosis of T cells induced by the absence of 
growth and survival factors, such as IL-2, IL-7, and IL-15278–280.  
In addition to the CD40L expression on T cells, CD40L can also be released from the cell 
surface as a soluble form (sCD40L)180. Today, the biological effect of T cell-derived sCD40L is 
still not known and only limited information regarding the mechanisms that controls the 
production of sCD40L is available. Currently, platelets are thought to be the main source of 
sCD40L producing nearly 95% of the plasma sCD40L pool and the role of circulating sCD40L in 
atherothrombosis is widely accepted281. Without any direct cell-cell interaction, sCD40L, retains 
its biological activity and acts as a cytokine. Of note, sCD40L concentrations are used as a 
reliable biomarker to detect inflammation and to predict the risk for several cardiovascular 
diseases281–283. Interestingly, T cells can also express CD40. The mechanisms behind T cell 
CD40 function, however, have not been clearly defined yet282. Burgeois et al demonstrated that 
in addition to bearing CD40L, both activated CD4+ and CD8+ cells express CD40. CD40-deficient 
CD8+ T cells are unable to differentiate into memory cells and do not react to signals from CD4+ 
T helper cells284. The authors suggested that CD8+ T cells receive CD4+ T cell help directly 
through CD40 and that this interaction is fundamental for the generation of CD8+ memory T 
cells284. 
In addition to the cells which are considered to be an important part of the adaptive immunity, 
activated cellular participants of the innate immune system are also known to express CD40. 
Monocytes and macrophages are central cells of the innate part of the immune system, 
responsible for defending against diverse pathogens. Although monocytes represent an 
important part of the host defense, accumulation of monocytes can be harmful and aggravate 
diseases such as atherosclerosis, arthritis, and multiple sclerosis285. Monocytes stimulated by 
ECs up-regulate CD40 expression in the presence of T cells. When T cells were separated from 
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monocyte-EC interaction, these monocytes did not show CD40 up-regulation286. The interaction 
between T cells and monocytes is bidirectional and activated monocytes are capable of 
activating other T cells. The binding of CD40L on monocytes induces IL-12 secretion, which 
elicits CD40L expression on T cells and the production of the pro-inflammatory cytokine IL-1β287. 
Signaling via CD40 in monocytes/macrophages results in nitric oxide generation, rescue from 
apoptosis and induction of MMP production262,288,289. The importance of CD40-dependent 
macrophage activation in host defense is supported by the finding that Cd40l-/- mice have 
defective macrophage effector function290.  
Besides the main players of cellular immunity, platelets are also well-equipped to facilitate 
leukocyte recruitment to sites of vascular injury and inflammation 192. Henn et al were first to 
prove that platelets interaction with leukocytes is also regulated strongly via the CD40-CD40L 
axis210. CD40L is rapidly presented to the platelet surface after platelet stimulation. The surface-
expressed CD40 ligand is then cleaved from the platelet over a period of minutes to hours 
subsequently generating sCD40L226. When expressed on the surface of platelets and exposed 
to CD40-bearing vascular cells, platelet-associated CD40L is capable of initiating various 
inflammatory responses, including expression of inflammatory adhesion receptors (e.g. E-
selectin, VCAM-1), expression of tissue factor, and release of chemokines (e.g. MCP1 and IL-8) 
and the production of matrix metalloproteinase (MMP) 9 227,228,291. As mentioned before, platelets 
contribute to more than 95% of the circulating sCD40L. Aside from CD40L and sCD40L, 
platelets can also express the receptor CD40. The role of this receptor on platelets is still under 
debate but it was shown that sCD40L is able to activate platelets in an autocrine manner and 
cause them to upregulate P-selectin expression and induce release of the chemoattractant β-
thromboglobulin and serotonin. Whereas the membrane-bound form from T cells triggers the 
release of biologically active RANTES stored in the platelets granules. The released RANTES 
activates ECs and mediates further T cell recruitement292. Platelets are known to interact with 
neutrophils and ECs293. CD40 was reported to be expressed on neutrophils and Vanichakaran et 
al demonstrated that the release of sCD40L from activated platelets stimulates neutrophils to 
release reactive oxygen species (ROS) which can subsequently stimulate more platelets293. In 
another study by Li et al, incubation with activated platelets led to enhanced MAC-1 expression 
on neutrophils, an effect diminished by addition of anti CD40L or anti P selectin antibodies294. In 
the same study they were able to show, that sCD40L promoted platelet-leukocyte activation and 
recruitment294. These findings suggest a mechanism in the recruitment of leukocytes and the 
formation of platelet-leukocyte aggregates through CD40-CD40L signaling. 
ECs also actively participate in both innate and adaptive immune responses. ECs are one of the 
first cell types to detect foreign pathogens and endogenous metabolite-related danger signals in 
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the bloodstream, in which ECs function as sensors for danger signals. Treatment with 
lipopolysaccharide (LPS) activates ECs, causing the production of pro-inflammatory cytokines 
and chemokines, which amplify the immune response by recruiting immune cells. Thus, ECs 
function as immune effectors and immune cell mobilizers. They induce cytokine production by 
immune cells that consecutively lead to an activation or suppression of the immune cell 
functions. Under certain conditions, ECs express CD40 as well as CD40L and serve as APCs by 
expressing MHC I and II molecules and presenting antigens to T cells. The function of the 
endothelium is influenced by multiple factors as a consequence of cell-cell interactions. The 
expression of adhesion molecules on vascular ECs determines the pattern of migration and 
extravasation of leucocytes in inflammation and immunity. The cell-cell communication between 
ECs and platelets has only recently received attention in systematic studies. In 2000 Kotowicz et 
al showed that costimulation with CD40L and IL-4 or IL-13 gives rise to a unique pattern of 
adhesion molecule expression by human umbilical vein ECs (HUVEC). CD40 ligation alone 
enhanced expression of VCAM-1, ICAM-1 and E-selectin whereas IL-4 and IL-13 increased 
expression of VCAM-1 and P-selectin. Just recently Gerdes et al extended the knowledge about 
platelet CD40-dependent EC interaction. The group demonstrated that Cd40−/− platelets showed 
less abundant adhesion to the endothelium in vivo295. Moreover, ex vivo stimulation of EC with 
either activated Apoe−/− or Cd40−/−Apoe−/− platelets revealed that also other adhesion molecules, 
such as VCAM-1, platelet EC adhesion molecule (PECAM), VE-cadherin, and P-selectin, were 
significantly decreased in the absence of platelet CD40295. These results implicate CD40/CD40L 
interactions between platelets and give rise to specific patterns of adhesion molecule expression 
and cytokine production that may have important implications for lymphocyte migration and 
function at sites of inflammation296. 
In summary studies in both mouse and man showed, that by virtue of the interaction of CD40 
and CD40L positive immune cells, the CD40L/CD40 pathway is critical to a variety of cell-
mediated immune responses and in the induction of inflammation.  
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1.10 The role of CD40/CD40L costimulation in atherosclerosis 
The CD40/CD40L dyad is one of the best- described costimulatory pair in the pathogenesis of 
atherosclerosis. The expression of both CD40 and CD40L was found on the vast majority of 
immune cells and non-immune cells present in the atherosclerotic lesion as well as on 
monocytes and circulating platelets252,297,298. In other words, nearly all atherosclerosis-related cell 
types are known to express at least one part of the receptor ligand dyad252,297,298. CD40 and 
CD40L are already expressed in early stages of atherosclerosis and are highest in late stage 
atherosclerotic lesions which are prone to rupture299. In general, stimulation of all CD40-
expressing cell types induces cell functions that contribute to inflammation, such as activation of 
chemokine and cytokine synthesis, enhancement of costimulatory and adhesion molecules, as 
well as up-regulation of proteolytic enzymes300. 
In 1997 Mach et al were the first to describe CD40L expression by human vascular ECs, SMC, 
and macrophages in vitro, and the co-expression with its receptor CD40 on all three cells types 
in human atherosclerotic lesions301. Shortly after the first description of CD40 and CD40L 
expression in atherosclerotic plaques Mach et al were also able to prove the functional 
relevance of CD40L in atherosclerosis302. They showed that the treatment of hyperlipidemic  
Ldlr-/- mice with an anti-CD40L antibody significantly reduces the size and lipid content of aortic 
atherosclerotic lesions302. The atheroma of mice treated with the anti-CD40L antibody contained 
fewer macrophages and T lymphocytes and exhibited decreased expression of vascular cell 
adhesion302. One year later Lutgens and colleagues revealed that CD40–CD40L signaling is 
important in late atherosclerotic changes, such as lipid core formation and plaque 
destabilization303. Apoe-/-Cd40l-/- mice exhibited a nearly 6-fold decrease in plaque area and 
displayed a remarkable change in plaque phenotype303. Advanced atherosclerotic lesions of 
Apoe-/- Cd40l-/- contained increased amounts of collagen and SMC, while plaque lipid levels and 
the number of inflammatory cells were strongly reduced303. In a follow up study Lutgens et al 
used an anti-CD40L antibody (MR-1) to block CD40 signaling in Apoe-/- mice either during the 
onset of disease or when advanced atherosclerotic lesions had formed304. In addition to limiting 
lesion progression, the anti-CD40L treatment changed the composition of atheroma in manners 
thought to favor plaque stability by reducing relative content of macrophages and lipid, as well as 
increasing relative content of SMC and collagen304. Both early and delayed treatment with an 
anti-CD40L antibody did not affect atherosclerotic lesion initiation but did result in the 
development of a lipid-poor collagen-rich stable plaque phenotype304.Corroborating these 
results, Schönbeck et al showed similar effects while using a different anti-CD40L antibody 
(M158) in Ldlr-/- mice which consumed a hypercholesterolemic diet305.  
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In contrast to the findings regarding CD40L, the results for CD40 were contradictory. Zirlik et al 
reported that Ldlr-/- Cd40-/- mice do not exhibit any changes in atherosclerosis and reported the 
discovery of Mac-1 as a novel alternative receptor for CD40L306. However, Cd40-/- 
Apoe-/- mice displayed decreased atherosclerosis with lesions only containing a few 
inflammatory cells306. This also holds true when transferring bone marrow of Apoe-/-Cd40-/-: into 
irradiated Ldlr-/- mice298.  
The previous investigations towards the role of CD40 and CD40L in atherosclerosis all agree in 
the fact that they focus on the consequences of a complete inhibition of CD40- CD40L signaling 
on all cell types in the different mouse models. Lievens et al were the first to study the CD40-
CD40L signaling in a more cell type-specific way, by injecting CD40L-deficient activated platelets 
into Apoe-/- mice125. The repeated injections of activated Cd40l−/− platelets into Apoe−/− mice 
strongly decreased both platelet and leukocyte adhesion to the endothelium and decreased 
plasma levels of the important pro-inflammatory chemokine CCL2 compared with platelets from 
wild type mice. Moreover, Cd40l−/− platelets failed to form pro-inflammatory platelet-leukocyte 
aggregates125. In addition they revealed the importance of CD40L expression on platelets for 
platelet-induced atherosclerosis as injection of Cd40l−/− platelets in contrast to Cd40l+/+ platelets 
did not promote lesion formation125. This was the first study to show that CD40L plays a pivotal 
role in atherosclerosis, not only by affecting platelet-platelet interactions but especially by 
activating leukocytes, thereby increasing platelet-leukocyte and leukocyte-endothelium 
interactions. In 2016 Gerdes et al confirmed the supposed role of CD40 and CD40L in the 
interaction of platelets, leukocytes and the endothelium295. The group showed that activated 
platelets isolated from Apoe-/-Cd40-/- mice adhered less to the endothelium upon injection into 
Apoe-/- mice when compared with CD40-sufficient platelets295. Furthermore, the lack of CD40 on 
injected platelets led to reduced leukocyte recruitment to the carotid artery295. When compared 
to mice that received Apoe-/- platelets, those injected with Apoe-/-Cd40-/- platelets exhibited a 
more than 2-fold reduction in atherosclerosis. The plaques of mice receiving CD40-deficient 
platelets were less advanced, contained less macrophages, neutrophils, and collagen, and 
displayed smaller lipid cores295. 
In addition to the investigations towards the role of CD40 and CD40L in atherosclerosis  
Lutgens et al did the first steps in unravelling the signaling mechanisms of CD40 and CD40L in 
atherosclerosis. To obtain insights about CD40-TRAF interactions and which of them are 
required in atherosclerosis, they used mice with targeted mutations at the CD40-TRAF2/3/5, 
CD40-TRAF6 and CD40-TRAF2/3/5/6 recognition sites. The mice with defective CD40-TRAF6 
signaling displayed a strong decrease in atherosclerotic plaque size. The data unveil a role for 
CD40–TRAF6, but not CD40–TRAF2/3/5, interactions in atherosclerosis298. 
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1.11 Hypothesis and outline of the thesis 
Many genes and processes are implicated in the pathogenesis of atherosclerosis. In addition, 
interaction between cells and their gene products is manifold and varies greatly during lesion 
maturation. Considering this and the limited knowledge regarding the cell type-specific CD40 
and CD40L interactions in athero-progression, the present studies aim to specify the cell type-
specific influence of costimulation via CD40/CD40L on atherosclerosis at early and late time 
points of atherogenesis. The research presented here will provide novel insights in the complex 
field of adaptive immunity and in the particular effects exerted by CD40 and CD40L in 
atherogenesis. As the CD40/CD40L dyad plays an imminent role in the interaction of T cells, B 
cells and DCs, it is important to understand the different pathways elicited by CD40 and CD40L 
to modulate and improve potential therapies. Cell type-specific gene modification is a useful 
technique for determining the role of a gene product in certain cell types, or when global 
modification is lethal. The cre/loxP system can be used to delete or activate a gene of choice in 
a cell type-specific manner. Accordingly, we use the system to create different, athero-prone  
Apoe-/- Cd40fl/flcre+ and Apoe-/- Cd40lfl/flcre+ mice with conditional CD40 or CD40L deficiencies on 
T cells, dendritic cells and platelets, to investigate the cell type-specific impact of these 
costimulatory molecules on the generation of atherosclerosis. In addition to atherosclerosis-
specific parameters such as plaque size and plaque phenotype, other organs and tissues will be 
analyzed to examine whether and how the different cell subsets of the adaptive and innate 
immune system are influenced by a deficiency of either CD40 or CD40L. Furthermore, in vitro-
based assays will be performed to elucidate the function of immune cells isolated and generated 
from different Apoe-/-Cd40fl/flCre+ and Apoe-/-Cd40lfl/flCre+ mice lines and their potential 
contribution to atherosclerosis. 
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2 MATERIALS AND METHODS 
2.1 General equipment 
Table 1: General equipment used for this thesis 
Equipment Modell Source 
Autoclave VX150 Systex, Linden, Germany 
Balance 
BP2100S 
R160P 
Sartorius, Goettingen, 
Germany 
Centrifuges 
5415R 
5810 
Eppendorf, Hamburg, 
Germany 
Multifuge 3S-R Heraeus 
Multifuge 40R Heraeus 
Thermo Scientific, Waltham, 
MA, USA 
Cryotome CM3050S Leica, Wetzlar, Germany 
Flow cytometer 
FACS Canto II 
FACS Aria III 
BD Biosciences, San Jose, 
CA, USA 
Heating block SBH130DC Stuart, Staffordshire, UK 
Incubator Binder CB150 Binder, Tuttlingen, Germany 
Laminar Flow Hood Herasafe (Heraeus) Thermo Scientific 
Luminex xMAP instrument MAGPIX Luminex, Austin, TX, USA 
Microplate reader Tecan GENios 
Tecan Group, Maennedorf, 
Switzerland 
Microscopes 
DMLB 
DM6000 
SP8 3X 
Leica 
Microtome RM2155 Leica 
pH-meter HI2211 pH/ORP meter 
Hanna Instruments, 
Voehringen, Germany 
Plate shaker Titramax 101 
Heidolph, Schwabach, 
Germany 
qPCR system 
7900 HT Fast Real-Time 
PCR System 
ViiA 7 Real-Time PCR 
System 
Thermo Scientific 
Spectrometer ND1000 Nanodrop Peqlab VWR, Radnor, PA, USA 
Thermal cyclers MyCyclerT100 Bio-Rad, Hercules, CA, USA 
Tube Rotator MACS Mix Tube Rotator 
Miltenyi, Bergisch-Gladbach, 
Germany 
Water purification system Milli Q Direct Q 16 
Merck Millipore, Billerica, 
MA, USA 
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2.2 Mice 
2.2.1 Generation of Apoe-/- Cd40flox/flox and Apoe-/- Cd40lflox/flox mouse lines 
Cd40flox/flox mice and Cd40lflox/flox mice were crossed with Apoe-/- mice (stock No. 002052, The 
Jackson Laboratory, Bar Harbor, Maine, USA) mice to generate Cd40flox/flox Apoe-/- mice or 
Cd40lflox/flox Apoe-/- mice, respectively. Cd40flox/flox mice were custom-designed and generated by 
Ozgene Pty Ltd (Bentley, Australia). A conditional allele was created by inserting loxP sites 
upstream of exon 2 and downstream of exon 3. Cre-mediated deletion of the two “floxed” exons 
induces a frameshift mutation (from translational reading frame 0 to 1). The resulting knockout 
(KO) is similar, in principle, to two previously published non-conditional alleles in which 
neomycin (neo) selection cassettes were used to disrupt exon 3265,307. Cd40lflox/flox mice were 
generated similarly by custom-design at Ozgene. For this purpose two loxP sites upstream and 
downstream of exon 3 were introduced. Cre-mediated deletion of exon 3 cause a translational 
frameshift (from phase 0 to 1), rendering the downstream exons non-function. 
2.2.2 Generation of Apoe-/- Cd40fl/fl Cre and Apoe-/- Cd40lfl/fl Cre mouse lines 
We then introduced several cell-specific CD40 and CD40L deficient mouse lines by 
crossbreeding Cd40flox/flox Apoe-/- Cre and Cd40lflox/flox Apoe-/- Cre mice with different transgenic 
mice in which Cre- recombinase was expressed under the control of cell type-specific 
enhancers, promoters or silencer.  
Table 2: Description of cre-recombinase positive mice used in this thesis 
Cell type Promotor Method 
T cells CD4 
The cre-recombinase is expressed under the control of the CD4 
enhancer/promoter/silencer, which becomes active at sequential 
stages of T cell development308. 
Dendritic 
Cells 
CD11c 
The recombination cassette containing the cre-recombinase 
open reading frame, followed by the bovine growth hormone 
(BGH) polyA signal and the FRT site-flanked prokaryotic Zeocin 
resistance cassette (ZeoR), replace the coding part of the first 
CD11c exon, and the ZeoR cassette was subsequently removed 
by FLP-mediated recombination309. 
Platelets Pf4 
A codon-improved cDNA for re-recombinase, inserted by 
homologous recombination into bacterial artificial chromosome 
(BAC) DNA containing the mouse Pf4 promotor310. 
Heterozygous mice then were intercrossed and Apoe-/- Cd40flox/flox and Apoe-/-Cd40lflox/flox 
littermates, respectively, were used to cross with different cre+-Mice. Housing and breeding of 
mice followed institutional guidelines. All animal experiments were approved by the local ethical 
committee for animal experimentation. 
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2.3.1 Genotyping 
Newly weaned mice were marked by individual ear notches and holes produced by an ear punch 
device. A tail biopsy of 1-2 mm length was taken for genotypic analysis of mice. The tail biopsy 
was incubated overnight at 56°C in 250 µl tissue lysis buffer (see 2.8) supplemented 1:100 with 
proteinase k solution (Qiagen, Hilden, Germany). Subsequently, automatic DNA isolation was 
performed with the QIAxtractor (Qiagen) according the manufacturer’s instructions. The isolated 
DNA was kept at 4°C and applied for polymerase chain reaction (PCR). 
The following PCR mastermixes were prepared for CD40, CD40L and ApoE genotyping 
reactions: 
Stock concentration   Volume in µl 
Dnase-/Rnase-free H2 O  -     12.75 
GoTaq Flexi buffer   5x     5 
MgCl2     25 mM     2 
dNTP mix    10 mM each    0.5 
forward Primer   10 µM     1.25 
reverse Primer   10 µM     1.25 
GoTaq DNA Polymerase  5 U/µl     0.25 
Genomic DNA    100 ng/µl    2 
GoTaq Flexi DNA polymerase and GoTaq Flexi buffer were obtained from Promega (Promega, 
Fitchburg, WI, USA). Dnase-/Rnase-free H2O, primer, magnesium chloride (MgCl2), and the 
deoxynucleotide triphosphate (dNTP, containing deoxyadenosine/-guanosine/-cytidine/-
thymidine triphosphate) mix were obtained from Sigma (Sigma Aldrich, St. Louis, USA). Two 
mastermixes each were prepared for CD40 and CD40L genotyping containing either wildtype or 
mutant allele detecting primer and an additional primer to detect the transposon of the delivering 
vector. The reaction has to be run in to separate mixes as the mutant fragment does not amplify 
in heterozygous samples. The PCR program for CD40 DNA detection was composed of an initial 
step at 94°C for 2 min followed by 35 cycles of each 30 sec at 94°C, 30 sec at 60°C, and 1 min 
at 72°C. Subsequently, the samples were incubated at 72°C for 5 min and 21°C for 5 min. 
 
Primer sequences for CD40 genotyping: 
CD40 12398  5' GTG AGA TGC TAG CCC TCC TG 3' 
CD40 12399  5'CAC GTC ATC TGC TGG TTT TC 3' 
CD40 12400  5' CGT GCA ATC CAT CTT GTT CA3’ 
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The amplified PCR products were each electrophoretically separated applying the QIAexcel 
Advanced System (Qiagen) according to the manufacturer’s instructions. Expected results are a 
wildtype product at 594 base pair (bp) length and a mutant product at 685 bp length. DNA 
samples from heterozygous mice would yield a product at 594 bp and 685 bp length. Also for 
CD40L and Apoe genotyping two mastermixes were prepared with the common CD40L or Apoe 
forward primer and either the wildtype reverse primer or the mutant reverse primer. The PCR 
program was composed of an initial step at 94°C for 5 min followed by 35 cycles of each 30 sec 
at 94°C, 30 sec at 60°C, and 1 min at 72°C. Subsequently, the samples were incubated at 72°C 
for 5 min and 21°C for 5 min. 
 
Primer sequences for CD40L genotyping: 
CD40L mutant forward    5' GCC CTG AAT GAA CTG CAG GAC G3' 
CD40L mutant reverse    5' GGG TAG CCA ACG CTA TGT C3' 
CD40L wildtype forward    5' GTT CCT CCA CCT AGT CAT TCA TC3' 
CD40L wildtype reverse    5'CCC AAG TGT ATG AGC ATG TGT GT 
 
Expected results for CD40L are a wildtype product at 250 bp length and a mutant product at 500 
bp length. DNA samples from heterozygous mice would yield a product at 250 bp and 500 bp 
length. 
 
Primer sequences Apoe genotyping: 
Apoe common forward  5’ GCC TAG CCG AGG GAG AGC CG 3’ 
Apoe wildtype reverse  5’ TGT GAC TTG GGA GCT CTG CAG C 3’ 
Apoe mutant reverse   5’ GCC GCC CCG ACT GCA TCT 3’ 
Expected results for Apoe are a wildtype product at 150 bp length and a mutant product at 245 
bp length. DNA samples from heterozygous mice would yield a product at 150 bp and 245 bp 
length. 
 
 
Primer sequences for Cre genotyping 
Pf4 cre forward    5’ CCC ATA CAG CAC ACC TTT TG 3’ 
Pf4 cre reverse    5’ TGC ACA GTC AGC AGG TT 3’ 
Expected results for Pf4 cre are no product for wildtype mice and a product at 450 bp length for 
Pf4 cre-positive animals.  
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CD4 cre forward    5' CGA TGC AAC GAG TGA TGA GG 3' 
CD4 cre reverse    5' GCA TTG CTG TCA CTT GGT CGT 3' 
Expected results for CD4 cre are no product for wildtype mice and a product at 250 bp length for 
CD4 cre-positive animals.  
 
CD11c internal control forward  5' GAT GTG CTC CAG GCT AAA GTT 3' 
CD11c internal control reverse 5' AGA AAC GGA ATG TTG TGG AGT 3' 
CD11c cre forward    5' TAT CTT CTA TAT CTT CAG GCG C 3' 
Cd11c cre reverse    5' GTG AAC GAA CCT GGT CGA AAT CAG 3' 
Expected results for CD4 cre are no product for wildtype mice and a product at 200 bp length for 
CD4 cre-positive animals. DNA samples from mice would yield a 500 bp length product for a 
successful PCR and no product for a failure of the PCR protocol. 
 
2.3.2 Surgical procedure 
Mice were administered a normal chow diet for 28 weeks or a high fat diet for 6 weeks, mice 
were euthanized i.p. with Ketamine/Xylazine and blood was obtained via cardiac puncture. 
Spleen, abdominal aorta, liver, aortic root, and lymph nodes were harvested after perfusion of 
the arterial tree with sodium nitroferricyanide(III) dehydrate (Sigma Aldrich) followed by 1% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) perfusion (Sigma Aldrich). Parts of 
the tissue were stored in RNAlater (Life Technologies, Carlsbad, USA) for 24 h at room 
temperature and afterwards at -80°C. Hearts were isolated and frozen in Tissue-tek (Sakura 
Finetek, Torrance, USA). The aortic arch and its main branch points were excised, fixed 
overnight in 1% PFA in PBS, and embedded in paraffin.  
 
2.3.2.1 Contact Hypersensitivity 
Mice were shaved and the skin of their abdomens using a small animal clipper. Then the mice 
were sensitized by the epicutaneous application of 20 µl 0.5% 2,4-dinitro-1-fluorobenzene 
(DNFB, Sigma-Aldrich) in 4:1 aceton-olive oil (AO, Sigma-Aldrich), onto the shaved abdomen. 
After 5 days the baseline ear thickness is measured prior to initiation of the efferent phase with a 
Dial Thickness Gage (Mitutoyo). Finally, the ear is treated epicutaneously with 10 µl of 0,2% 
DNFB (in 4:1 AO on each side of the right ear). Ear thickness of the treated (right) and the 
untreated (left) ear is measured 24 hours after treatment. The change in ear thickness was 
measured by calculating the difference between treated ear and untreated ear. Mice were 
anaesthetized and blood was obtained via cardiac puncture. Spleen and lymph nodes were 
Material and Methods 
 
38 
 
harvested. Parts of the tissue were stored in RNAlater (Life Technologies) for 24 h at room 
temperature and afterwards at -80°C. Ears were excised, fixed overnight in 1%PFA in PBS, and 
embedded in paraffin. 
2.4 Protein assays 
2.4.1 Flow cytometry 
Aortae were digested with an enzymatic cocktail (Collagenase I, 450 U/ml; collagenase XI, 250 
U/ml; hyaluronidase, 120 U/ml; deoxyribonuclease (DNase) I, 120 U/ml; all Sigma Aldrich) in 
PBS containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Thermo 
Scientific) for 30 min at 37°C as previously described.209 Single cell suspensions of the aortic 
lysates were prepared by filtering the aortic tissue through a 50 µm cell strainer (BD 
Biosciences). Aortic lysates were washed with 1x PBS and resuspended in 100 µl 1x 
PBS/staining mix (maximum 2 staining panels were applied due to low abundance of 
leukocytes). Cell suspensions were prepared from harvested spleens and lymph nodes by 
tearing the tissues apart. Single cell suspensions were prepared by meshing the tissue through 
a 70 µm cell strainer (BD Biosciences). Splenic cells were erylysed (6 ml for a whole spleen) for 
3 min on ice, washed and filtered through a 70 µm cell strainer. Freshly-drawn blood was 
incubated with red blood cell lysis buffer (5 ml for 1 ml blood) for 10 min at room temperature 
and subsequently washed. If the pellet was still containing too many red blood cells, another 
lysis step was performed (3 ml, 3 min, wash). Wash steps were performed with 1x PBS. Pellets 
from lymph nodes were resuspended in 1 ml PBS and pellets from whole spleens in 6 ml PBS. 
Blood leukocytes were resuspended in 100 µl/staining mix. Subsequently, 100 µl of cell 
suspension were stained with a viability dye (Live/Dead fixable Aqua/Violet/Near-Infrared; Life 
Technologies) to discriminate between living and dead cells according the manufacturer’s 
instruction concomitantly with Fc-Block (anti-CD16/32-antibody, functional grade, clone:93, 
1:100, eBioscience, San Diego, CA, USA). 1x PBS was used for Live/Dead staining as protein 
components of buffers, such as bovine serum albumin (BSA), could reduce staining efficacy thus 
producing false negative results. Single cell suspensions were incubated (20 min, dark, room 
temperature) and washed with FACS buffer to remove remnant Live/Dead dye. Subsequently, 
cells were incubated for 20 min on ice with 50 µl of antibody mixes with antibodies from BD 
Biosciences, eBioscience, Biolegend (San Diego, CA, USA), or Novus Biologicals (Littleton, CO, 
USA) (Table 3). An additional washing step was performed after antibody-staining with FACS 
buffer to remove unbound antibodies. In case intracellular stainings were performed the 
Foxp3/Transcription Factor Staining Buffer Set was used according the manufacturer’s 
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instructions (eBioscience). To determine the level of apoptosis, stainings were performed for 
fluorochrome-conjugated Annexin V (Biolegend) and simultaneous exclusion of dead cells 
determined by Live/Dead staining (Life Technologies) according the manufacturer’s protocol. 
Apoptosis stainings were analyzed immediately. Other stainings were fixed with 1% PFA in 
FACS buffer and analyzed within the following days. Single cell suspensions were analyzed 
using a FACS Canto II (BD Biosciences) and data were analyzed using Flowjo v.10 (Flowjo, 
LLC, Ashland, USA). 
Table 3: Antibodies used for flow cytometry  
Antigen Source and reactivity Clone Dilution Source 
CD45 
APCe780 
Rat-anti-mouse (IgG2b, κ) 30-F11 1:400 eBioscience 
CD4 V500 Rat-anti-mouse (IgG2a, κ) RM4-5 1:200 BD Biosciences 
CD8a e450 Rat-anti-mouse (IgG2a, κ) 53-6.7 1:200 eBioscience 
Foxp3 PE 
Rat-anti-
mouse/rat/pig/canine/bovine 
(IgG2b, κ) 
FJK-16s 1:40 eBioscience 
CD3 FITC 
Armenian Hamster-anti-
mouse (IgG) 
45-2C11 1:200 eBioscience 
CD25 APC Rat-anti-mouse (IgG1, λ) PC61.5 1:300 eBioscience 
CD44 APC 
Rat-anti-mouse/human 
(IgG2b, κ) 
IM7 1:1000 eBioscience 
CD25 APC Rat-anti-mouse (IgG2b, κ) RM134L 1:100 Biolegend 
CD40 PE Rat-anti-mouse (IgG2a, κ) 1C10 1:100 eBioscience 
CD70 PE Rat-anti-mouse (IgG2b, κ) FR70 1:100 eBioscience 
CD154 PE-
Cy7 
Armenian Hamster-anti-
mouse (IgG) 
MR1 1:100 Biolegend 
CD62L PE-
Cy7 
Rat-anti-mouse (IgG2a, κ) MEL-14 1:800 eBioscience 
CD11b PerCp-
Cy5.5 
Rat-anti-mouse (IgG2b, κ) M1/70 1:300 eBioscience 
MHC II Rat-anti-mouse (IgG2b, κ) 
M5/114.15.
2 
1:500 Biolegend 
CD11c PE-
Cy7 
Armenian Hamster-anti-
mouse (IgG) 
N418 1:1000 eBioscience 
CD21/CD35 Rat-anti-mouse (IgG2a, λ) eBio8D9 1:100 eBioscience 
IgD FITC Rat-anti-mouse (IgG2a, κ) 
1-26c(11-
26) 
1:100 eBioscience 
 
APC =Allophycocyanin, PE=Phycoerythrin, FITC = Fluorescein Isothiocyanate, PerCp = 
Peridinin chlorophyll, Cy = Cyanine 
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2.4.3 Plasma preparation and lipid analysis 
Plasma was isolated by centrifugation (500 x g, 15 min, 4°C) of EDTA-anticoagulated blood. 
Plasma cholesterol concentration was determined using a colorimetric assay (Roche, Basel, 
Switzerland) modified to microtiter format. In brief, the plasma samples were diluted 1:5 with 
0.9% saline on ice. A standard (Roche/Hitachi; 152 mg/dl accordingly 3.95 mmol/l) was serially 
diluted 1:2, 1:4, 1:8, 1:16 and 1:32 with 0.9% saline on ice. Subsequently, 2 µl of each standard, 
sample and blank (0.9% saline) were transferred to a flat bottom microtiterplate (BD 
Biosciences) on ice. To increase the range of the standard 2 µl and 4 µl undiluted standard was 
added to the respective wells.  After adding 200 µl reagent CHOD-PAP (Roche) to each well the 
microtiter-plate was gently mixed. Following incubation at room temperature for 30 min 
absorbance at 505 nm wavelength was measured using a 96-well plate reader (Tecan GENios). 
For calculating the cholesterol content of the sample the following equation was used: 
 
Sample (mean) x standard-concentration (mmol/l) 
Concentration (mmol/l) =   
Standard (mean) 
 
Hematologic analysis was performed with a ScilVet abc Plus+ (ScilVet, Viernheim, Germany). 
2.4.4 Plasma analysis 
Murine plasma was analyzed for cytokine levels, general Ig levels and oxLDL-reactive Ig using 
multiplex bead-based assays (eBioscience) and enzyme-linked immunosorbent assays (ELISA). 
2.4.4.1 Anti-oxLDL-Ig ELISA 
The abundance of antibodies detecting oxLDL in plasma of mice was detected via ELISA. In 
brief, a 96-well polystyrene microplate (Costar 3690, Corning, Corning NY, USA) was incubated 
with 50 µl per well of 10 µg/ml oxLDL in PBS pH 7.4 at 4°C overnight. Wells were washed twice 
with PBS, blocked 1h at room temperature with 1% gelatin (Sigma Aldrich) in PBS and washed 
twice with PBS. Subsequently, 50 µl of pre-diluted mouse plasma (1:20, 1:200, 1:1000) in 0.1% 
gelatin/Tris-buffered saline (TBS) were added per well and incubated for 2 h at room 
temperature. After incubation, wells were washed thrice with 0.05% PBS-Tween (PBS-T) and 50 
µl of the biotinylated anti-mouse IgG-antibodies listed below were added (each antibody was 
diluted 1:25000 in 0.1% gelatin/TBS): 
 
• Biotin-SP-conjugated Goat anti-mouse IgG1, 
• Biotin-SP-conjugated Goat anti-mouse IgM, µ chain, 
• Biotin-SP-conjugated Goat anti-mouse total IgG, 
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• Biotin-SP-conjugated Goat anti-mouse total IgG2b, 
• Biotin-SP-conjugated Goat anti-mouse total IgG3, 
• Biotin-SP-conjugated Goat anti-mouse total IgG2a, 
 
All antibodies were obtained from Jackson ImmunoResearch Labs and handled according the 
manufacturer’s data sheets. Subsequent to incubation for 1 h at room temperature with 
biotinylated antibodies, wells were washed thrice in 0.05% PBS-T and 50 µl of streptavidin 
conjugated to horse radish peroxidase (HRP, 1:1000 in 0.1% gelatin/TBS) were added  
(1 h, room temperature, dark). After washing with 0.05% PBS-T (4x), 50 µl 3,3',5,5'-
Tetramethylbenzidin (TMB) substrate (1-Step Ultra TMB ELISA substrate, Thermo Scientific) 
were added for 2-10 min depending of titers. The substrate is converted into blue product in 
presence of HRP activity. The addition of 1 M hydrochloric acid (HCL) stopped the reaction and 
changes the substrate to a yellow color. Absorbance was analyzed with an 96-well plate reader 
(Tecan GENios) at 450 nm wavelength with reference wave length set at 570 nm.  
2.4.4.3 Cytometric bead Arrays 
Murine plasma from 28-week-old mice was analyzed for T helper cytokine abundance with the 
mouse Th1/2/17/22 13-plex kit FlowCytomix Multiplex Kit (eBioscience) which allows for the 
simultaneous detection of, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IL-21, IL-22, IL-27, 
IFNγ and TNFα. Levels of circulating Ig subclasses (IgA, IgG1, IgG2a, IgG2b, IgG3, IgM) from 
the same mice were assessed with the mouse Ig isotyping 6-plex kit (eBioscience). Both assays 
are bead-based and follow a similar principal as a sandwich ELISA. Analysis was performed with 
a flow cytometer (BD FACS Canto II, BD Biosciences). In brief, fluorescently-marked polystyrol 
beads are pre-coupled with antibodies specifically detecting the respective analyte(s) of interest. 
A single bead population was only coupled with one specific capturing antibody. A mixture of 
different bead populations was incubated with plasma samples for 2 h. The bead-bound-analyte 
from the plasma sample was detected by a biotinylated detection antibody. Subsequent 1 h 
incubation with PE-conjugated streptavidin- binding to the biotinylated analyte-bead-complex 
allowed for quantification of the respective analyte. The bead samples were acquired with a BD 
FACS Canto II (BD Biosciences). Up to 20 bead sets could be analyzed in one fluorescent 
channel as the beads are distinguishable by size (4 µm and 5 µm) and different intensities of the 
fluorochrome labeling the bead populations. Here, beads were labeled with a fluorochrome 
emitting in the far-red channel at 690 nm wavelength. First beads were separated by size by 
displaying size (front scatter) and granularity (side scatter). Gating on the size-separated bead 
populations allowed for further discrimination in fluorescence intensity by displaying fluorescence 
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emitted in the APC channel. Mean fluorescence intensities (MFI) of each bead population for 
fluorescence emitted in the PE channel were acquired and standard curves based on the MFI 
obtained from standard cytokine beads were used for quantification of sample analyte 
concentration. Flow cytometer data was analyzed with the FlowCytomix Pro 3.0 analysis 
software to obtain plasma cytokine or Ig concentrations. During the course of this thesis the 
manufacturer replaced the bead array technology analyzed by flow cytometry with the 
ProcartaPlex immunoassays using Luminex xMAP technology for the multi-analyte detection. 
Here, we applied the ProcartaPlex mouse Th1/Th2/Th9/Th17/Th22/Treg cytokine panel (17 plex) 
to simultaneously analyze plasma concentration of IL-1α, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10,IL-12, 
IL-13, IL-17, IL17A, IL18, IL-21, IL-22, IL-27, IFNγ , TNFα and GM-CSF. Plasma was obtained 
from Cd40flox/flox Apoe-/- Cd11cCre+, Cd40flox/flox Apoe-/- CD11Cre-, Cd40lflox/flox Apoe-/- Cd4Cre+ 
and Cd40lflox/flox Apoe-/- Cd4Cre-. The xMAP technology is also a bead-based technique which 
applies beads which are internally labeled with fluorescent dyes to produce a specific spectral 
address. The beads are magnetized thus allowing for convenient washing steps in a 96-well 
plate. The beads are coupled with antibodies which will capture the specific analyte which in turn 
will be bound by a biotinylated detection antibody. Quantification will follow the binding of 
streptavidin-PE-conjugates to the detection antibody. Again, MFI of each bead population for 
fluorescence emitted in the PE channel were acquired and standard curves based on the MFI 
obtained from standard cytokine incubated with beads were used for quantification of sample 
analyte concentration. The samples were analyzed with the Luminex platform MAGPIX 
(Luminex). Data was analyzed with the xPONENT software controlling the MAGPIX platform 
(Luminex). 
 
2.4.5 Histochemistry (morphometry and histology) 
Hearts were cut in 8 µm-thick serial sections beginning from the onset of the aortic valves until 
the valves disappeared. Serial sections were stained with Oil Red O (Sigma) to determine lipid 
depositions and analyzed with a Leica DM6000 microscope (Leica Microsystems) equipped with 
a computerized morphometry system (LAS 4.6 analysis, Leica Microsystems). In brief, air-dried 
cryostat sections were pre-incubated with 60% 2-propanol (10x dipping) and subsequently kept 
15 min in the Oil Red O-working solution (180 ml Oil red O-stock solution and 120 ml deionized 
water filtered 1 h after mixing to remove precipitated salts). Excess Oil Red O solution was 
washed away by dipping 10 x in 60% 2-propanol. The sections were rinsed 5 min in tap water 
and counterstained with hemalaun (Sigma) in deionized water for 30 s followed by rinsing 5 min 
in tap water. Oil red O-stained sections were embedded in Immu-Mount (Thermo Scientific). 
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Serial paraffin sections of the aortic arch, the abdominal aorta and ears were stained with 
Hematoxylin & Eosine (H&E) and analyzed with a Leica DM6000 microscope (Leica 
Microsystems). Paraffin section were first deparaffinized with xylene and then rehydrated with 
the help of an descending ethanol (ETOH) series (100% ETOH, 96% ETOH, 70%ETOH, 
50%ETOH) and deionized water. The sections were then stained with hematoxylin in deionized 
water for 2 min followed by rinsing 10 min in tap water. Afterwards the sections were 
counterstained with Eosine for 5 min. Excess Eosine was washed away by dipping 1x in 
deionized water. Finally the sections were dehydrated with the help of an ascending ethanol 
series (50%ETOH, 70%ETOH, 96%ETOH, 100%ETOH) and fixated in xylene for 2 min. H&E-
stained sections were embedded in Immu-Mount (Thermo Scientific).The tissue sections with 
insufficient quality were excluded from further analysis, which may influence the individual 
parameter group size.  
2.4.6 Immunohistochemistry 
Selected murine tissue cryosections were fixed in ice-cold acetone prior to incubation with 
antibodies against alpha smooth muscle actin (α-SMA), CD3, CD4, Foxp3 and MAC3. The 
primary antibody binding of non-fluorescent conjugated antibodies was detected either by 
incubation with fluorochrome- (Alexa Fluor 488, Alexa Fluor 594, Cy3 or horse-radish 
peroxidase-conjugated secondary antibodies and diaminobenzidine (ABC kit, Vector Labs, 
Burlingame, USA). To amplify signal strength for α-SMA staining, a primary antibody against α-
SMA conjugated with FITC and secondary antibody directed against FITC and conjugated with 
Alexa Fluor 488 were used. Tissue sections were counterstained with hematoxylin or 4’,6-
Diamidino-2-phenylindol (DAPI, Life Technologies), respectively, mounted with DAKO 
fluorescent mounting medium (Dako, Agilent Technologies, Santa Clara, CA, USA), and images 
were recorded with a Leica DM6000 microscope equipped with a DFC295 and DFC365FX 
camera (Leica).CD4- and Foxp3-stained cells were counted. α-SMA-, MAC3-positive areas were 
analyzed by applying color threshold measurements. Tissue sections with insufficient quality 
were excluded from further analysis, which influences the individual parameter group size.  
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Table 4: Primary antibodies used in immunohistochemistry 
Antigen Source and reactivity Clone Dilution Source 
CD3 
Armenian Hamster-anti-mouse 
(IgG1, κ) 
145-2C11 1:100 BD Biosciences 
CD4 Rat-anti-mouse (IgG2a, κ) RM4-5 1:100 BD Biosciences 
Foxp3 
Rat-anti-
mouse/rat/pig/canine/bovine 
(IgG2b, κ) 
FJK-16s 1:50 eBioscience 
α−SMA- 
Mouse-anti-
mouse/rabbit/human/pig (IgG2a) 
FITC conjugated 
1A4 1:1000 Sigma Aldrich 
CD8 Rat-anti-mouse (IgG2a) YTS105.18 1:100 
AbD Serotec, 
Puchheim, 
Germany 
MAC3 Rat-anti-mouse (IgG1, κ) M3/84 1:200 BD Biosciences 
     
 
Table 5: Secondary antibodies used in immunohistochemistry 
Source and Reactivity Conjugate Dilution Source 
Donkey-anti-rat Alexa Fluor488 1:300 Thermo Scientific 
Mouse-anti-FITC Alexa Fluor488 1:400 
Jackson 
ImmunoResearch, 
West Grove, PA, 
USA 
Goat-anti-armenian 
hamster 
Cy3 1:300 Thermo Scientific 
Goat-anti-mouse Alexa Fluor594 1:300 Thermo Scientific 
Goat-anti-rabbit Star 635P 1:300 
Abberior, 
Goettingen, 
Germany 
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2.5 Cell culture and functional assays 
Cell culture was performed under sterile conditions in a laminar flow hood. Cells were 
maintained in a carbon dioxide incubator at 37°C and a humidified 5% CO2 atmosphere. FBS 
was incubated at 56°C for 30 min to inactivate the complement proteins and stored at -20°C until 
use. According to cell types specific media were used.  
2.5.1 CD4+ T cell isolation 
T cells were sorted isolated from spleen and lymph nodes. CD4+ T cells were negatively sorted 
using antibody-conjugated magnetic beads (Dynabeads Untouched Mouse CD4, Life 
Technologies) and dynal isolation buffer. In brief, an antibody-mix was used to label non-CD4+ T 
cells. The addition of Fc-binding magnetic beads bound the labeled cells in the tube while 
separating untouched CD4+ T cells. Tregs were sorted by either flow cytometry sorting for 
CD3+CD4+CD25high cells (BD FACS Aria III, BD Biosciences) or using an untouched CD4 
negative magnetic bead-sort followed by a CD25 positive magnetic bead sort according to the 
instructions of the manufacturer (Dynabeads Flowcomp Mouse CD4+CD25+ Treg cells kit, Life 
Technologies). T Cells were cultured in T cell medium (see 2.9). 
 
2.5.2 T cell proliferation assay 
Sorted CD4+ T cells from Apoe-/- mice were stained with carboxyfluorescein succinimidyl ester 
(CFSE, Life Technologies). In brief, T cells were adjusted to 1x106/100 µl in 37°C pre-warmed 
PBS and stained with 3 µM CFSE for 15 min at 37°C in a water bath while shaking the tube 
every 2 min. Subsequently, the T cells were washed twice with T cell medium and adjusted to 
1x106/ml. 5x104 CFSE-labeled T cells were co-cultured in a 1:1 ratio with anti-CD3/CD28 
antibody-conjugated beads (Life Technologies) for 72 hours. T cell proliferation was determined 
by CFSE dilution measured by flow cytometry. 
The proliferation index was calculated by multiplying the percentages of cells in a specific CFSE-
dilution-population with the number of their respective generation starting from the first 
proliferated generation defined as “1” (undevided is”0”). 
	  = ((1%	 × 	1) + (2%× 2) + (3%× 3	) + (4% × 4) + (5% × 5) + (6%× 6)) 	 
PI= Proliferationindex, n= CFSE Dilution, % percentage of total cells 
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2.5.3 Treg suppression assay 
CFSE-labeled T cells (5x104), as described above, were co-cultured in a 1:1 ratio with anti-
CD3/CD28 antibody-conjugated beads (Life Technologies) and varying concentrations of Tregs 
from Apoe-/- Cd4Cre+ and Cd40lflox/flox Apoe-/- Cd4Cre-  mice for 72 h. T cell proliferation was 
determined by CFSE dilution measured by flow cytometry. 
 
2.6 Biomolecular methods 
2.6.1 RNA isolation 
All reagents were obtained from Qiagen if not stated otherwise. Total ribonucleic acid (RNA) was 
isolated from tissue stored in RNAlater (Ambion, Thermo Scientific) at -80°C according to the 
protocol of Qiagen RNeasy Mini Kit II. The entire procedure was performed under RNase-free 
conditions and partly on ice. The tissue samples were thawed and the amount of tissue was 
determined to use a maximum of 100 mg per sample. A stainless steel bead (7 mm diameter) 
was added along with the tissue sample removed from RNAlater to a 2 ml tube and kept on ice. 
Before placing the tube in the TissueLyser with a 12-Tube LT Adapter 1 ml Qiazol Lyses 
Reagent was added. Lysis was performed for 5 min at 50 Hz. The lysate was transferred to a 
new microcentrifuge tube and incubated at room temperature for 5 min so nucleoprotein 
complexes were able to dissociate. After incubation 200 µl Roti® - Phenol/C I (Roth, Karlsruhe, 
Germany) was added and the tube was shaken vigorously for 15 s. Another incubation step for 3 
min. at room temperature was performed and thereafter all samples were centrifuged at 12,000 
x g for 15 min at 4°C. After centrifugation 3 (or 4) Phases appeared in the tube: a) an upper, 
colorless, aqueous phase containing RNA b) a white interphase c) a lower, red, organic phase 
and d) a clear phase below the red phase (only in tissues with high fat content). The upper, 
aqueous phase was transferred gently to a new tube without interfering with DNA- and protein-
containing phases. One volume of 70% ethanol was added to the transferred RNA-containing 
phase and the tube was vortexed. Up to 700 µl of sample was transferred to an RNeasy Mini 
spin column placed in a supplied 2 ml tube. After closing the lid, the sample was centrifuged for 
15 sec at 8,000 x g at room temperature. The flow-through was discarded. This procedure was 
repeated until the entire remainder of the sample was used. For digestion of potentially 
contaminating genomic DNA the ribonuclease (RNase)-Free DNase set supplied with DNase I, 
buffer RDD and RNase-free water was used. Lyophilized DNase I was dissolved in 550 µl of 
RNase-free water to prepare a DNase I stock solution. After adding 350 µl of buffer RW1 to the 
RNeasy spin column the column was centrifuged at 5000 x g for 15 sec at room temperature. 
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For each sample 10 µl DNase I stock solution were added to 70 µl buffer RDD. Subsequently, 
80 µl of DNase I incubation mix was directly added to the middle of the RNeasy spin column 
membrane and incubated for 15 min at room temperature. Following incubation 350 µl RW1 
buffer was applied to the RNeasy spin column and the column centrifuged for 15 sec at 8000 x 
g. The obtained flow-through was discarded. The membrane of the RNeasy spin column was 
washed twice with 500 µl buffer RPE supplied with 96% Ethanol. Following centrifuging the 
column for 15 sec at 8000 x g, a second drying step at 8000 x g for 2 min was performed. All 
flow-through was discarded. For elution of the RNA the RNeasy spin column was placed in a 
new 1.5 ml collection tube and 50 µl of RNase-free water was added to the membrane. The 
column was centrifuged for 1 min at 8000 x g. Purity and yield of total RNA of each preparation 
were assessed spectrophotometrically at OD260/OD280 employing a nanodrop (Peqlab). A value 
of OD260/OD280 lower than 1.7 led to the disqualification of these samples. Samples were stored 
at -80°C until further use. 
2.6.2 cDNA synthesis 
RNA isolated from aortas was reverse transcribed with the SuperScript® VILO™ complimentary 
DNA (cDNA) Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. In brief, 4 µl 
5X VILO™ Reaction Mix and 2 µl 10X SuperScript® Enzyme Mix were added on ice. The 
concentration of RNA adjusted to the sample with the lowest concentration with DNAse-/RNAse-
free water (Sigma Aldrich) for equal amounts of starting material, and 14 µl of RNA were added. 
The total reaction volume was 20 µl. The content of the tubes was mixed gently and incubated at 
25°C for 10 min. Subsequently, the mixture was incubated at 42°C for 1 h and the reaction 
stopped by heating to 85°C for 5 min.  
2.6.3 Real-time polymerase chain reaction 
Quantitative PCR (qPCR) was performed with TagMan® gene expression assays (Thermo 
Fisher Scientific) on a 7900HT Fast Real Time PCR system (Thermo Fisher Scientific). 
TagMan® pobes were obtained from Thermo Fisher Scientific. TagMan® probes are listed 
below (see 2.6.4). 
For a single real-time PCR reaction 
5 µl   2 ng/µl cDNA, 
5µl   2x FAST® Mastermix 
0.5µl  TagMan® assay 
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were mixed on ice. If higher sample numbers were processed a master mix was prepared in a 
tube on ice and kept in the dark. Each PCR reaction was pipetted in duplicate. The PCR 
program was composed of an initial step at 95°C for 20 sec followed by 40 cycles of each 1 sec 
at 95°C and 20 sec at 60°C. Subsequently, a dissociation cycle was performed with 15 sec at 
95°C, 1 min at 60°C, and followed by 15 sec at 95°C with a 2% ramp rate. The obtained data 
from real-time PCR for the respective genes and tissues was analyzed by applying the 2∆∆  
method.210 β-actin expression was considered to be equal in a respective tissue upon 
administration of atherogenic diet and therefore was used as reference. 
2.6.4  Table 6: List of genes and TagMan® probes for gene expression analysis 
Gene TagMan probe 
IL-1β 
Mm00434228_m1 (Thermo 
Fisher Scientific) 
IL-2 
Mm01340213_m1 Thermo Fisher 
Scientific 
IL-6 
Mm00446190_m1 Thermo Fisher 
Scientific 
Il-10 
Mm00439614_m1 Thermo Fisher 
Scientific 
IL-12 p35 
Mm00434165_m1 Thermo Fisher 
Scientific 
Foxp3 
Mm00475162_m1 Thermo Fisher 
Scientific 
IFNγ 
Mm01168134_m1 Thermo Fisher 
Scientific 
CD69 
Mm01183378_m1 Thermo Fisher 
Scientific 
TGFβ 
Mm01178820_m1 Thermo Fisher 
Scientific 
TNFα 
Mm00443258_m1 Thermo Fisher 
Scientific 
2.7 Statistical analysis 
Data is presented as average ± standard deviation (SD). Student’s t test was used to analyze 
data for statistical significance with GraphPad Prism v.5 software (GraphPad Software Inc., La 
Jolla, USA). A p value of <0.01 was considered statistical significant.  
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2.8 Buffers 
Tissue lysis buffer 
10 mM Tris 
10 mM EDTA 
10 mM Sodium chloride (NaCl) 
0.5% Sarcosyl (N-Lauroylsarcosine sodium salt) 
adjusted to 0.5 Liter with distilled H2O. 
 
Erythrocyte lysis buffer 
10 mM Potassium hydrogen carbonate (KHCO3) 
150 mM Ammonium chloride (NH4Cl) 
0.1 mM EDTA 
adjusted to 1 Liter with distilled H2O and pH 7.2-7.4. 
FACS buffer 
1x PBS 
0.5% BSA 
0.01% Sodium azide (NaN3) 
Fixation/Permeabilization working solution (from Foxp3 staining set, eBioscience) 
Dilute 3x Fixation/Permeabilization 3 times in Fixation/Permeabilization diluent. 
Permeabilization buffer (from Foxp3 staining set, eBioscience) 
Dilute the 10x Permeabilization Buffer (00-8333-56) 10 times in distilled water. 
Dynal isolation buffer 
1x PBS 
0.1% BSA 
2 mM EDTA 
CFSE label buffer 
1x PBS 
0.1% BSA 
Citrate saline buffer  
135 mM Potassium chloride 
15 mM Sodium citrate 
In distilled H2O. 
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Oil Red O-stock solution 
1 g Oil Red O (Sigma Aldrich) 
200 ml 99% 2-propanol 
2.9 Media 
T cell medium 
All reagents were obtained from (A) Thermo Scientific and (B) Sigma Aldrich. 
RPMI1640 with Glutamax (A) 
10% FBS (A) 
100 U/ml Penicillin (A)  
100 µg/ml Streptomycin (A) 
10 mM Hepes (B) 
1x MEM non-essential amino acids (B) 
1 mM Sodium pyruvate (B) 
50 µM 2-Mercaptoethanol (B) 
D10 medium 
DMEM (Dulbecco’s Modified Eagle Medium) with 4,5 g/L glucose and pyruvate (Life 
Technologies) 
10% FBS 
100 U/ml Penicillin  
100 µg/ml Streptomycin  
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 3 RESULTS 
3.1 Experimental setup of the cell type-specific CD40-CD40L study and 
generation of cell type-specific deletion of CD40 and CD40L. 
Apoe-/- mice were crossed with Cd40fl/fl or Cd40lfl/fl mice and bred with mice expressing the 
recombinase cre under control of a cell type-specific promotor. The resulting cre+ animals and 
their cre- littermates were sacrificed at the age of 28 weeks on regular chow diet or after 
consuming a hypercholesterolemic diet (0.15% cholesterol, 21% fat) for 6 weeks. Cryo sections 
(8µm) of the aortic sinus and paraffin sections of the aortic arch (4µm) including its main branch 
points (brachiocephalic trunk, left common carotid artery, left subclavian artery) were prepared 
and analyzed for atherosclerotic lesion size, histology, and cellular composition of the 
atherosclerotic plaques. Flow cytometry was performed to monitor potential changes in the 
abundance, activation status and survival of immune cells in lymph nodes, blood, and spleen 
(Figure 4 A).To confirm the cell type-specific deletion of either CD40 or CD40L different assays 
were used, depending on the cell type that was supposed to be depleted of CD40 or 
CD40L.Flow cytometric measurements of splenocytes from Apoe-/-Cd40fl/flCd11cCre+ and Apoe-/-
Cd40fl/flCd11cCre- animals demonstrated specific deletion of CD40 on B220-/CD11c+ 
splenocytes (Figure 4 B). To prove the specific deletion of CD40L on CD4+ T cells via cre-
recombinase, CD4+ and CD4- cells were isolated and analyzed for CD40L mRNA expression. 
Indeed, mRNA isolated from isolated CD4+ cells, or isolated CD4- cells of the Apoe-/-
Cd40lfl/flCd4Cre+ mice did not show detectable CD40L expression, even after 40 cycles of the 
qPCR program. In contrast mRNA from CD4+ cells isolated from Apoe-/-Cd40lfl/flCd4Cre- mice 
showed a CD40L expression after 11 to 18 cycles of the qPCR program (Figure 4 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Experimental setup of the cell type-specific CD40-CD40L study. 
(A) Apoe-/-mice were crossed with Cd40fl/fl or Cd40lfl/fl mice and a cell type-specific cre-recombinase was introduced 
through breeding with cre+ or cre- mice. (B) The cell type-specific deletion of CD40 in CD11c+ cells is shown via a 
representative flow cytometric histogram (right), CD40 expression on splenic CD11c+ cells from wild type (Apoe-/-
Cd40
fl/fl
CD11cCre
-), Apoe-/-Cd40fl/flCD11cCre+, mice with a global CD40 deletion (Apoe-/-Cd40-/-) and a fluorescence 
minus one (FMO) are represented. (C) Cycle threshold of CD40L mRNA (left), analyzed via qPCR, from isolated CD4+ 
or CD4-splenocytes of Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40lfl/flCd4Cre- mice (n.d.= not detectable). 
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3.2 T cell-specific deletion of CD40L decreases atherogenesis in early 
and late stage of atherosclerosis and promotes a stable plaque 
phenotype. 
CD40L is predominately found on activated cells, the most characteristic of which are activated 
and/or differentiated T cells251. Therefore we started our studies by investigating the role of role 
of T cell-specific CD40L in atherosclerosis. To identify and characterize the possible effect of T 
cell-specific CD40L we decided to use a mild form of hyperlipidemia for our initial experiments, 
where we fed mice for 28 weeks on a normal chow diet. Prior to our studies, we wanted to 
exclude any secondary effects of T cell CD40L deficiency on the cholesterol mechanism or 
blood parameters. Accordingly, we measured body weight, plasma cholesterol concentration 
and basic hematological parameters of 28 week old male Apoe-/-Cd40lfl/fllCd4Cre+ and Apoe-/-
Cd40lfl/flCd4Cre- mice. These analyses did not reveal any significant differences between Apoe-/-
Cd40lfl/fllCd4Cre+ and Apoe-/-Cd40lfl/flCd4Cre- mice (Table7). 
Table 7. Body weight, hematological 
parameters, and plasma cholesterol 
content in Apoe-/-Cd40lfl/fllCd4Cre- mice 
(n=17) and Apoe-/-Cd40lfl/flCd4Cre+mice 
(n=19. Data is presented as mean±SD. 
 
 
 
 
Since the deletion of CD40L on T cells did not interfere with blood parameters or cholesterol 
metabolism we analyzed the atherosclerotic lesion area in the aortic arch and in the aortic sinus.  
Quantification of atherosclerotic lesion development in mouse models is of primary interest, 
since it enables the evaluating of risk factors and disease development. The histological 
examination of H&E-stained paraffin sections of the aortic arch revealed significantly reduced 
lesion areas in Apoe-/-Cd40lfl/fllCd4Cre+ mice. The absolute atherosclerotic lesion area in the 
aortic arch, whit its three main branch points ( brachiocephalic trunk, left common carotid artery 
and left subclavian artery) of 28 week old male Apoe-/-Cd40lfl/fllCd4Cre+ mice displayed a nearly 
30% reduction in lesion area compared to Apoe-/-Cd40lfl/flCd4Cre- littermate controls  
(Figure 5 A, B). 
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Figure 5. T cell-specific deletion of CD40L does reduce early plaque formation in the aortic arch. 
Total atherosclerotic plaque area sections hematoxylin-and-eosin-stained longitudinal section of the aortic arch, 
including the brachiocephalic trunk, left carotid, and left subclavian artery from 28 week-old male  
Apoe
-/-
Cd40l
fl/fl
Cd4Cre
-
 or Apoe
-/-
Cd40l
fl/fl
Cd4Cre
+ mice. (A) Quantification of total plaque size and (B) representative 
photomicrographs of hematoxylin-and-eosin-stained longitudinal section. n=7 (Apoe-/-Cd40lfl/flCd4Cre-), n=8 (Apoe-/-
Cd40l
fl/fl
Cd4Cre
+) Scale bar = 200 µm. Data is presented as mean±SD. *=p<0.01 
To further analyze the effect of the T cell-specific CD40L deficiency on lesion initiation and to 
validate our finding of a significantly decreased absolute plaque area in the aortic arches of 
Apoe-/-Cd40lfl/flCd4cre+ mice, we analyzed lesion size in cryosections of the aortic sinus, as a 
second main region of lesion progression. This analysis revealed a 30% reduction in absolute 
and relative lesion area in Apoe-/-Cd40lfl/flCd4Cre+ compared to Apoe-/-Cd40lfl/flCd4Cre- mice 
confirming the findings in the aortic arch (Figure 6 A-C).  
 
Figure 6. T cell-specific deficiency of CD40L alleviates atherosclerosis 
Quantification of lesion area and atherosclerotic plaque area in cross-sections at indicated positions of the aortic sinus 
at different stages from 28-week-old, male Apoe-/-Cd40lfl/flCd4Cre- or Apoe-/-Cd40lfl/flCd4Cre+ mice. (A) Lesion areas 
in stages 104-624. (B) Average of lesions area stages 312-520 as percentage of total vessel area. (C) Representative 
photomicrographs showing Oil-Red-O-stained sections. n= 13-17 (Apoe-/-Cd40lfl/flCd4Cre-); n=16-19  
(Apoe-/-Cd40lfl/flCd4Cre+) Scale bar = 200 µm. data is presented as mean±SD:*=p<0.0 
Measuring lesion size is required to determine if a particular pharmacological treatment or 
genetic loss/enhancement of function has a direct effect on atherosclerosis. However, evaluation 
of atherosclerosis should not solely be determined by measuring the size of an atherosclerotic 
lesion. In fact, even more information about the process of atherogenesis can be gathered from 
a detailed histological and morphological examination as it pertains to the cellular and 
extracellular composition of the lesion which may offer significant mechanistic insight into the 
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atherogenic process itself. Thus, we determined the cellular composition of the lesions of the 
aortic sinus from 28 week- old male Apoe-/-Cd40lfl/fllCd4Cre+ Apoe-/-Cd40lfl/fllCd4Cre- mice. Our 
detailed immunohistomorphological quantification of lesional macrophages and SMCs, the most 
abundant cell types in atherosclerosis, revealed a significantly decrease in infiltrated 
macrophages and a significant increase in the SMC content in the late stage lesions of the aortic 
sinus of 28 week- old male Apoe-/-Cd40lfl/fllCd4Cre+ mice, characteristics which are associated 
with a stable plaque phenotype (Figure 7 A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Lack of T cell-specific CD40L alters cellular plaque composition. 
Immunofluorescent stainings in cross-sections of the aortic sinus from 28-week-old, male Apoe-/-Cd40lfl/flCd4Cre- or 
Apoe
-/-
Cd40l
fl/fl
Cd4Cre+
 mice. Quantifications and representative photomicrographs are displayed for each staining. 
The dashed lines separate the atherosclerotic lesion from the lumen (L). Analyzed for (A) MAC3+ area and (B) α-
SMA+ area. n=8-10 (Apoe-/-Cd40lfl/flCd4Cre) n=7-10 (Apoe-/-Cd40lfl/flCd4Cre+). Scale bar = 200 µm. Data is presented 
as mean±SD.*=p<0.01 
Immunohistological stainings for CD4+ cells demonstrated a lower amount of CD4+ cells in the 
plaque of 28 week- old Apoe-/-Cd40lfl/fllCd4Cre+ mice compared to the littermate controls  
(Figure 8 A, B). 
 
Figure 8. Lack of CD4 specific CD40L alters cellular plaque composition and reduces invasion of CD4
+
 cells. 
Immunofluorescent stainings in cross-sections of the aortic sinus from 28-week-old, male Apoe-/-Cd40lfl/flCd4Cre- or 
Apoe
-/-
Cd40l
fl/fl
Cd4Cre+
 mice analyzed for CD4+ cells. The dashed lines separate the atherosclerotic lesion from the 
lumen (L). Quantification (A) and representative photomicrographs (B) are displayed for each staining.  
n=9-10 (Apoe-/-Cd40lfl/flCd4Cre) n=8-10 (Apoe-/-Cd40lfl/flCd4Cre+) Scale bar = 200 µm. Data is presented as 
mean±SD. 
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The first aim of the study was to provide a broad overview about the role of T cell-specific 
CD40L in the different stages of atherosclerosis as well as under the influence of different 
hyperlipidemic conditions. To this end we employed a second mouse model to identify an 
association between T cell CD40L deficiency and appearance of atherosclerotic lesions in more 
severe hypercholesterolemia. This status is achieved by feeding a fat- and cholesterol-enriched 
Western type diet for 6 weeks. Apoe-/-Cd40lfl/flCd4Cre+ mice showed a 50% reduced lesion area 
compared to littermate controls consuming a WD for 6 weeks (Figure 9 A-C). 
 
Figure 9 T cell-specific CD40L deficiency influence diet induced atherosclerosis. 
Quantification of lesion area and atherosclerotic plaque area in cross-sections at indicated positions of the aortic root 
at different stages after administering a hypercholesterolemic diet for 6 weeks to male Apoe-/-Cd40lfl/flCd4Cre- or  
Apoe
-/-
Cd40l
fl/fl
Cd4Cre
+ mice. (A) Lesion areas in stages 104-624. (B) Average lesion area in stages 312-520 as 
percentage of total vessel area. (C) Representative photomicrographs of Oil Red O-stained sections.  
n=11-14 (Apoe-/-Cd40lfl/flCd4Cre-), n=10-13 (Apoe-/-Cd40lfl/flCd4Cre+) Scale bar = 200 µm. Data is presented as 
mean±SD.*=p<0.01; ****=p<0.0001 
Resembling the immunohistological data from the 28 weeks study, the reduction in plaque size 
in diet-induced atherosclerosis was also accompanied by changes in the cellular composition in 
the plaques of Apoe-/-Cd40lfl/fllCd4Cre+ mice. Analysis of the distribution of single plaques scaled 
by size showed that Apoe-/-Cd40lfl/fllCd4Cre+ tend to acquire more “small-” and “medium-” sized 
plaques, whereas Apoe-/-Cd40lfl/fllCd4Cre- mice displayed more than 60% of their plaques in the 
“large” plaque tertile (Figure 10 A). In addition, the plaques of the Apoe-/-Cd40lfl/fllCd4cre+ mice 
presented more nuclei per area resembling a higher cellularity of the atherosclerotic plaque 
(Figure 10 B). This increased cellularity was mostly derived from an increase in SMCs, 
suggesting a less inflammatory and rather pro-fibrotic plaque phenotype. This hypothesized less 
inflammatory plaque phenotype was further substantiated by the decreased number of infiltrated 
macrophages in the lesions of Apoe-/-Cd40lfl/fllCd4cre+ mice (Figure 7 C, D). 
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Figure 10. Lack of T cell-specific 
CD40L alters cellular plaque 
composition in diet induced 
atherosclerosis. 
Quantifications of immunofluorescent 
staining in cross-sections of the aortic 
sinus from Cd40lfl/flCd4cre- and 
Cd40l
fl/fl
Cd4cre
+ mice after administering 
a hypercholesterolemic diet for 6 weeks. 
Quantifications are displayed for each 
staining.  
(A) Analyzed for distribution of “large” 
(>20*103µm),”medium” (10-20*103µm) 
and “small” (<10*103µm) plaque sizes, 
(B) plaque cellularity represented as 
DAPI+ nuclei per mm2 plaque area,  
(C) α-SMA+ area  and MAC3+ area (D). 
n=8-10 (Apoe-/-Cd40lfl/flCd4Cre) n=7-10 
(Apoe-/-Cd40lfl/flCd4Cre+). Data is 
presented as mean±SD.*=p<0.01 
 
By immunohistochemistry we were able to demonstrate, that the variance of plaque sizes in this 
model was also attended by a smaller amount of infiltrated CD4+ cells in the plaque of ascending 
aortas of Apoe-/-Cd40lfl/fllCd4Cre+ mice compared to those of littermate controls (Figure 11 A, B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Lack of T cell specific CD40L alters cellular plaque composition and reduces invasion of CD4
+
 cells 
in diet accelerated form of atherosclerosis. 
Immunofluorescent stainings in cross-sections of the ascending aorta after administering a hypercholesterolemic diet 
for 6 weeks to male Apoe-/-Cd40lfl/flCd4Cre- or Apoe-/-Cd40lfl/flCd4Cre+ mice analyzed for CD4+ cells The dashed lines 
separate the atherosclerotic lesion from the lumen (L). (A) Quantifications of analyzed CD4+ cells and representative 
photomicrographs (B) are displayed for each staining. n=8-10 (Apoe-/-Cd40lfl/flCd4Cre) n=7-10 (Apoe-/-
Cd40l
fl/fl
Cd4Cre
+) Scale bar = 200 µm. Data is presented as mean±SD. 
In sum, mice lacking CD40L on T cells showed smaller lesions and more stable plaque 
phenotypes characterized by a decreased infiltration of CD4+ cells in both models of early and 
late stage atherosclerosis and under the influence of different hypercholesterolemic burden. 
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3.3 T cell-specific CD40L deficiency decreases systemic and thymic 
Treg abundance without altering their regulatory capacity 
Interestingly, our data of both models, advanced atherosclerosis after 28 week chow diet and 
accelerated atherosclerosis after 6 week WD, indicated that the abundance of lesional  
CD4+ T cells is decreased in Apoe-/-Cd40lfl/fllCd4Cre+ mice. To evaluate this phenomenon, to test 
its local or systemic appearance and to examine the reason for the reduced CD4+ T cell 
population in Apoe-/-Cd40lfl/fllCd4Cre+ mice, we analyzed the abundance of CD4+ Tregs in Apoe-/-
Cd40lfl/fllCd4Cre+ mice.  
Flow cytometric measurements of lymphoid organs and blood of Apoe-/-Cd40lfl/fllCd4cre- and 
Cre+ animals were used to investigate possible changes in the Treg abundance. These analyses 
showed that the lack of T cell-specific CD40L led to significant decreased Treg numbers. As 
shown by flow cytometry of Foxp3+ T cells in spleen, lymph node and blood, the results 
suggested a systemic rather than local phenomenon causing the reduced CD4+ population 
(Figure 12 A, B, C). 
 
Figure 12. Loss of CD4
+
 specific CD40L decreases systemic and aortic Treg abundance. 
Flow cytometric analysis of splenic, lymphoid and blood cells for Foxp3+ cells from 28 weeks old, male Apoe-/-
Cd40l
fl/fl
Cd4Cre
+ or Apoe-/-Cd40lfl/flCd4Cre- mice. (A) Flow cytometry analysis of splenic cells, (B) lymphoid cells and 
(C) blood cells, from Apoe-/-Cd40lfl/flCd4Cre+ or Apoe-/-Cd40lfl/flCd4Cre- mice analyzed for Foxp3+ cells.  
n= 8-10 (both groups). Data is presented as mean±SD. *=p<0.01;**=p<0.001; ****=p<0.0001 
In addition to the systemic reduction of Tregs, the immunohistological stainings for Foxp3+  cells 
in the plaque of ascending aorta of Apoe-/-Cd40lfl/fllCd4Cre+ mice at 28 weeks of age also 
revealed decreased lesional Treg numbers (Figure 13 A, B).  
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Figure 13. Loss of CD4
+
 specific CD40L decreases systemic and aortic Treg abundance. 
Immunofluorescent staining in cross-sections of the ascending aorta analyzed for Foxp3+ cells from 28 weeks old, 
male Apoe-/-Cd40lfl/fl Cd4Cre+ or Apoe-/-Cd40lfl/flCd4Cre- mice. The dashed lines separate the atherosclerotic lesion 
from the lumen (L). (A) Quantification of immunofluorescent cross sections of the ascending aorta analyzed for 
Foxp3+ and representative photomicrographs (B) are displayed for staining of Foxp3+ cells. n= 8-10 (both 
groups).Scale bar = 200 µm. Data is presented as mean±SD. *=p<0.01 
To verify our findings of an overall reduction of Treg numbers in Apoe-/-Cd40lfl/flCd4cre+ mice 
compared to their littermate controls, we repeated flow cytometric measurements and 
immunohistological stainings with lymph nodes, spleens, blood and ascending aortas of animals 
which consumed a WD diet for 6 weeks. Similar data were obtained by flow cytometric analysis 
of the systemic Treg abundance in the diet-accelerated model of atherosclerosis. The 
percentage of Foxp3+ cells was significantly decreased in lymph nodes, spleens and blood of 
Apoe-/-Cd40lfl/fllCd4Cre+ mice following 6 weeks of WD (Figure 14 A-C). These results suggest a 
cholesterol-independent connection between T cell-specific CD40L deficiency and decreased 
systemic Treg numbers.  
 
Figure 14. Loss of T cell-specific CD40L decreases systemic and aortic Treg abundance in diet-induced 
atherosclerosis. 
Flow cytometry analysis of Foxp3+ cell distribution in cell suspensions from spleen, lymph nodes and blood from 
Apoe
-/-
Cd40l
fl/fl 
Cd4Cre
+ or Apoe-/-Cd40lfl/flCd4Cre- mice after consuming a hypercholesterolemic diet for 6 weeks. 
Analysis of (A) lymphoid, (B) splenic and blood cells (C), n= 4 (both groups). Data is presented as mean±SD. 
****=p<0.00=1 
To investigate whether the systemic and local reduction of Treg numbers in blood, lymphoid 
organs, and aortic lesions may be a consequence of decreased development or a higher 
apoptotic rate of these cells, thymic cell suspensions were assessed by flow cytometry. These 
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analyses revealed significantly decreased numbers of thymic Foxp3+ cells in  
Apoe-/-Cd40lfl/fllCd4Cre+ mice. Both developmental stages of CD4+Tregs, namely CD25-Foxp3+ 
and CD25+Foxp3+ cells, were significant reduced in Apoe-/-Cd40lfl/fllCd4Cre+ animals when 
compared to their littermate controls (Figure 15 A, B). These results suggest a role for T cell-
specific CD40L in the induction and maturation of CD4+Tregs. 
 
Figure 15. Lack of CD40L on T cells reduces thymic Treg abundance. 
Abundance of thymic CD4+Cd25+Foxp3+ cells and CD4+CD25-Foxp3+ cells in Apoe-/-Cd40lfl/fllCd4Cre- or  
Apoe
-/-
Cd40l
fl/fll
Cd4Cre
+
 mice assayed by flow cytometry. (A) Quantification of percentage of CD4+CD25+Foxp3+ cells 
(right) and CD4+CD25-Foxp3+ cells (left). (B) Representative plots gated on living CD4+ cells are displayed. n=5 for 
both genotypes. Data is presented as mean±SD.*=p<0.01 
The reduced number of Treg and precursors in the thymus was not accompanied by increased 
Annexin-V staining of CD4+CD25+ cells indicating a significantly decreased rate of apoptosis of 
Tregs in the thymus (Figure 16 A-C).  
 
Figure 16. Lack of CD40L on T cells does not alter the apoptotic tendency of thymic Tregs. 
(A) Quantification of thymic CD4+CD25+ cells in Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-Cd40lfl/fllCd4Cre+ mice assayed by 
flow cytometry. CD4+CD25+ cells of thymic cell suspensions were analyzed by flow cytometry for apoptosis by 
Annexin-V binding and Live/Dead fixable staining exclusion. Quantification (B) and representative plots (C) n=9 
(Apoe-/-Cd40lfl/fllCd4Cre-); n=6 (Apoe-/-Cd40lfl/fllCd4Cre+). Data is presented as mean±SD. ***=p 0.0001-0.001 
Apoe-/-Cd40lfl/fllCd4Cre+ mice showed a strong reduction of Tregs. However, this phenotype 
appeared non-linked to a higher atherosclerotic burden or a pro-inflammatory plaque phenotype 
as reflected in smaller lesion size and decreased numbers of immune cell infiltrates. In contrast 
and somewhat counterintuitive the reduced percentage of anti-inflammatory Tregs was 
accompanied by smaller, more stable lesions in both mild and accelerated atherosclerosis. 
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Accordingly, we hypothesized that the mild anti-inflammatory and anti-atherosclerotic plaque 
phenotype may relate to an improved suppressive capacity per single Treg in  
Apoe-/-Cd40lfl/fllCd4Cre+ mice. To validate our assumptions we performed a suppression assay 
by co-culturing CFSE-labeled and anti-CD3/CD28-stimulated CD4+ T cells with varying numbers 
of Tregs from Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-Cd40lfl/fllCd4Cre+ mice. Notably, flow cytometric 
analysis of CSFE dilution after 72 hours did not show any difference in the fraction of divided 
conventional T cells, indicating a similar suppressive capacity between wildtype- and CD40L-
deficient Tregs (Figure 17 A).  
Figure 17. T cell-specific deficiency of  
CD40L does not influence the suppressive 
capacity of Treg cells. 
Varying numbers of Tregs isolated from spleen 
of Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-
Cd40l
fl/fll
Cd4Cre
+ mice were co-cultured with 
CFSE labeled CD4+CD25- conventional 
responder T cells from Apoe-/-Cd40lfl/fllCd4Cre- 
mice and anti CD3/Cd28 stimulatory beads for 
72 hours. CFSE dilution was measured and 
frequency of divided responder T cells is 
displayed. n=5 (Apoe-/-Cd40lfl/flCd4Cre-); n= 5 
(Apoe
-/-
Cd40l
fl/fl
Cd4Cre
+
). Data is presented as 
mean±SD. 
 
To recapitulate this section, we can state that the analysis of the abundance and fitness from 
systemic and thymic Tregs from Apoe-/-Cd40lfl/fllCd4Cre+ mice showed a decrease in Treg 
numbers, yet, their suppressive activity and apoptotic phenotype remained unchanged.  
3.4 T cell-specific deletion of CD40L results in an anti-inflammatory 
phenotype and reduced T effector cell function due to systemically 
decreased concentration of IL-2  
Despite of diminished abundance of Tregs, the plaque size in Apoe-/-Cd40lfl/fllCd4Cre+ mice was 
decreased. Therefore, we investigated whether the reduction of lesional CD4+ T cell- and Treg 
numbers were caused by, or resulted in changes of pro-inflammatory genes. Accordingly, we 
analyzed gene expression in lymph node and spleen of Apoe-/-Cd40lfl/fllCd4Cre- or  
Apoe-/-Cd40lfl/fllCd4Cre+ mice at 28 weeks of age revealing a widespread modification of pro- and 
anti-inflammatory gene distribution in mice lacking CD40L on T cells (Figure 18 A, B).  
The changes in expression pattern were accompanied by a markedly reduced expression of the 
Cd4 gene. Furthermore Cd69 as a marker for T cell activation was weakly expressed in mRNA 
in lymph node and spleen of Apoe-/-Cd40lfl/fllCd4Cre+ mice after 28 weeks of chow diet. We also 
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analyzed Il2 mRNA levels finding a significant reduction of Il2 expression in lymph node and 
spleen of Apoe-/-Cd40lfl/fllCd4Cre+ mice (Figure 21 A, B). Concurrently to the decremented 
expression of T cell-associated genes Cd4, Cd69 and, Il2 the pro-inflammatory Th1-associated 
genes Ifng, Tnfa, and Il1b also showed a significantly reduced expression in lymph nodes and 
spleen of mice lacking CD40L on CD4+ cells. In addition, the expression of the pro-inflammatory 
cytokine Il12p35 was equally disturbed in lymphatic organs of Apoe-/-Cd40lfl/fllCd4Cre+ mice 
(Figure 18 A, B). In contrast, expression analysis of lymph node and spleen from Apoe-/-
Cd40lfl/fllCd4Cre+mice revealed a significant increase in the anti-inflammatory cytokines Il10 and 
Tgfb. The diminished number of Tregs, as seen by flow cytometry (Figure 17 and 18) and the 
impaired expression of Cd4, was supported by the significantly reduced expression of the Treg-
associated Foxp3 gene (Figure 18 A, B). 
 
Figure 18. T cell-specific deletion of CD40L causes shift to a more anti-inflammatory milieu. 
Relative mRNA expression analyzed by quantitative PCR in lymph nodes and spleen of male 28 weeks old Apoe-/-
Cd40l
fl/fll
Cd4cre
-
 or Apoe-/-Cd40lfl/fllCd4cre+ mice. Red rectangles symbolize pro-inflammatory genes, green rectangle 
symbolizes anti-inflammatory genes. Relative mRNA expression in (A) lymph node and in (B) spleen of male 28 
weeks old Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-Cd40lfl/fllCd4Cre+ mice. n=13-17(Apoe-/-Cd40lfl/flCd4Cre-); n= 16-19 
(Apoe
-/-
Cd40l
fl/fl
Cd4Cre
+
). Data is presented as mean±SD. *=p<0.01;**=p<0.001;***=p 0.0001-0.001;****=p<0.0001 
Taken together these data indicate an altered inflammatory phenotype in Apoe-/-Cd40lfl/fllCd4Cre+ 
mice, compared to littermate controls. This was demonstrated by the down regulation of 
inflammatory gene expression, the upregulation of anti-inflammatory genes and an altered 
activation status of the T cell and Treg population. The data of the immunohistological analyses, 
flow cytometry measurements and gene expression assays all suggested an altered T cell 
phenotype. Hence, we hypothesized that the reduced T cell abundance was due to an impaired 
reactivity of these cells. To test for changes in proliferation of T cells from  
Apoe-/-Cd40lfl/fllCd4Cre+ mice compared to littermate control, an in vitro proliferation assay was 
performed (Figure 19 A-D). Anti-CD3 and anti-CD28 stimulation (72h) was used to mimic the 
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interaction with antigen-presenting cells via TCR-Ligation and costimulation in vivo. Upon this 
stimulation, flow cytometric measurements of CFSE dilution in activated T cells and the 
calculation of a proliferation-index as a marker of cell-expansion demonstrated comparable 
values between Apoe-/-Cd40lfl/fllCd4cre- and Apoe-/-Cd40lfl/fllCd4cre+ mice (Figure 19 A). The 
indistinguishable proliferation is also reflected by representative histograms of CFSE dilution in 
the CD4+ cell population from Apoe-/-Cd40lfl/fllCd4Cre- and Apoe-/-Cd40lfl/fllCd4Cre+ mice  
(Figure 19 B). The percentage of cells per stage of division did also not reveal any differences in 
the proliferation pattern between Apoe-/-Cd40lfl/fllCd4Cre- and Apoe-/-Cd40lfl/fllCd4Cre+ mice 
(Figure 19 C). Based on the fact that the majority of T cells responds to IL-2, and produce it 
upon activation, differences in responsiveness in a proliferative assay can be partially reflected 
by differences in IL-2 production by the responding T cells311. Indeed, ELISA of the cell culture 
supernatant of the cultured T cells revealed, that the concentration of IL-2 also did not differ 
between T cells isolated from Apoe-/-Cd40lfl/fllCd4Cre- and Apoe-/-Cd40lfl/fllCd4Cre+ mice  
(Figure 19 D).  
Figure 19. Lack of T cell-specific CD40L 
does not influence in vitro proliferation of 
CD4
+
 cells. 
In vitro proliferation assay of Cd4+ cells of 
Apoe
-/-
Cd40l
fl/fll
Cd4cre
- or Apoe-/-
Cd40l
fl/fll
Cd4Cre
+ mice. CD4+ cells isolated 
from spleen of Apoe-/-Cd40lfl/fllCd4Cre- or 
Apoe
-/-
Cd40l
fl/fll
Cd4Cre
+ mice were labeled with 
CFSE and cultured anti CD3/CD28-stimulatory 
beads for 72 hours. CFSE dilution was 
measured and frequency of divided CD4+ cells 
displayed. (A) Quantification of proliferation 
capacity displayed as proliferation index (fold 
expansion over the culture time). (B) 
Representative histograms for CFSE dilution 
of Apoe-/-Cd40lfl/fllCd4Cre- and Apoe-/-
Cd40l
fl/fll
Cd4Cre
+ CD4+ cells. (C) Alternative 
format to display CFSE dilution in CD4+ cells. 
(D) Quantification of IL-2 concentration via 
ELISA in cell culture supernatant after 72 
hours. n=5 (Apoe-/-Cd40lfl/flCd4Cre-); n= 5 
(Apoe
-/-
Cd40l
fl/fl
Cd4Cre
+
). Data is presented as 
mean±SD.190 
Taken together, in these antigen-unspecific proliferation assays we were not able to detect 
differences in the proliferation or in the IL-2 production of CD4+ cells from Apoe-/-Cd40lfl/fllCd4Cre- 
and Apoe-/-Cd40lfl/fllCd4Cre+ mice.  
The capability of T cells to proliferate and maintain cell-specific functions after exogenous 
CD28/CD3 stimulation appears unchanged in Apoe-/-Cd40lfl/fllCd4Cre+ mice. We questioned if the 
activation status of those cells differs in the two models of atherosclerosis previously employed. 
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By analyzing the CD62L-distribution on CD4+ cells in cell suspensions of lymph nodes and 
spleen by flow cytometric measurements we were able to detect that CD4+ cells of  
Apoe-/-Cd40lfl/fllCd4cre+ mice exposed a higher percentage of CD62L+ cells after 28 weeks of age 
(Figure 20 A, B, C). 
 
Figure 20. Lack of CD40L on T cells leads to a reduced number of activated CD4
+
T cells.  
Flow cytometric measurements of CD4+ cell populations in lymph nodes and spleen of male 28 weeks old  
Apoe
-/-
Cd40l
fl/fll
Cd4Cre
-
 or Apoe-/-Cd40lfl/fllCd4Cre+mice. Abundance of CD4+subtypes in (A) lymph nodes and (B) 
spleen of Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-Cd40lfl/fllCd4Cre+ mice assayed by flow cytometry. Representative plots 
gated on living CD4+ cells (C) are displayed. n=13-17 (Apoe-/-Cd40lfl/flCd4Cre-); n= 17-19 (Apoe-/-Cd40lfl/fl Cd4Cre+). 
Data is presented as mean±SD. *=p<0.01 
CD62L is also expressed on subsets of CD8+ cells, which can be further differentiated by their 
expression of CD44. The percentage of naïve (CD62L+CD44-) CD8+ T cells, were significant 
higher in Apoe-/-Cd40lfl/fllCd4Cre+ mice compared to Apoe-/-Cd40lfl/fllCd4Cre- mice. At the same 
time the percentage of central memory (CD62L+CD44+) CD8+ T cells and effector (CD62L-
CD44+) CD8+ T cells were reduced (Figure 21 A-C).  
 
Figure 21 Lack of CD40L on CD4
+
 cells leads to a reduced number of activated CD8
+
T cells.  
Flow cytometric measurements of CD8+ T cell populations in lymph nodes and spleen of male 28 weeks old  
Apoe
-/-
Cd40l
fl/fll
Cd4Cre
-
 or Apoe-/-Cd40lfl/fllCd4Cre+ mice. Abundance of CD8+ subtypes in (A) lymph nodes and (B) 
spleen of Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-Cd40lfl/fllCd4Cre+ mice assayed by flow cytometry. Representative plots 
gated on living CD8+ cells (C) are displayed. n=13-17 (Apoe-/-Cd40lfl/flCd4Cre-); n= 17-19 (Apoe-/-Cd40lfl/flCd4Cre+). 
Data is presented as mean±SD. *=p<0.01; **=p<0.001 
In summary, we show that the deletion of T cell-specific CD40L results in a decrease of 
activated CD4+ and CD8+ cells and an increase of naïve cells in both T cell compartments. 
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3.5 T cell-specific deletion of CD40L affects B cell phenotype and 
decreases IgG2b and IgM titers  
Since our experiments showed an altered activation status in T helper and T effector cells in 
Apoe-/-Cd40lfl/fllCd4Cre+ mice we next investigated whether the specific interaction of antigen-
binding and -presenting B cells and helper T cells is influenced. CD40 signaling by B cells is 
required for the generation of high titers of isotype-switched, high affinity antibody and for the 
development of humoral immune memory. The engagement of CD40 expressed on the surface 
of antigen-activated B cells by CD40L expressed on activated CD4+ T cells is essential for the 
initiation and progression of a thymus-dependent humoral immune response236. In vivo, CD40 
engagement is required for germinal center formation and progression, as well as antibody 
isotype switching and affinity maturation. These processes are essential for the generation of 
memory B cells and long-lived plasma cells246,312. Accordingly, we investigated the alterations of 
phenotypes, i.e. differentiation and activation, of B cells upon T cell-specific deletion of CD40L. 
In a first step we analyzed the general abundance of immunoglobulin subclasses in the plasma 
of atherosclerotic mice with a multiplex bead-based assay. Indeed, hyperlipidemic mice with a 
deficiency of CD40L on T cells displayed decreased titers of IgG2b, IgE and IgM (Figure 22). 
Figure 22. T cell-specific CD40L deficiency 
decreases IgG2b and affects IgM plasma 
abundance. 
Antibody abundance in plasma of 28 week old Apoe-/-
Cd40l
fl/fll
Cd4Cre
+
 and Apoe-/-Cd40lfl/fllCdC4Cre- mice as 
analyzed by murine multiplex bead-based technology 
detection antibodies. Plasma level expression for  
respective Ig of 28 week old Apoe-/-Cd40lfl/fllCd4Cre+ 
and Apoe-/-Cd40lfl/fllCd4Cre- mice analyzed by multiplex 
bead-based technology n=10 (both groups). Data is 
presented as mean±SD. *=p<0.01; **=p<0.001 
 
 
 
Since the general concentration of immunoglobulin subclasses does not allow predictions about 
reactivity and concentration of Ig specifically binding atherosclerosis-associated antigens, such 
as oxLDL, we performed specific ELISA detecting oxLDL-binding immunoglobulins in plasma 
(Figure 23 A, B). We detected significant less oxLDL-specific total IgG, total IgG2b and IgM in the 
plasma of Apoe-/-Cd40lfl/fllCd4Cre+ mice (Figure 23 A). These results indicated decreased 
abundance of Ig subclasses which are considered as both pro-atherogenic (e.g. total IgG) and 
anti-atherogenic (e.g. IgM).   
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Figure 23. T cell-specific CD40L deficiency decreases oxLDL specific-IgG2b and oxLDL specific total IgG 
plasma abundance. 
Antibody abundance in plasma of 28 week old Apoe-/-Cd40lfl/fllCd4Cre+ and Apoe-/-Cd40lfl/fllCd4Cre- mice as analyzed 
by ELISA and respective murine detection antibodies. (A) Plasma abundance of antibodies detecting oxLDL of 28 
week old Apoe-/-Cd40lfl/fllCd4Cre+ and Apoe-/-Cd40lfl/fllCd4Cre- mice. Quantification for optic density acquired at 450nm 
wavelength of 1:20 diluted plasma is displayed. (B) Dilution series (1:20, 1:100; 1:1000) of plasma and respective 
ODs are displayed for each antibody. n=10 (Apoe-/-Cd40lfl/flCd4Cre-);n=10 (Apoe-/-Cd40lfl/flCd4cre+). Data is presented 
as mean±SD. *=p<0.01; ****=p<0.0001 
In a seccond step we assessed the B cell phenotypes in spleens of Apoe-/-Cd40lfl/fllCd4Cre+ mice 
with particular focus on their content of marginal zone and follicular B cells. Follicles are always 
adjacent to T cell zones and this arrangement allows activated follicular B cells and activated  
T helper cells to migrate towards each other and interact at the interface of these two  
areas 135,136,138. Hence, follicular B cells are particularly well-suited to participate in T cell-
dependent immune responses to protein antigens. IgD+CD21-/low or conventional follicular B cells 
undergo isotype switching and affinity maturation in the spleen and lymph nodes in response to 
T cell-dependent antigens and become either plasma cells that secrete large amounts of 
antibody, or memory B cells with the ability to produce specific antibodies upon re-exposure to 
the same antigen135,136,138. IgD-CD21low marginal zone B cells reside in the marginal sinus of the 
white pulp in the spleen and are positioned to immediately respond to antigens in the blood that 
are filtering through the spleen139.  
The analyses revealed an increased abundance of total B cells, a decreased percentage of 
follicular B cells and concordantly an increased percentage marginal zone B cells in spleen of  
Apoe-/-Cd40lfl/fllCd4Cre+mice (Figure 24 A,B). 
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Figure 24. Lack of CD40L on T cells alters B-cell abundance and affects B cell composition. 
(A) Abundance of CD19+ .IgD+CD21-/low (follicular B cells) and IgD-CD21low (marginal zone B cells) in spleen of  
Apoe
-/-
Cd40l
fl/fll
Cd4cre
-
 or Apoe-/-Cd40lfl/fllCd4Cre+ mice assayed by flow cytometry. (B) Representative plots gated 
CD19+cells. n=10 (Apoe-/-Cd40lfl/flCd4Cre-); n= 10 (Apoe-/-Cd40lfl/fl Cd4Cre+).Data is presented as mean±SD. *=p<0.01; 
**=p<0.001 
In sumary, we demonstrated that the lack of CD40L on Tcells led to changes in the B cell 
population with an increased abundance of B cells and marginal zone B cells. Changes in the B 
cell population co-incided with overall decreased plasma level of antigen-specific and -unspecific 
immunoglobulins in Apoe-/-Cd40lfl/fllCd4Cre+mice. 
3.6 T cell-specific deletion of CD40L results in an impaired antigen 
presentation in an in vivo model of antigen-specific DC-dependent T 
cell activation. 
Our analyses of the T and B cell population in Apoe-/-Cd40lfl/fllCd4Cre- and  
Apoe-/-Cd40lfl/fllCd4Cre+ mice revealed profound discrepancies in abundance, phenotype, and 
activation status of those cells. Both cell types are normally tightly connected with DCs via 
different signals such as TCR, BCR and costimulatory molecules (e.g. CD40-CD40L). To clarify 
the changes in the relationship between T cells, B cells and DCs we employed an additional in 
vivo model.  
Contact hypersensitivity (CHS) relies exclusively on the proper function of antigen presentation 
between T cells and DCs including efficient antigen capture in the skin, antigen processing, 
transport to lymphoid tissues such as the draining lymph nodes, and antigen presentation to 
naïve T cells31,313,314. Several studies recently suggested that CD40-CD40L interaction is 
required during the T cell-mediated and -dependent CHS responses314,315.  
The procedure (i.e. exposure of epidermal cells to exogenous hapten) results in a delayed-type 
hypersensitivity reaction that can be measured and quantified. The Langerhans cell (LC), a skin-
restricted DC subpopulation, is the critical antigen-scavenging and presenting cell in this model. 
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LCs initiate sensitization to Th1-specific haptens (e.g.DNFB) by presenting antigens to CD4+ T 
lymphocytes which, in turn, secrete lymphokines and recruit other cells to the site of the reaction. 
To investigate the involvement of T cell-specific CD40L in this process we examined DNFB-
induced CHS in Apoe-/-Cd40lfl/fllCd4Cre- and Apoe-/-Cd40lfl/fllCd4Cre+ mice. Twenty-four hours 
after re-challenging ears of DNFB-sensitized Apoe-/-Cd40lfl/fllCd4cre- and Apoe-/-Cd40lfl/fllCd4Cre+ 
mice were excised for histological analysis. We identified that CHS was reduced in Apoe-/-
Cd40lfl/fllCd4Cre+ mice, evoked by less cellular inflammatory infiltrate and less edema in the 
dermal tissue of the ear of DNFB-sensitized and -challenged Apoe-/-Cd40lfl/fllCd4Cre+ mice 
(Figure 25 A, B). 
 
Figure 25. DNFB-induced CHS response is attenuated in mice lacking CD4 specific CD40L. 
Physiologic and histologic assessment of ears during induction of CHS, in response to DNFB. (A) Changes in the ear 
measurements 24 hours after DNFB challenge of sensitized Apoe-/-Cd40lfl/fllCd4Cre- or Apoe-/-Cd40lfl/fllCd4Cre+.mice. 
Data represent changes in ear thickness of the untreated ear versus the sensitized ear of each animal. (B) 
Representative histological analysis of hematoxylin-and-eosin-stained ear tissues of Apoe-/-Cd40lfl/fllCd4cre- or Apoe-/-
Cd40l
fl/fll
Cd4Cre
+ mice. n=5 (Apoe-/-Cd40lfl/flCd4Cre-); n= 5 (Apoe-/-Cd40lfl/fl Cd4Cre+). Scale bar = 200 µm. Data is 
presented as mean±SD. **=p<0.001 
These results indicate that CD40L-expressing T cells are required for CHS responses to DNFB. 
To further investigate the underlying mechanisms, that result in an impaired mounting of an 
antigen-specific CHS response, we performed additional flow cytometry measurements of the 
ear draining lymph nodes and spleens of Apoe-/-Cd40lfl/flCd4Cre- and Apoe-/-Cd40lfl/fllCd4Cre+ 
mice to characterize the T cell population in those mice. Supporting our earlier findings in 
atherosclerosis, the Foxp3+ Treg population was significant decreased in draining lymph nodes 
of Apoe-/-Cd40lfl/flCd4Cre+ mice (Figure 26 A). Further analyses of the CD4+ population in lymph 
nodes of Apoe-/-Cd40lfl/flCd4Cre+ mice also revealed a significantly higher percentage of CD62L+ 
cells as well as significant decreased percentages of activated CD62L-CD4+ cells  
(Figure 26 C, B). Reflecting the reduced activation status of the CD4+ T cells, CD8+ T cells also 
showed a significant higher percentage of CD62L+CD44-CD8+ cells and a decreased ratio of 
CD62L-CD44+CD8+ cells in Apoe-/-Cd40lfl/flCd4Cre+ mice compared to Apoe-/-Cd40lfl/flCd4Cre- 
mice while central memory (CD62L+CD44+) CD8+ T cells were unaffected (Figure 26. D-F). 
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Figure 26. Deletion of CD4 specific CD40L leads to a reduced number of activated T cells and Tregs in skin 
induced. 
Flow cytometry analysis of cell suspensions from the ear draining lymph nodes 24 hours after DNFB challenge of 
sensitized Apoe-/-Cd40lfl/flCd4Cre+ or Apoe-/-Cd40lfl/flCd4Cre- mice. CD4+ cells were analyzed for their Foxp3 (A) and 
CD62L (B, C) distribution. CD8+ cells were analyzed for their CD44 and CD62L distribution (D, E; F).  
n=5 (Apoe-/-Cd40lfl/flCd4Ccre-); n= 3-4 (Apoe-/-Cd40lfl/flCd4Cre+). Data is presented as mean±SD. *=p<0.01; 
****=p<0.0001 
We further examined the role of T cell-specific CD40L in regulating of phenotype and function of 
DCs. Flow cytometric analysis of draining lymph nodes from Apoe-/-Cd40lfl/fllCd4Cre- and  
Apoe-/-Cd40lfl/fllCd4Cre+ mice did not reveal any differences in DC density (Figure 27 A). We 
therefore tested the activation status of the DCs of Apoe-/-Cd40lfl/fllCd4Cre- and  
Apoe-/-Cd40lfl/fllCd4Cre+ mice and examined the effect of CD4+ specific deletion of CD40L on DC 
costimulatory expression and detected differences in the expression of the CD40-CD40L-
dependent costimulatory molecules CD86 and OX40L (Figure 27 B, C). The presumably 
CD40/CD40L-independent expression of the costimulatory molecule CD70 appeared unchanged 
between Apoe-/-Cd40lfl/fllCd4cre- and Apoe-/-Cd40lfl/fllCd4cre+ mice (Figure 27 B, C).  
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Figure 27. Lack of T cell-specific CD40L  
does not change DC numbers but 
reduces the expression of the 
costimulatory molecules OX40L and 
CD86.  
Flow cytometry analysis of cell 
suspensions from ear draining lymph 
nodes 24 hours after DNFB challenge of 
sensitized Apoe-/-Cd40lfl/fl Cd4Cre+ or  
Apoe
-/-
Cd40l
fl/fl
Cd4Cre
- mice. (A) DC 
percentage and (B) costimulatory molecule 
expression on DCs of Apoe-/-Cd40lfl/fl 
Cd4Cre
+ 
or Apoe
-/-
Cd40l
fl/fl
Cd4cre
- 
mice 
were analyzed. (C) Representative flow 
cytometric histograms depicting CD70, 
CD86 and OX40L expression on DCs. 
 n=7 (Apoe-/-Cd40lfl/flCd4Cre-); n= 5 (Apoe-/-
Cd40l
fl/fl 
Cd4Cre
+
). Data is presented as 
mean±SD. *=p<0.01 
 
 
 
 
 
 
 
 
 
In a second approach, we tested whether the unchanged abundance of DCs coincides with 
unaltered distribution of DC subtypes. Indeed, we detected an increased abundance of CD8-
CD11b+ DCs, and concordantly a decreased percentage CD8+CD11b- DCs in lymph nodes of 
Apoe-/-Cd40lfl/fllCd4Cre+ mice compared to controls 24 hours after DNFB-challenge  
(Figure 28 A, B). 
 
Figure 28. T cell-specific deletion of CD40L alters the ratio of CD8
+
CD11b
-
 to CD8
-
 CD11b
+
 DCs in hapten 
induced hypersensitivity. 
Flow cytometric measurement of the abundance of CD8-CD11b+ and CD8+CD11b- in cell suspensions from  
ear-draining lymph nodes 24 hours after DNFB challenge of sensitized Apoe-/-Cd40lfl/flCd4Cre+ or Apoe-/-
Cd40l
fl/fl
Cd4Cre
- mice. Percentage of (A) CD8+CD11b- DCs and of (B) CD8-CD11b+ DCs. (C) Representative flow 
cytometric plots pre-gated on CD11c+MHCII+ cells. n=5 (both groups). Data is presented as mean±SD. *=p<0.01; 
**=p<0.001 
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In summary, the activation status and morphology but not the frequency of DCs was changed in 
ear-draining lymph nodes between Apoe-/-Cd40lfl/fllCd4Cre- and Apoe-/-Cd40lfl/fllCd4Cre+ mice 
suggesting that T cell-specific CD40L is dispensable for the generation while it is essential for 
the activation and maturation of T cell-stimulating CD8+CD11b- DCs. 
3.7 DC-specific deletion of CD40 decreases atherogenesis in late 
stage of atherosclerosis. 
The studies we conducted on the role of T cell specific CD40L in atherosclerosis demonstrated 
that the deficiency of CD40L primarily leads to an altered activation state of T and B cells. In 
general, DCs play the main role in initiating antigen-specific adaptive immune responses 
especially via T cell activation32,316. Hence, we focused on the deficiency of CD40 on DC that 
might lead to similar results as the lack of its counterpart CD40L on T cells. Accordingly, we 
generated mice lacking CD40 exclusively on DCs by crossing Apoe-/-Cd40fl/fl mice to  
Cd11cCre+ mice and evaluated atherosclerosis in Apoe-/-Cd40fl/flCD11cCre+ and littermate 
control mice at 28 week of age to maintain comparability to our previous model.  
Similar to our initial experiments on mice with a deficiency of CD40L on platelets or T cell we 
excluded any secondary effects of DC CD40 deficiency on the cholesterol metabolism or basic 
blood parameters.  
The analyses did not exhibit any significant differences in body weight, cholesterol level and the 
blood count of 28 week old male Apoe-/-Cd40fl/flCd11cCre- or Apoe-/-Cd40lfl/flCd11cCre+-mice 
indicating that CD40 deficiency on DCs does not interfere with a proper cholesterol metabolism 
and blood parameters (Table 9.)  
 
Table 8. Body weight, hematological parameters, 
and plasma cholesterol content in Apoe-/-Cd40fl/fl 
Cd11ccre
- (n= 12)  or Apoe-/-Cd40fl/flCd11ccre+ 
(n= 15) mice. Data is presented as mean±SD. 
 
 
 
 
 
 
The quantitative analysis of late stage atherosclerosis and under mild hypercholesteremic 
conditions revealed a 24% reduction in absolute and relative lesion area between  
Apoe-/-Cd40lfl/flCd11cCre+ mice and littermate control mice at the age of 28 weeks  
(Figure 29 A-C). 
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Figure 29. CD11c-specific CD40 deficiency attenuates advanced atherosclerosis. 
Quantification of lesion area and atherosclerotic plaque area in cross-sections at indicated positions of the aortic root 
at different stages from 28-week-old, male Apoe-/-Cd40fl/flCd11cCre-or Apoe-/-Cd40lfl/flCd11Ccre+-mice. (A) Lesion 
areas in stages 104-624. (B) Average lesion area in stages 312-520 as percentage of total vessel area. (C) 
Representative photomicrographs of Oil Red O-stained sections; n=9 (both groups) Scale bar = 200 µm. Data is 
presented as mean±SD. *=p<0.01; **=p<0.001 
Considering the comparability of reduction and assumed connectivity of CD40 on DCs and 
CD40L on T cells the next experiments addressed the question whether this alteration also 
involved a change in the T cell, B cell, or DC population.  
3.8 DC-specific CD40 deficiency decreases systemic Treg abundance. 
To examine the possible downstream impacts of the disrupted CD40-CD40L dyad between  
T cells and DCs in Apoe-/-Cd40lfl/flCd11cCre+ mice, we determined the abundance of the Treg 
subpopulation. Indeed, lack of DC-specific CD40 led to significantly decreased abundance of 
Foxp3+ cells in spleen, lymph node, and blood of Apoe-/-Cd40fl/fllCd11cCre+ mice compared to 
Apoe-/-Cd40fl/fllCd11cCre- controls (Figure 30 A-C). 
 
Figure 30. Loss of DC-specific CD40 decreases systemic Treg abundance.  
Flow cytometric analysis of splenic, lymphoid and blood cells and immunofluorescent staining in cross-sections of the 
ascending aorta analyzed for Foxp3+ cells from 28 weeks old, male Apoe-/-Cd40fl/flCd11cCre+ or  
Apoe
-/-
Cd40
fl/fl
Cd11cCre
- mice. Flow cytometry analysis of (A) splenic cells, (B) lymphoid cells and (C) blood cells.  
n= 6-7 (Apoe-/-Cd40fl/flCd11cCre-); n= 10-12 (Apoe-/-Cd40fl/flCd11cCre+). Data is presented as mean±SD. *=p<0.01; 
****=p<0.0001 
Notably, the strong reduction in Tregs does not correlate to higher atherosclerotic burden, a 
phenomenon resembling the findings in mice with a T cell-specific CD40L deficiency. 
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3.9 DC-specific deletion of CD40 results in an anti-inflammatory 
phenotype and reduced T effector cell function due to systemically 
decreased concentration of IL-2  
Despite diminished Tregs numbers, the lesions in Apoe-/-Cd40fl/fllCd11cCre+ mice were smaller in 
comparison to their littermate controls prompting us to examine potential mechanisms of their 
reduced presence by gene expression analyses of immune-relevant genes. Indeed, the 
examination of lymph nodes and spleen unveiled widespread modification of pro- and anti-
inflammatory gene distribution in Apoe-/-Cd40fl/fllCd11cCre+ mice at 28 weeks of age  
(Figure 31 A, B). The modifications shared similarities with those already detected in spleen and 
lymph nodes of Apoe-/-Cd40lfl/fllCd4Cre+ mice (Figure 18 A, B).  
The pattern of gene expression were dominated by a reduced expression of the pro-
inflammatory Th1-associated genes Ifng, Tnfa, and Il1b in lymph node and spleen of mice 
lacking CD40 on CD11c+ cells. Furthermore, the expression of the pro-inflammatory cytokine 
Il12p35 and Il6 was also decreased in the spleen of Apoe-/-Cd40fl/fllCd11ccre+ mice. In contrast 
expression of the anti-inflammatory cytokines Il10 and Tgfb was accelerated in mice lacking 
CD40 on DCs. The diminished number of Tregs, as seen by flow cytometry (Figure 33) and the 
impaired expression of Cd4, was corroborated by the significantly reduced mRNA expression of 
the Treg-associated Foxp3 gene (Figure 31 A, B). 
 
Figure 31. DC-specific deletion of CD40 causes shift to a more anti-inflammatory milieu. 
Relative mRNA expression analyzed by quantitative PCR in lymph nodes and spleen of male 28 weeks old Apoe-/-
Cd40
fl/fll
Cd11cCre
-
 or Apoe-/-Cd40fl/fllCd11cCre+ mice. Red rectangles symbolize pro-inflammatory genes, green 
rectangle symbolizes anti-inflammatory genes. (A) Relative mRNA expression in lymph node and (B) in spleen of 
male 28 weeks Apoe-/-Cd40fl/fllCd11cCre- or Apoe-/-Cd40fl/fllCd11cCre+ mice. n=10(Apoe-/-Cd40ll/flCd11cCre-); n= 12 
(Apoe
-/-
Cd40
fl/fl 
Cd11cCre
+
) Data is presented as mean±SD. *=p<0.01; **=p<0.001; ***=p 0.0001-0.001; ****=p<0.0001 
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To further characterize the T cell phenotype and the activation status of the CD4+ and CD8+ T 
cell subpopulation, we performed flow cytometric measurements on cell suspensions of lymph 
nodes and spleen from Cd40fl/fllCd11cCre- and Cd40fl/fllCd11cCre+ mice. Indeed, CD4+ cells in 
lymph nodes and spleen of Apoe-/-Cd40fl/fllCd11cCre+ mice exhibited a higher percentage of 
CD62L+ cells after 28 weeks of age when compared to Apoe-/-Cd40fl/fllCd11cCre- controls  
(Figure 32 A, B, C). The percentage of naïve (CD62L+CD44-) CD8+ T cells was also significant 
higher in the spleen of mice with CD40-deficient DCs. This reduction was accompanied by 
decreased percentages of central memory (CD62L+CD44+) CD8+ T cells and effector  
(CD62L-CD44+) CD8+ T cells (Figure 32 E, F). In contrast to the splenic population the 
percentage of the central memory CD8+ T cell population was increased in suspensions of 
lymph nodes from mice with a DC-specific CD40 deficiency (Figure 32 D). In summary those 
results demonstrated a decrease in activated CD4+ and CD8+ cells and a higher percentage of 
naïve CD4+ and CD8+ cells. 
 
Figure 32. Lack of CD40 on DCs leads to a reduced number of activated T cells. 
Flow cytometric measurements of CD4+ and CD8+ T cell populations in lymph nodes and spleen of male 28 weeks old 
Apoe
-/-
Cd40
fl/fll
Cd11cCre
-
 or Apoe-/-Cd40fl/fllCd11cCre+ mice. Abundance of CD4+ subtypes in (A) lymph nodes and (B) 
spleen Apoe-/-Cd40fl/fllCd11cCre- or Apoe-/-Cd40fl/fllCd11cCre+  mice assayed by flow cytometry. Abundance CD8+ 
subtypes in (D) lymph nodes and (E) spleen, of Apoe-/-Cd40fl/fllCd11cCre- or Apoe-/-Cd40fl/fllCd11cCre+ mice assayed 
by flow cytometry. Representative plots gated on living CD4+ cells (C) and CD8+ cells of lymphocytes (F) are 
displayed. n=7 (Apoe-/-Cd40fl/flCd11cCre-); n= 9 (Apoe-/-Cd40fl/fl Cd11cCre+). Data is presented as mean±SD. *=p<0.01 
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3.10 DC-specific deletion of CD40 affects B cell phenotype and 
decreases IgG2b and IgM titers  
Our experiments showed an altered activation status in T helper and T effector cells in  
Apoe-/-Cd40fl/fllCd11cCre+ mice. Maintaining our previous strategy we analyzed the B cell 
population regarding differences in the B cell T cell interaction and the humoral immune 
response in DC-specific CD40-deficient mice. We analyzed the phenotype, i.e. differentiation 
and activation, of B cells by measuring antigen-specific and unspecific antibodies in plasma. 
Using a multiplex bead-based assay to determine the concentration of antigen-unspecific  
Ig-subclasses we revealed a decreased abundance of IgG2a, IgG2b, IgE, and IgM antibodies in 
the plasma of Apoe-/-Cd40fl/fllCd11cCre+ (Figure 33). 
Figure 33. DC-specific CD40 deficiency 
decreases IgG2, IgE and IgM plasma 
abundance. 
Antibody abundance in plasma of 28 week old 
Apoe
-/-
Cd40
fl/fll
Cd11cCre
+
 and Apoe-/-
Cd40
fl/fll
Cd11cCre
- mice as analyzed by murine 
multiplex bead-based technology detection 
antibodies. Plasma level expression for respective 
Ig of 28 week old Apoe-/-Cd40fl/fllCd11cCre+ and 
Apoe
-/-
Cd40
fl/fll
Cd11cCre
- mice analyzed by 
multiplex bead-based technology (B) Plasma 
abundance of antibodies detecting oxLDL of 28 
week old Apoe-/-Cd40fl/fllCd11cCre+ and  
Apoe
-/-
Cd40
fl/fll
Cd11cCre
- mice. Quantification for 
optic density acquired at 450nm wavelength of 
1:20 diluted plasma is displayed. (C) Dilution 
series (1:20, 1:100; 1:1000) of plasma and 
respective ODs are displayed for each antibody.  
n=7 Apoe-/-Cd40fl/flCd11cCre-);n=9 (Apoe-/-Cd40fl/fl 
Cd11cCre
+
). Data is presented as mean±SD. 
*=p<0.01; **=p<0.001 
In addition, when employing an ELISA for oxLDL-binding immunoglobulins, we detected 
significant less oxLDL-specific IgG2b and IgM in the plasma of Apoe
-/-Cd40fl/fllCd11cCre+ mice 
(Figure 34).  
Figure 34. DC-specific CD40 deficiency 
decreases oxLDL specific IgG2b and IgM 
plasma abundance.  
Abundance of antibodies detecting oxLDL in 
plasma of 28 week-old Apoe-/-Cd40fl/fllCd11cCre+ 
and Apoe-/-Cd40fl/fllCd11cCre- mice. Quantification 
for optic density acquired at 450nm wavelength of 
diluted (1:20) plasma is displayed. n=10 (both 
groups) Data is presented as mean±SD. 
*=p<0.01; **=p<0.001 
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In summary, the data revealed a decreased abundance of antigen-specific and unspecific 
immunoglobulin subclasses, which are considered both pro-atherogenic (e.g. Ig2b) and anti-
atherogenic (e.g. IgM) in Apoe-/-Cd40fl/fllCd11cCre+ mice. 
3.11 DC-specific deletion of CD40 results in an impaired antigen 
presentation in an in vivo model of antigen specific DC-dependent T 
cell activation. 
Our analyses of adaptive immune cells in Apoe-/-Cd40lfl/fllCd11cCre+ mice revealed 
discrepancies in abundance, phenotype, and activation status of T cells and B cells between 
Apoe-/-Cd40fl/fllCd11cCre+ and control mice.  
Because of the already mentioned connection of T and B cells with DCs and to characterize this 
tight relationship, we once again used CHS as an additional in vivo model. We examined the 
DNFB-induced CHS in Apoe-/-Cd40fl/fllCd11cCre- and Apoe-/-Cd40fl/fllCd11cCre+ mice. Analysis of 
ears from Apoe-/-Cd40fl/fllCd11cCre- and Apoe-/-Cd40fl/fllCd11cCre+ mice collected twenty-four 
hours after challenging with DNFB, revealed an attenuated CHS in  
Apoe-/-Cd40fl/fllCd11cCre+ mice. The DNFB-sensitized and -challenged ears displayed less 
cellular inflammatory infiltrate and less edema in the dermal tissue (Figure 35 A, B).  
 
Figure 35. DNFB-induced CHS response is attenuated in mice lacking DC-specific CD40. 
Physiologic and histologic assessment of ears during induction of CHS, in response to DNFB. (A) Changes in the ear 
measurements 24 hours after DNFB challenge of sensitized Apoe-/-Cd40fl/fllCd11cCre- or  
Apoe
-/-
Cd40
fl/fll
Cd11cCre
+ mice. Data represent changes in ear thickness of the untreated ear versus the sensitized 
ear of each animal. (B) Representative histological analysis of hematoxylin-and-eosin-stained ear tissues. n=5 (for 
both groups). Scale bar = 200 µm. Data is presented as mean±SD. **=p<0.001 
Flow cytometric analyzes of cell suspension of the ear-draining lymph nodes of DC CD40 
deficient mice demonstrated a decrease in the Foxp3+ Treg population (Figure 36 A). Further 
analyses of the CD4+ and CD8+ T cell population revealed a significantly higher percentage of 
CD62L+CD4+ cells as well as decreased percentage of CD62L-CD44+CD8+ cells  
(Figure 36 C, E), reflecting the earlier detected reduced activation status of CD4+ T and CD8+ T 
cells in Apoe-/-Cd40lfl/fllCd4Cre+ mice. 
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Figure 36. Deletion of DC-specific CD40 leads to a reduced number of activated T cells and Tregs in skin 
induced hypersensitivity. 
Flow cytometry analysis of cell suspensions from the ear-draining lymph nodes 24 hours after DNFB challenge of 
sensitized Apoe-/-Cd40fl/flCd11cCre+ or Apoe-/-Cd40fl/flCd11cCre- mice. CD4+ cells were analyzed for their Foxp3 (A) 
and CD62L (B, C) distribution. CD8+ cells were analyzed for their CD44 and CD62L distribution (D- F). n=4-6 (Apoe-/-
Cd40fl/flCd11cCre-); n= 6-7 (Apoe-/-Cd40fl/flCd11cCre+). Data is presented as mean±SD.*=p<0.01;**=p<0.001 
We further examined the role of DC-specific CD40 in the regulation of the appearance and 
function of DCs. Flow cytometric examination of the DC distribution in ear draining lymph nodes 
of Apoe-/-Cd40fl/fllCd11cCre- and Apoe-/-Cd40fl/fllCd11cCre+ mice did not show any difference in 
percentage of CD11c+MHCII+ DCs (Figure 37 A). In contrast to the unchanged DC density we 
were detected differences in the expression of the CD40-CD40L dependent costimulatory 
molecules CD86 and OX40L, which were significant decreased in Apoe-/-Cd40fl/fllCd11cCre+ 
mice (Figure 37 B, C). The presumably CD40/CD40L-independent expression of the 
costimulatory molecule CD70 was unchanged (Figure 37 B, C).  
Figure 37. Lack of DC-specific CD40 does not affect DC number but their expression of the costimulatory 
molecules OX40L and CD86. Flow cytometry analysis of cell suspensions from ear-draining lymph nodes 24 hours 
after DNFB challenge of sensitized Apoe-/-Cd40fl/fl Cd11cCre+ or Apoe-/-Cd40fl/flCd11cCre- mice. (A) DC percentage 
and (B) costimulatory-molecule expression on DCs were analyzed. (C) Representative flow cytometric histograms 
depicting CD70, CD86 and OX40L expression on DCs. n=5 (Apoe-/-Cd40fl/flCd11cCre-); n= 6 (Apoe-/-Cd40fl/fl 
Cd11cCre
+
). Data is presented as mean±SD. *=p<0.01 
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In a second flow cytometry panel, we addressed unchanged abundance of DCs that may 
correspond to unchanged distribution of DC subtypes. We analyzed the DC population for their 
percentage of CD8+CD11b- and CD8-CD11b+ DCs. Flow cytometry measurements exhibited 
decreased percentage CD8+CD11b- DCs in lymph nodes of Apoe-/-Cd40fl/fllCd11cCre+mice 24 
hours after DNFB-challenge (Figure 38 A, B). 
 
Figure 38. DC-specific deletion of CD40 alters the ratio of CD8
+
CD11b
-
 to CD8
-
CD11b
+
 DCs in hapten-induced 
hypersensitivity. 
Flow cytometric measurement to check the abundance of CD8+CD11b- and CD8-CD11b+ in cell suspensions from ear-
draining lymph nodes 24 hours after DNFB challenge of sensitized Apoe-/-Cd40fl/flCd11cCre+ or Apoe-/-
Cd40
fl/fl
Cd11cCre
-
.
 (A) Percentage of CD8+CD11b- DCs and of (B) CD8-CD11b+ of sensitized Apoe-/-Cd40fl/fl 
Cd11cCre
+ or Apoe-/-Cd40fl/flCd11cCre- mice. n=5-6 (Apoe-/-Cd40fl/flCd11cCre-); n= 7 (Apoe-/-Cd40fl/flCd11cCre+). Data 
is presented as mean±SD. **=p<0.001 
Paralleling our earlier findings in mice with a T cell-specific deletion of CD40L the summarized 
results provide additional support for the previously indicated requirement of CD40-CD40L 
interaction for CHS responses to DNFB. 
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3.12 Platelet specific deletion of CD40L does not affect advanced 
atherosclerosis. 
Today platelets are seen as true immune cells and by using a platelets from Cd40l-/- mice 
Lievens et al were able to investigate the role of CD40L in atherosclerosis. They demonstrated 
that platelet CD40L plays a crucial role in initiation and progression of atherosclerosis by 
facilitating platelet–leukocyte aggregate formation and promoting adherence of platelets and 
leukocytes to the endothelium125. In addition platelets are known to be the main source for the 
soluble form of CD40L which serum levels in human and mice associates with cardiovascular 
diseases281. Thus, we sought to investigate the role of platelet-specific CD40L in atherosclerosis. 
Similar to our previous investigations we started our studies by searching for possible changes 
in cholesterol metabolism and blood parameters of mice lacking CD40L on platelets. These 
analyses did not reveal any significant differences between Apoe-/-Cd40lfl/fllPf4Cre- and Apoe-/-
Cd40lfl/fllPf4Cre+ mice  at 28 weeks of age (Table 9).  
Table 9. Body weight, hematological 
parameters, and plasma cholesterol 
content in Apoe-/-Cd40lfl/fllPf4Cre- mice 
(n=12) and Apoe-/-Cd40lfl/flPf4Cre+ mice 
(n=14). Data is presented as mean±SD. 
 
 
 
 
 
Once we ensured that the deletion of CD40L on platelets did not interfere with basic blood 
parameters or cholesterol metabolism, we analyzed the atherosclerotic lesion area in the aortic 
arch and the ascending aorta of the platelet CD40L-deficient and control mice in advanced stage 
atherosclerosis and under mild hypercholesteremic conditions. Surprisingly, the histological 
analyses did not reveal any differences between mice lacking CD40L on platelets and animals 
which expressed CD40L on platelets. The absolute atherosclerotic lesion area in the aortic arch, 
of Apoe-/-Cd40lfl/fllPf4Cre+ mice, were similar to those of littermate controls (Figure 39). 
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Figure 39. PF4-specific CD40L deficiency does not influence early plaque formation in the aortic arch. 
Hematoxylin-and-eosin-stained longitudinal section of the aortic arch, including the brachiocephalic trunk, left carotid, 
and left subclavian artery from 28 week-old male Apoe-/-Cd40lfl/flPf4Cre- or Apoe-/-Cd40lfl/fllPf4Cre+ mice.  
(A) Quantification of total plaque size and (B) representative photomicrographs. n=13 (Apoe-/-Cd40lfl/flPf4Cre-), n=14 
(Apoe-/-Cd40lfl/flPf4Cre+) Scale bar = 200 µm. Data is presented as mean±SD. 
To confirm these results, atherosclerotic burden was also quantified in the aortic sinus, which, 
after 28 weeks of normal chow diet, contained more advanced atherosclerotic lesions than the 
aortic arch. Accordingly, we performed quantitative analysis of ORO- stained cryosections of the 
aortic sinus. Reflecting the results of the invariant lesion size in the aortic arch, the 
measurements did not show any differences in absolute or relative lesion area between Apoe-/-
Cd40lfl/flPf4Cre+ mice and Apoe-/-Cd40lfl/flPf4Cre- mice at the age of 28 weeks (Figure 40 A-C).  
 
 
 
 
 
 
 
 
 
Figure 40. Platelet-specific CD40L deficiency does not affect advanced atherosclerosis. 
Quantification of lesion area and atherosclerotic plaque area in cross-sections at indicated positions (µm above the 
appearance of the aortic valves) of the aortic sinus from 28-week-old, male Apoe-/-Cd40lfl/flPf4Cre-or  
Apoe
-/-
Cd40l
fl/fl
Pf4Cre
+-mice. (A) Lesion areas in stages 104-728. (B) Average lesion area in stages 312-520 as 
percentage of total vessel area. (C) Representative photomicrographs of Oil Red O-stained sections. n=12-13 (Apoe-/-
Cd40l
fl/fl
Pf4Cre
-), n=10-13 (Apoe-/- Cd40lfl/flPf4Cre+) Scale bar = 200 µm. Data is presented as mean±SD.  
Additionally, we determined the cellular composition of the lesions of the aortic sinus from Apoe-/-
Cd40lfl/flPf4Cre+ and Apoe-/-Cd40lfl/flPf4Cre- mice. Our detailed immunohistomorphological 
quantification of lesional macrophages and SMCs the most abundant cell types in 
atherosclerosis and the analysis of CD4+ cells revealed, that neither the content of lesional CD4+ 
T cells, nor macrophages or SMC content in atherosclerotic lesions of the aortic sinus differed 
between 28 week-old Apoe-/-Cd40lfl/flPf4Cre+ and littermate controls (Figure 41 A, B, C). 
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Figure 41. Platelet-specific CD40L does not affect cellular plaque composition. 
Immunofluorescent stainings in cross-sections of the aortic sinus from 28 week old Apoe-/-Cd40lfl/fl Pf4Cre+ or Apoe-/-
Cd40l
fl/fl
Pf4Cre
- mice. Quantifications and representative photomicrographs are shown for each staining. The dashed 
lines separate the atherosclerotic lesion from the lumen (L). Analyzed for (A) MAC3+ area, (B) α-SMA+ area and (C) 
CD4+ cells. n=12-13 (Apoe-/-Cd40lfl/flPf4Cre) n=10-13 (Apoe-/-Cd40lfl/flPf4Cre+). Scale bar = 200 µm. Data is presented 
as mean±SD. 
In summary, we showed that platelet specific deficiency of the costimulatory molecule CD40L 
does not affect atherosclerosis progression or lesion composition. Our analyses did not show 
any variances in size lesions during either early or late stages of disease under conditions of 
mild hypercholesteremia. 
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3.13 Analyzing the role of platelet- and T cell-specific CD40 expression 
in atherosclerosis 
Besides the role as the predominant CD40L-expressing cells, both T cells and platelets also 
express a certain amount of CD40317. Thus, we aimed to evaluate the consequences of a 
deletion of CD40 on those cell types. 
In analogy to our previous studies we addressed the secondary effects of the different cell type-
specific deletions of CD40 by monitoring body weight and blood parameters. Notably, body 
weight or blood count of male Apoe-/-Cd40fl/fllPf4Cre- and Apoe-/-Cd40fl/fllPf4Cre+ mice at 28 week 
of age did not reveal significant differences (Table 10).  
Table 10.  
Body weight and hematological 
parameters of Apoe-/-Cd40fl/fllPf4Cre- 
and Apoe
-/-
Cd40
fl/fl
Pf4Cre
+ mice.  
n= 13 (Apoe-/-Cd40fl/fllPf4cre-) 
n= 19 (Apoe-/-Cd40fl/fllPf4cre+):  
Data is presented as mean±SD. 
 
 
 
We then analyzed the lesion area of the ascending aortae in late stage atherosclerosis and 
under mild hypercholesteremic conditions. These measurements did not show any differences in 
absolute or relative lesion area between Apoe-/-Cd40fl/fllPf4Cre- and Apoe-/-Cd40fl/fllPf4Cre+ mice 
(Figure 42 A-C). 
 
Figure 42. Platelet-specific CD40 deficiency does not influence advanced atherosclerosis.  
Quantification of atherosclerotic plaque area in cross-sections of the aortic sinus from 28-week-old, male Apoe-/-
Cd40
fl/fl
Pf4Cre
-or Apoe-/-Cd40fl/flPf4Cre+mice. (A) Lesion areas in stages 104-728. (B) Average lesion area in stages 
312-520 expressed as percentage of total vessel area. (C) Representative photomicrographs of Oil Red O-stained 
sections. n=13 (Apoe-/-Cd40fl/flPf4Cre), n=19 (Apoe-/- Cd40fl/flPf4Cre+) Scale bar = 200 µm. Data is presented as 
mean±SD.  
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Since we could not detect any alterations in lesion progression in mice lacking platelet-specific 
CD40 we next analyzed lesion progression in Apoe-/-Cd40fl/flCd4Cre- and Apoe-/-Cd40fl/flCd4cre+ 
mice. 
 
Table 11.  
Body weight and hematological 
parameters of Apoe-/-Cd40fl/fllCd4cre- and  
Apoe
-/-
Cd40
fl/fl
Cd4cre
+ mice.  
n= 7 (both groups) 
Data is presented as mean±SD. 
 
 
 
Again, the data did not reveal any difference in body weight, or blood count parameters between 
Apoe-/-Cd40fl/fllCd4Cre- and Apoe-/-Cd40fl/flCd4Cre+ mice (Table 11). However, the measurement 
of the lesions size in ascending aortae of Apoe-/-Cd40fl/flCd4cre- and Apoe-/-Cd40fl/flCd4cre+ did 
not display any difference in absolute or relative values in 28 week-old male mice  
(Figure 43. A-C). 
 
Figure 43. T cell-specific CD40 deficiency does not influence advanced atherosclerosis. 
Quantification of lesion area and Atherosclerotic plaque area in cross-sections at indicated positions of the aortic root 
at different stages from 28-week-old, male Apoe-/-Cd40fl/flCd4Cre-or Apoe-/-Cd40l/flCd4Cre+-mice. (A) Lesion areas in 
stages 104-624. (B) Average lesion area in stages 312-520 as percentage of total vessel area. (C) Representative 
photomicrographs of Oil Red O-stained sections. n=7 (Apoe-/-Cd40fl/flCd4cre), n=7 (Apoe-/- Cd40fl/flCd4Cre+)  
Scale bar = 200 µm. Data is presented as mean±SD.  
 
In summary, our data do not provide any evidence for a prominent, if any, role of platelet- or  
T cell-specific CD40 in atherosclerosis. 
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 4 DISCUSSION 
The study of murine models of atherogenesis over the last two and a half decades has been 
extremely valuable in revealing the mechanisms that are operative in initiating lesion 
development as well as their progression and regression. The CD40-CD40L dyad is one of the 
most potent costimulatory pathways active in atherosclerosis318,319. Genetic deficiency in CD40L 
or pharmacological inhibition of CD40L results in the development of a stable atherosclerotic 
plaque phenotype303,304. This phenotype can even be established when antibody treatment is 
delayed until advanced plaques have developed in late stages of the disease303. However, the 
mechanisms of CD40-CD40L signaling are complex. In atherosclerotic lesions both CD40 and 
CD40L are expressed on the vast majority of immune cells present in the plaque, on vascular 
cells (ECs and SMCs), as well as on platelets and monocytes in the circulation210,239,240–243. Yet, 
the contribution of CD40-CD40L signaling on each of the different cell types towards plaque 
development has been undefined so far. Therefore, this thesis aimed to elucidate cell type-
specific CD40L-CD40L interactions in atherosclerosis. To this end, we analyzed CD40-CD40L-
dependent interactions of DCs, T cells, and B cells, as the central players of the adaptive 
immune system, in greater detail. Additionally we performed initial studies to get a surface 
impression of the contribution of platelet specific CD40-CD40L interactions to atherosclerosis. 
4.1 Establishing the cre/loxP system to investigate the cell type-
specific role of CD40-CD40L interactions in atherosclerosis 
Deletion of ubiquitously expressed genes often results in severe phenotypes that interfere with 
the analysis of particular cell types or tissues. To overcome this limitation, we used a conditional 
knockout approach to examine the role of cell type-specific CD40-CD40L interactions in 
atherogenesis. To our knowledge, this is the first report of examining the effects of cell type-
specific CD40-CD40L interactions in atherosclerosis in vivo. Although Lutgens and others 
previously tested mice with a global CD40 or CD40L deficiency in atherosclerosis, they did not 
report the impact of cell type-specific deficiency of CD40 or CD40L on atherosclerosis302–305,320. 
Hence, our approach resembles a further refinement of the global deficiency model in that it 
allows deeper understanding of the contribution of CD40-CD40L interaction on the level of a 
single cell population and may elucidate new potential targets and strategies to modulate cell 
functions in order to ameliorate the disease. 
Methodologically we took advantage of the cre/loxP- system inserting by gene targeting two 
loxP-sites around a functionally essential part of the gene of interest, thus making a minimal 
change that leaves the gene completely functional321. The power of the cre-recombinase-based 
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strategies depend very much on utilization of functional and well-characterized transgenic lines 
expressing the recombinase with a sufficient level and specificity to achieve the desired type of 
gene alterations. In our studies we were able to prove that our cre-promoter constructs (CD4 
and CD11c) led to specific and complete alteration of CD40L and CD40 expression on the 
designated cell types without any undesirable side-effects to the metabolism of mice.  
4.2 Deficiency of CD40-CD40L signaling in DCs and T cells leads to 
insufficient DC maturation. 
In peripheral tissues DCs are functionally immature, adapted to capturing and processing 
antigens but lack the requisite signals to stimulate T cells. Following antigen recognition in the 
context of a pathogenic inflammatory stimulus, immature DCs begin to mature and undergo 
phenotypic and functional changes that result in the complete transition from antigen-capturing 
cells to professional APCs322,323.  
The present study indicates that DC-specific inhibition of CD40-CD40L costimulation decreases 
the inflammatory T cell responses, which is associated with reduced disease symptoms.  
DC-specific CD40 deficiency caused a substantial decrease in atherosclerotic lesion size 
accompanied by less infiltration of CD4+ T cell, less macrophages and more SMCs. The 
alteration in lesion size and composition was accompanied by a reduced percentage of activated 
T effector cells and a shift in the systemic cytokine milieu towards a Th2 cell response. In 
addition, CD40-deficiency in DCs alleviated inflammatory responses as demonstrated by 
systematically decreased expression of pro-inflammatory and increased expression of anti-
inflammatory immunoglobulins. Interaction of CD40 on DCs with CD40L on T cells leads to 
proper DC activation and renders them potent in T cell priming and cytokine production263,324,325. 
The ability of DCs to regulate immunity is dependent on DC maturation. During their conversion 
from immature to mature cells, DCs undergo a number of phenotypical and functional changes. 
Inefficient activation leads to lacking or inadequate secondary signals, such as CD86 and 
OX40L, resulting in anergy of the lymphocyte267. Notably, our data demonstrated that DCs of 
Apoe-/-Cd40lfl/flCd4Cre+ as well as Apoe-/-Cd40fl/flCd11cCre+ mice featured a decreased 
expression of CD86 and OX40L compared to their respective controls despite the presence of a 
cognate antigen, such as oxLDL or DNFB. This may indicate that the pronounced anti-
inflammatory phenotype of DC-specific CD40-deficient and T cell-specific-CD40L deficient mice 
is likely evoked trough insufficient DC maturation. As described earlier, a productive T cell 
priming depends in part on instructing cytokines provided by mature DCs326–328. Expression of 
cytokines as one of the major functions of mature DCs is regulated through ligation of CD40L to 
CD40 and the distinct cytokine patterns released by mature DCs ultimately determine their 
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Th1/Th2 polarizing capacities252,325,329,330–333. Mature DCs are a relevant source of IL-12, the 
principal cytokine that drives Th1 polarization and IL-12 production is controlled by the nature of 
the maturation stimulus, by environmental factors, and by feedback signals from T cells through 
costimulatory molecules including CD40L66,263,264,334. Interaction of DCs and T cells involves 
CD40-CD40L interaction and leads to TRAF6 recruitment to the cytoplasmatic domain of CD40. 
This interaction subsequently results in the activation of the p38 MAP kinase (MAPK) and Jun 
kinase (Jun) leading to production of cytokines such as IL-12 and IL-6335,336. DCs from TRAF6-
deficient mice fail to upregulate maturation markers (e.g., MHCII and CD86) and cannot produce 
IL-6 or IL-12 in response to CD40L336. In agreement, our results revealed that the DC-specific 
deletion of CD40 as well as the T cell-specific deletion of CD40L resulted in an altered cytokine 
milieu characterized by upregulation of anti-inflammatory cytokines (e.g., IL-10 and TGFβ) and 
downregulation of pro-inflammatory cytokines (e.g. IFNγ, TNFα, IL-1β, IL-12 (IL-12p35) and IL-6) 
This suggests an insufficient induction of the T helper cell response since the presence of the 
cytokines IFNγ, IL-10, and IL-12 during the maturation process is essential for induction of the T 
helper cell responses66,67. IFNγ is produced by a variety of leukocyte populations including Th1 
cells, natural killer cells, macrophages and DCs and is an important mediator for DC maturation 
and the DC-mediated T helper cell activation67,79–81. The presence of IFNγ induces DCs to 
release large amounts of IL-12, which can stimulate a Th1 immune response66,264,337. The 
release of autocrine IL-10, however, blocks the DC maturation process by interfering with up-
regulation of costimulatory molecules and production of IL-12, subsequently limiting the ability of 
DCs to initiate a Th1 response263,264,338. Hence, the reduced number of activated T cells in Apoe-
/-Cd40lfl/flCd4Cre+ as well as Apoe-/-Cd40fl/flCd11cCre+ may be due to the insufficient 
costimulatory capacity of DCs and their inability to produce inflammatory cytokines, both of 
which are important for the activation of T cells and generation of Th1 cells.  
Figure 46: CD40-CD40L 
interactions between DCs and T 
cells. 
CD40 is upregulated on activated 
mature DCs and CD40L is 
expressed on activated T cells. 
Engagement of CD40 on DCs 
induces positives signaling that 
leads to expression of CD86 and 
the production of IL-2, IL-12 and 
IL10. IL-12 skews CD4+ T cells 
towards Th1 differentiation in. In 
addition to IL-12, CD40L signaling 
in T cells induces IFNγ production 
(Modified from Ma and Clark329). 
Discussion 
 
86 
 
In summary, our data suggest that the requirement of Th1 cells for DC maturation in previous 
studies is a reflection of the fact that DCs require the CD40 maturation signals induced during 
cognate interaction with CD40L-bearing CD4+ T cells to become efficient APCs.  
To shed further light on the phenotype and maturation levels of DCs in Apoe-/-Cd40lfl/flCd4Cre+ 
and Apoe-/-Cd40fl/flCd11cCre+ mice we employed CHS as a powerful in vivo model. CHS 
exclusively relies on the proper function of antigen presentation between T cells and DCs and 
several studies recently suggested that CD40-CD40L interaction is required during the T cell-
mediated and -dependent CHS responses314,315. Upon application to the skin, haptens 
immediately interact with keratinocytes (KC), LCs and dermal dendritic cells (dDC) 339. Hapten 
binding to KCs causes them to release cytokines like IL-1β and TNFα339. This may activate LCs 
and dDCs, prompt them to take up antigen, and migrate to the draining lymph node where 
present the hapten-antigen to naïve T-cells339. DNFB application to dDCs in vitro upregulates 
MAPK and CD40340. Consistent with the hypothesis that CD40 plays a critical role in DC function 
and antigen presentation, CD40-deficient DCs seem incapable of generating a proper cell-
mediated immune response to the hapten DNFB. This was associated with reduced cellular 
inflammatory infiltrate, less edema in the dermal tissue of the ears of Apoe-/-Cd40lfl/flCd4Cre+ and 
Apoe-/-Cd40fl/flCd11cCre+ mice. Furthermore, our data revealed decreased numbers of 
CD8+CD11b- DCs in Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice. In fact, 
CD8+CD11b- lymphoid resident DCs are superior in cross-presentation, induction of Th1 cells, 
uptake of dead cells, production of IL-12, and capture of antigen from migratory DCs or from 
blood341. The reduction of IL12-producing CD8+CD11b- DCs was concordantly with the 
aforementioned systematically reduced expression of Th1-related cytokines in mRNA from 
lymph nodes of Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice. In addition, Apoe-/-
Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice displayed an increased ratio of CD8-CD11b+ 
DCs which are found in most of the lymphoid tissue (lymphoid-resident DC) but also in non-
lymphoid tissues (migratory DCs)342,343. CD11b+ DCs are less efficient in cross-presentation and 
production of specific cytokines, such as IL-12 but potent sources of IL-6 and IL-23340,341341. 
Taken together, these results indicate that DC-specific CD40 regulates the critical processes 
required for maturation, activation, and development of DCs, the primary cellular bridge between 
innate and adaptive immunity. In addition, they provide evidence that DC-specific CD40 and  
T cell-specific CD40L are important for the development of DC subsets. 
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4.3 Inhibition of CD40-CD40L-dependent crosstalk between DCs and T 
cell affects T cell proliferation and differentiation  
Naïve CD4+ T cells depend on the presentation of a cognate antigen and a CD40-CD40L signal 
by DCs to undergo activation and differentiation. In vitro, CD40-deficient DCs are partially 
defective in priming CD8+ T cells, suggesting a major role for CD40-CD40L interactions in DC 
licensing344.  
Our studies revealed defects in mounting an effective Th1 response in Apoe-/-Cd40lfl/flCd4Cre+ 
and Apoe-/-Cd40fl/flCd11cCre+ mice. In addition, these mice with a lack of DC-specific CD40  or 
with a T cell-specific CD40L deficiency displayed a decrease in atherosclerotic lesion size which 
was accompanied by less infiltrated CD4+ T cells, systematically decreased expression of 
cytokines related to T cell activation and polarization and a high abundance of naïve CD4+ and 
CD8+ T cells. Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice both displayed low 
levels of systemic IL-2 expression which is not surprisingly since the production of IL-2 is highly 
CD40-CD40L dependent72. Without the presence of sufficient IL2- levels naïve T cell cannot 
enter the cell cycle72.Upon successful activation by DCs Th1 cell polarization is then initiated in 
response to IFNγ and IL-12 produced by APCs67,79–81. The expression of both systemic IFNγ and 
IL-12 was significantly downregulated in Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ 
mice. This data points to a generally hampered Th1 polarization as expression of both, a 
polarizing cytokine and an effector cytokine, are reduced. In summary, this led us to the 
assumption that Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice harbor decreased 
numbers of activated and pro-atherogenic Th1 cells58,62,76. 
Furthermore, our studies provided additional information for an altered activation status of T cells 
in mice with a deficiency of DC-CD40 or T cell-CD40L. DCs from Apoe-/-Cd40lfl/flCd4Cre+ and  
Apoe-/-Cd40fl/flCd11cCre+ mice featured a decreased OX40L expression despite the presence of 
a cognate antigen. This corroborates our assumption of an insufficient T cell activation since the 
costimulatory signals from OX40-OX40L to T cells are essential to promote division and survival 
of T cells and previously studies of OX40L-deficient mice or with blocking antibodies to OX40L 
revealed a reduced expansion or functional priming of CD4+ T cells345–349. Initially, an in vitro T 
cell proliferation assay did not exhibit any differences in the mitotic capacity of T cells from  
Apoe-/-Cd40lfl/flCd4Cre+ or Apoe-/-Cd40fl/flCd11cCre+ mice compared to littermate controls. 
However, this only holds true under an unpremeditated point of view. To interpret the results 
correctly one has to take into consideration that both of those mouse lines presented significant 
lower Treg numbers which presumably results in a lower suppressive capacity. Thus, total T cell 
cultures from Apoe-/-Cd40lfl/flCd4Cre+ or Apoe-/-Cd40fl/flCd11cCre+* should be expected to 
proliferate at a higher rate. The comparable rates of T cell proliferation between  
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Apoe-/-Cd40lfl/flCd4Cre+ or Apoe-/-Cd40fl/flCd11cCre+ mice and control mice thereby indicate an 
altered or impaired proliferative capacity of non-regulatory T cells from Apoe-/-Cd40lfl/flCd4Cre+ 
and Apoe-/-Cd40fl/flCd11cCre+ mice. However, these results provide only room for speculation yet 
no evidence about the proliferation capacity of T cells. To make an accurate statement we have 
to conduct an additional proliferation assays with separated Tregs and T cells. As it is generally 
accepted that inflammatory Th1-type responses are pro-atherogenic, it is reasonable to 
postulate that the absence of CD40- (Apoe-/-Cd40fl/flCd11cCre+) or CD40L-  
(Apoe-/-Cd40lfl/flCd4Cre+) induced cytokine production following cognate T cell DC interaction 
results in a defective Th1 response which influence atherosclerotic plaque progression58,61,62,76. 
The proposed role of CD40-CD40L interactions in DC-T cell crosstalk is summarized in Figure 
45. 
Figure 45. Role of CD40-CD40L 
interaction for activation and 
differentiation of T cells. 
Mature dendritic cells (DCs) activate 
and polarize naïve T cells into different 
T helper cell (Th) subsets through 
antigen presentation to the T cell 
Receptor (TCR), secretion of cytokines 
and costimulatory cytokines. The 
presence of IL-12 and IL-18 causes 
Th1 skewing. Naive CD4+ T cells 
commit to a Th2 lineage under the 
influence of IL-4. Th17 differentiation 
requires a combination of several 
cytokines, including IL-6, TGFβ, IL-21, 
IL-23, and IL-1β. The mechanisms 
behind follicular helper T cell (Tfh) 
induction are not known yet. 
M1;classical macrophage, oxLDL; 
oxidized low density lipoprotein 
(Modified from Tse et al) 62. 
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4.4 Deficiency of CD40-CD40L signaling between DCs and T cells 
impedes the homeostasis of regulatory T cells by altering IL-2 levels 
Several studies have shown that Treg cell development is reduced in the absence of the CD40-
CD40L pathway350–352. However, these studies did only take global CD40- or CD40L-deficiency 
into account.  
Here we studied the possible role of T cell- and DC-specific CD40-CD40L interactions in Treg 
development and homeostasis. Extensive analyses showed a significant reduction of mature 
Treg numbers in blood, lymph node, spleen, and aortic lesions and pre-Tregs numbers in the 
thymus of Apoe-/-CD40lfl/flCd4Cre+ and Apoe-/-CD40fl/flCd11cCre+ mice. Tregs are formed in the 
thymus and their development is highly dependent on the cytokine IL-2 which was also 
decreased systemically in both of our mouse models311,353. IL-2 is an autocrine T cell survival 
factor important for peripheral Treg maintenance since Tregs are not able to synthetize IL-2 
themselves311. In the periphery DCs and activated T cells are the most potent producers of IL-2, 
however the precise mechanisms involved in the process have not been identified yet. 
Combined with our findings of insufficient DC maturation and T cell activation and the fact that 
the amount of IL-2 produced by T cells correlates with the extent of costimulation from DC in 
vitro and in vivo, the decreased Treg numbers strongly suggest that CD40-CD40L interactions 
participate in the process of Treg development354,355. However, CD40-CD40L interaction appears 
irrelevant for Treg function since neither the deficiency of T cell-specific CD40L nor the 
deficiency of CD40 on DCs changed the suppressive activity of Tregs. Our proposed model for 
the role of CD40-CD40L in Treg homeostasis is summarized in Figure 46. In summary, we have 
demonstrated that thymic and systemic Tregs are reduced but functional without an intact 
CD40–CD40L signaling on DCs or T cells. However, the exact mechanisms behind the reduction 
still need to be elucidated.  
Figure 46. Proposed model for 
the CD40-CD40L dependent 
regulation of Treg homeostasis. 
Tregulatory cells (Tregs) are 
controlled by responder T cells via 
the level of available IL-2. Upon 
activation by T cell receptor (TCR) 
interactions and additional 
costimulation via CD80/CD86 and 
CD40/CD40L by dendritic cells 
(DCs), T cells produce IL-2. The 
secreted IL-2 then leads to 
proliferation and survival of Tregs. 
M1;classical macrophage. oxLDL; 
oxidized low density lipoprotein 
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4.5 CD40-CD40L signaling between DCs, T cells, and B cells is 
required for optimal B cell responses. 
Both DCs and B cells express CD40 constitutively and interact with T cells via CD40L ligation. 
Yet, until today CD40-CD40L interactions have not been extensively studied in the context of 
DC-B cell interaction. The current paradigm professes that CD40L provides signals to B cells 
that induce proliferation, immunoglobulin switching, antibody secretion and rescue from 
apoptosis244,273,274,356–365. However, human and mouse B cells also express CD40L on their 
surface following activation and can release a soluble form of the ligand366–368. Thus it is possible 
that in addition to their T cell directed interaction, B cells may also interact with DCs via CD40-
CD40L.  
Primary B cells rapidly undergo spontaneous apoptosis in culture even in the presence of 
serum369,271. However, treatment with CD40L, B cell activating factor of the TNF family (BAFF), 
and LPS can all rescue B cells from apoptosis369,271. Furthermore, B cells undergo antibody- or 
Ig- class switching in vivo after immunization or infection or upon appropriate activation in 
vitro246. Engagement of the CD40 receptor on B cells by CD40L provides crucial signaling for 
class-switch recombination (CSR). Additionally, cytokines produced by T helper cells and DCs 
determine the isotype B cells will switch to156,369,370,373. Previous reports demonstrated a 
reduction in B cell responses and germinal center formation in CD40-deficient mice265. Plasma of 
Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice showed decreased concentrations of 
total IgG and IgG2b which are elicited through a Th1 cytokine-response and considered pro-
atherogenic148. The concentration of plasma IgM was also decreased compared to littermate 
control mice. Overall decreased abundance of immunoglobulins is not necessarily affecting the 
presence of antigen-specific immunoglobulins. However, oxLDL-reactive immunoglobulin levels 
in Apoe-/-Cd40lfl/flCd4Cre+ and Apoe-/-Cd40fl/flCd11cCre+ mice resembled their overall abundance. 
The decreased immunoglobulin abundance may result from an altered activation status of B 
cells in both mouse models. Fully activated B cells start to produce antibodies in a secreted form 
rather than a membrane-bound form157. If they encounter specific signaling molecules via their 
CD40 and cytokine receptors, they then undergo antibody class switching to produce IgG, IgA or 
IgE antibodies (from IgM or IgD) 358,359,361. In contrast to other immunoglobulins the IgA 
production is thereby partially independent of CD40-CD40L engagement since two members of 
the TNF-family, BAFF and APRIL, have been shown to stimulate CSR to IgG and IgA in both 
human and murine B cells271,371,372. Monocytes and DCs express BAFF, whereas APRIL is 
expressed by monocytes, macrophages, DCs, and activated T cells272. B cells express all three 
receptors BAFF-R, B-cell maturation antigen (BCMA) and transmembrane activator and CAML 
interactor (TACI) for these cytokines and previous studies showed that IgA production is not 
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abrogated in mice and humans deficient in CD40L or CD40307,373. Indeed, our studies also 
demonstrated comparable levels of CD40L-independent IgA in Apoe-/-Cd40lfl/flCd4Cre+, Apoe-/-
Cd40fl/flCd11cCre+ and the respective control mice. The reduction of pro-atherogenic 
immunoglobulin subclasses furthermore seems linked to changes in the B2- B cell population. 
Total IgG, IgG1 and, IgG2b are considered pro-atherogenic and produced by B2 
cells173,174,177,178. Depletion of B2 cells reduced the aforementioned pro-atherogenic Ig 
subclasses and mice were protected from atherosclerosis148. Notably Apoe-/-Cd40lfl/flCd4Cre+ 
displayed a decreased percentage of follicular B2 B cells whereas the percentage of marginal 
zone B2 B cells was increased. Follicular B-2 B cells are known to be particularly well-suited to 
participate in T cell-dependent immune responses to protein antigens and undergo isotype 
switching and affinity maturation in the spleen and lymph nodes in response to T cell-dependent 
antigens to either become plasma cells that secrete large amounts of antibody, or memory B 
cells with the ability to produce specific antibodies upon re-exposure to the same 
antigen135,136,138. Marginal zone B cells are considered part of the innate immune system and 
immediately respond to antigens in the blood. Thus, they are considered T cell-independent and 
consequently also CD40-CD40L independent374. 
Taken together our data suggest an altered B cell activation status and therefore reduced 
numbers of pro-inflammatory immunoglobulins due to the missing costimulatory CD40-CD40L 
signal from either T cells (CD40L) or DCs (CD40). Figure 47 shows a proposed model for the 
role of CD40-CD40L interactions for the crosstalk between DCs, T cells and B cells in 
atherosclerosis. 
Figure 47. Proposed model of CD40-
CD40L-dependent DCs, T cells and B 
cell crosstalk. CD40-CD40L signaling on 
dendritic cells (DCs) induces T cell 
activation which mediates class-switch 
recombination (CSR) and secretion of 
Immunoglobulin (Ig)G and IgA antibodies 
In general, CSR requires two signals. The 
first is through cytokines. Two members of 
the TNF- family, B cell activating factor 
(BAFF), and a proliferation-inducing ligand 
(APRIL), can stimulate CSR to IgG and 
IgA. Monocytes and dendritic cells express 
BAFF, whereas APRIL is expressed by 
monocytes, macrophages, dendritic cells, 
and activated T cells. These cytokines bind 
to B cells. The second signal is delivered 
by ligation of CD40 on B cells with its 
ligand CD40L on T cells. In addition DCs 
transfer antigen to B cells, which results in 
up-regulation of CD40L on B cells. 
M1;classical macrophage. oxLDL; oxidized 
low density lipoprotein. (Modified from 
Wykes et al.368). 
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4.6 Platelet-specific deletion of CD40L does not affect atherosclerosis  
The pioneering work of Henn and coworkers established that CD40L and CD40 also exist in 
platelets210. They showed that CD40L is cryptic in unstimulated platelets but rapidly becomes 
exposed on the platelet surface after platelets are activated210. In addition elevated levels of 
sCD40L associate with acute coronary syndromes, percutaneous coronary interventions, and 
cardiopulmonary bypass375. Platelets are considered an important reservoir of this protein in 
circulation, because platelet count is correlated with levels of plasma sCD40L and essentially all 
of the sCD40L generated during the clotting of whole blood is derived from platelets210.  
Contrary to previous reports which ascribed platelet CD40L a key role in platelet-platelet 
interactions in thrombus formation and stability, our results do not point towards a crucial 
function of platelet CD40L in mediating inflammatory processes in atherosclerosis317. In this 
thesis we are the first to describe that neither PF4-specific CD40 nor CD40L are major 
contributors to atherosclerosis progression. Although we cannot completely exclude that the 
presence of CD40 and CD40L on the platelet surface or the interaction of other cells via CD40 
and CD40L with platelets is implicated in the pathogenesis of atherosclerosis, our data seem to 
disqualify PF4-dependent CD40 and CD40L expression as a target for intervention.  
The contradictory findings may derive from the differences to previously used models. These 
earlier studies were either performed with isolated platelets from mice with a systemic CD40L or 
CD40 deficiency or by administration of antibodies which bind systemically to CD40L or 
CD40125,210,227,291,376. Hence, it is possible that the platelet function was influenced by the 
systemic deficiency or inhibition of CD40L or CD40. Furthermore, the usage of isolated and in 
vitro-activated platelets bears the risk of contamination by lymphocytes which would influences 
lesion progression and has to be seen as a rather non-physiological model125,295.  
Although our approach allows us to eliminate certain critical points like the impact of a systemic 
CD40L or CD40 deficiency, the influence of other CD40L-deficient lymphocytes, and the need 
for an in vitro activation of platelets it still bears disadvantages. In contrast to our CD4- and 
CD11c-Cre+ mouse lines we were so far not able to prove that the PF4-linked cre-recombinase 
led to a successful deletion of CD40L or CD40 on platelets in our mice. The efficiency of the 
PF4-Cre-mediated excision in megakaryocytes and platelets was previously demonstrated for 
several proteins by Tiedt et al. 69. However, Horrillo et al recently demonstrated that the floxed 
CD40L allele was efficiently excised in in vitro differentiated megakaryocytes from PF4-Cre+ 
mice but not from circulating platelets22. Platelets of cre+ mice carried similar amounts of the 
CD40L normal transcript which points to a deficient cre-mediated excision and that Pf4-driven 
cre expression fails to excise CD40L during in vivo differentiation of megakaryocytes22. 
Accordingly, this could also hold true for Apoe-/-Cd40lfl/fllPf4Cre+ mice and may explain their 
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unaffected atherosclerotic burden. Additionally, the origin of membrane-bound CD40L on 
platelets has not been clearly demonstrated yet.  
The presence of CD40L or CD40 on platelets was previously demonstrated exclusively via flow 
cytometry or immunoblotting210,377. For decades, the general observation of platelet RNA and the 
characterization of reticulated platelets were used to estimate the rate of thrombopoiesis. 
However, the actual transcripts represented by this RNA were of little interest with the 
assumption that the RNA was merely a remnant from the precursor megakaryocyte. Over the 
past decade, finite but steady observations added support to the concept that platelet RNA is 
biologically and patho-physiologically meaningful380–382. Although platelets are anucleate cells, 
they retain mRNA, functional splicing, and translational machinery and there is a strong 
correlation between transcript abundance and protein expression378–380. In 2011 Rowley et al 
provided next-generation sequencing analysis which revealed new insights into the human and 
murine platelet transcriptomes. However, they also did not detect CD40L mRNA in human or 
murine platelets381. Accordingly, the lack of CD40L mRNA expression in murine platelets led to 
the assumption that the protein is synthesized early in platelet differentiation by  
megakaryocytes 377. The Pf4-linked cre-recombinase targets all platelet progenitors, thus, 
CD40L-deficient megakaryocytes should pass on this deficiency to proplatelets and platelets 
which should presumably result in a aforementioned reduction of atherosclerosis125. However, 
our studies did not reveal any differences in the atherosclerotic burden of  
Apoe-/-Cd40lfl/fllPf4Cre+ mice.  
Furthermore, the literature provides information which led us hypothesize, that platelets may not 
acquire CD40L from megakaryocytes but from plasma. In fact, platelets can take up fibrinogen 
from the plasma and release it after platelet activation and arterial thrombosis is dependent on 
platelet aggregation, a process mediated by the binding of soluble fibrinogen to glycoprotein  
IIb-IIIa (GPIIb-IIIa) on the surface of stimulated platelets382–384- GPIIb/IIIa antagonists are 
effective in these indications because they inhibit platelet aggregation385. It has been well 
documented that uptake and the delivery of fibrinogen to α-granules is mediated by GPIIb-
IIIa186,386. Finally, during platelet activation, α-granules undergo exocytosis by which their 
fibrinogen content is released to the exterior and GP IIb/IIIa antagonists are capable of inhibiting 
platelet aggregation385. Two forms of CD40L are present in lymphocytes, a cell-bound form with 
a molecular weight of 39 kDa and various soluble forms (sCD40L) with a molecular weight of 31, 
18 or14 kDa. Thus, even in a trimeric state the molecular weight of CD40L is rather small when 
compared to that of fibrinogen with a molecular weight of 340 kDa185–188. An initial study showed 
that sCD40L also binds directly to GP IIb/IIIa and is responsible for the formation of stable 
arterial thrombosis291,387. In addition, inhibitory effects of GPIIb/IIIa antagonists and aspirin on the 
release of sCD40L during platelet stimulation were demonstrated385. Collectively, these 
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observations suggest for a possible uptake and storage of CD40L in the α-granula by platelets 
and would explain the inefficient deletion of CD40L by PF4-dependent cre-excision. Yet, the 
exact mechanisms behind the presentation and origin from CD40L on the platelet surface as 
well as sCD40L require further investigation. 
In summary, our data demonstrated the need for additional experiments to confirm the efficiency 
of the Pf4-linked CD40L or CD40 excision in platelets and progenitor cells and highlight the need 
for a proof of the validate protein depletion in vivo for every novel cre/loxP combination. 
4.7 Conclusion and future perspectives 
The continuing and increasing impact of atherosclerosis on morbidity and mortality in the 
western society and the rapid emergence of atherosclerosis in Asia and the rest of the world, 
despite the advances in diagnosis and therapy, highlights the importance to understand its 
pathogenesis in order to develop effective treatment or prevention388. The main goal of the 
studies in this thesis was to unravel the mechanisms of cell type-specific CD40-CD40L 
interactions in atherosclerosis. To this end, this thesis provides important insight into the cell 
type-specificity of CD40-CD40L interactions and their downstream impact on atherosclerosis 
progression. We demonstrate significant differences in the impact of systemic and cell type-
specific CD40-CD40L interactions on atherosclerosis. We recognized that both T cell-specific 
CD40L and DC–specific CD40 are responsible for the pro-atherosclerotic effect of CD40-CD40L 
interactions. As systemic anti-CD40 or anti-CD40L intervention is not feasible, hence more 
specific approaches are required. In this regard, the cell type-specific modulation of CD40 on 
DCs and CD40L on T cells through conditional genetic approaches is more specific and results 
in a strong reduction of atherosclerosis. This method might circumvent problems like complete 
immune suppression or thromboembolemic events seen after long- term treatment with anti-
CD40 antibodies389. It is likely that the approach of CD40 or CD40L inhibition on a specific cell 
population, apart from the difficulties for its technical implementation, is still too broad to use in a 
clinical setting as long-term treatment during atherosclerosis and could still compromise the 
patients´ host defense. However, cell type-specific targeting of certain cell subsets might resolve 
this issue, for example by targeting specific T cell- or DC subsets using the CRISPR/cas9 
system, although this has to be investigated and requires many more years of development. 
New therapeutic approaches might induce selective suppression of pro-atherogenic immune 
responses or activation of anti-atherogenic responses to combat atherosclerosis. In that respect, 
knowledge regarding of cell type-specific CD40-CD40L interactions is of particular interest to 
provide new potential therapeutic targets that will be more efficient and safer than systemic 
CD40-CD40L inhibition. 
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5 SUMMARY 
Cardiovascular diseases are still the leading cause of mortality worldwide. And atherosclerosis is 
its most underlying cause. Atherosclerosis is a lipid driven chronic inflammatory disease of the 
arterial wall, involving both innate and adaptive immune responses during pathogenesis. 
Specialized immune cells such as monocytes, B cells, T cells and dendritic cells (DCs) 
contribute to disease progression or by counterbalancing the inflammatory responses.  
A system that has been shown to be an efficient conductor and modulator of immune cell 
responses is the CD40-CD40L dyad. CD40 is a member of the tumor necrosis factor receptor 
(TNFR) superfamily and is activated by CD40 ligand (CD40L). CD40 and CD40L both are 
expressed on the majority of immune and non-immune cells. However, the specific contribution 
of CD40-CD40L signaling on the different single cell types towards atherosclerosis progression 
has been undefined so far. The goal of the studies presented in this thesis was to unravel the 
cell type-specific mechanisms of CD40-CD40L interactions in atherosclerosis. Therefore, we 
used the cre/loxP system to create different, athero-prone Apoe-/- Cd40fl/flcre+ and Apoe-/- 
Cd40lfl/flcre+ mice with conditional CD40 or CD40L deficiencies on T cells, DCs and Platelets to 
investigate the cell type-specific impact of these costimulatory molecules on the generation of 
atherosclerosis. The main focus thereby was layed on the impact of T cell and DC specific 
deficiencies of CD40 and CD40L on atherosclerosis. Since platelets are also known to express 
CD40 or CD40L and to participate in the development and progression of atherosclerosis, a 
second study was established  to serve as a basis for future, more detailed studies of the role of 
platelet- specific CD40 and CD40L interactions. 
Hyperlipidemic mice with a CD40L deficiency on T cells or a CD40 deficiency on DCs developed 
significantly smaller atherosclerotic lesions than control animals after 28 weeks of normal diet, 
and after 6 weeks of a cholesterol-enriched diet. The altered lesion size was accompanied by a 
modified anti-inflammatory phenotype of the lesional cellular components, which was 
characterized by an increased proportion of stabilizing smooth muscle cells and a reduced 
number of anti-inflammatory immune cells, such as macrophages and T cells. Multiple 
mechanisms contribute to decreased athero-progression in T cell CD40- as well as DC-CD40-
deficient mice. T cell CD40L-deficient and DC CD40-deficient hyperlipidemic mice displayed 
systematically reduced expression of pro-inflammatory cytokines such as interleukin (IL)-1 beta, 
IL-2, IL-12, and interferon gamma, and increased expression of anti-inflammatory cytokines IL-
10 and transforming growth factor beta. This anti-inflammatory milieu ensures a reduced 
recruitment of immune cells into the atherosclerotic lesion and thus contributes to a decreased 
pathogenesis. Furthermore, we found indications in both mouse lines for a change in the 
development and activation status of the T cells and DCs as well as within their subpopulations. 
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Thus, mice with a deficiency of CD40L on T cells or a deficiency of CD40 on DCs show a 
systemic reduction in the expression of cytokines and gene markers associated with the 
activation of T cells (IL-2, CD69). This change is also reflected within the T cell populations of 
both mouse lines which had a reduced proportion of activated effector T cells and an increased 
ratio of naïve T cells. The reason for this change appears to stem from the interruption of the 
CD40-CD40L signals between T cells and DCs.  
To unravel changes in the relationship between T cells and DCs we employed Contact 
hypersensitivity (CHS) as an additional in vivo model. The model allows to test for a proper 
antigen presentation between T cells and DCs including efficient antigen capture, -processing, -
transport and the antigen presentation to naïve T cells. Indeed, DCs from T cell CD40L- and DC 
CD40-deficient mice have a higher proportion of immature inactivated DCs, which have a lower 
capacity for antigen presentation and T cell activation.  
Furthermore, hyperlipidemic mice, with a T cell-specific CD40L deficiency and also mice with a 
DC-specific deficiency of CD40 show a systemic reduction of regulatory T cells (Treg), which 
also depend on IL-2 cytokine production. However, despite their reduced number, they have the 
same suppressive capacity as Tregs from control animals. The lack of costimulatory CD40-
CD40L signals on T cells or DCs also lead to an insufficient activation of B cells and to a 
different secretion of immunoglobulins. B cells from mice with a deficiency of CD40L on T cells 
and from mice with a deficiency of CD40 on DCs produce fewer immunoglobulins with a smaller 
proportion of pro-inflammatory and an increased proportion of anti-inflammatory 
immunoglobulins. Therefore, the reduced atherogenesis by T cell-specific CD40L and DC-
specific CD40 deficiency appears to be due to the systemic reduction of the adaptive immune 
response. The disturbed CD40-CD40L interactions between T cells, DCs, and B cells lead to 
inadequate antigen-detection and -presentation and thus to a dampened pro-inflammatory 
immune reaction. 
In contrast to animals lacking CD40L on T cells mice with a deficiency of CD40L on platelets 
show no change in lesion size or phenotype. The absence of platelet-specific CD40L expression 
does not appear to affect their contribution to the progression of atherosclerosis.  
In summary, these results underline the pro-atherosclerotic effects of CD40-CD40L interactions 
in a cell type-specific context, that these effects vary between different cell types and ascribe 
CD40-CD40L interactions between DCs and T cells a central role in atherosclerosis. 
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6 ZUSAMMENFASSUNG 
Herz-Kreislauf-Erkrankungen sind nach wie vor die führenden Todesursache weltweit. 
Atherosklerose ist dabei die häufigste Ursache. Atherosklerose ist eine lipidgetriebene 
chronische entzündliche Erkrankung der Arterienwand, die sowohl angeborene als auch 
adaptive Immunantworten während der Pathogenese beinhaltet. Spezielle Immunzellen wie,T-
Zellen und dendritische Zellen (DCs) tragen zum Fortschreiten der Krankheit bei. 
Ein System, das sich als wirksamer Modulator von Immunzellenreaktionen erwiesen hat, ist das 
CD40-CD40 Ligand(L)-Paar. CD40 ist ein Mitglied der Tumor-Nekrose-Faktor-Rezeptor (TNFR)-
Superfamilie und wird durch CD40L aktiviert. CD40 und CD40L sind beide auf der Mehrheit der 
Immun- (z.B T Zellen, B Zellen und DCs) und Nicht-Immunzellen (z.B. Plättchen) exprimiert. Der 
genaue Einfluss der CD40-CD40L-Signale auf einzelnen Zelltypen und die 
Atheroskleroseentwicklung ist bisher allerdings noch unbekannt. Ziel der in dieser Arbeit 
vorgestellten Studien war es, diese zelltypspezifischen Mechanismen der CD40-CD40L-
Wechselwirkungen innerhalb der Atherosklerose aufzuklären. 
Das Hauptaugenmerk dieser Arbeit lag daher auf der Untersuchung der Auswirkungen von  
T Zell spezifischer Deletion von CD40L und DC-spezifischer Deletion von CD40 auf 
Atherosklerose. Naive T-Zellen benötigen eine Aktivierung durch DCs um in periphere Gewebe 
wie beispielsweise atherosklerotische Plaques einwandern zu können. Die Wechselwirkung der 
beiden Zellarten wird dabei unter anderem durch kostimulatorische CD40-CD40L Signale 
vermittelt. Die beiden Zelltypen sind daher ein viel versprechendes Ziel um mehr über die Rolle 
von zellspezifischen CD40-CD40L Interaktionen in der Atheroskleroseentwicklung zu erfahren. 
Neben der Untersuchung der T Zell- und DC-spezifischen Rolle von CD40-CD40L Interaktionen 
sollte mit dieser Arbeit aber auch ein Grundstein für zukünftige Untersuchungen der Plättchen 
spezifischen Rolle von CD40 und CD40L auf die Atherosklerose gelegt werden.  
Um die Auswirkungen der jeweiligen spezifischen Deletionen auf die Atherosklerose zu 
analysieren etablierten wir daher mit Hilfe des Cre/loxP- Systems, Mauslinien mit 
zelltypspezifischen Deletionen von CD40 oder CD40L auf T Zellen, DCs und Plättchen.  
Die von uns generierten hyperlipidemische Mäuse, mit einer CD40L Defizienz auf T Zellen oder 
eine CD40 Defizienz auf DCs entwickelten nach 28 Wochen normaler Diät sowie nach 6 
Wochen einer cholesterinreichen Diät, signifikant kleinere atherosklerotische Läsionen als 
Kontrolltiere. Die veränderte Läsiongröße wurde dabei durch einen veränderten 
entzündungshemmenden Phänotyp der Läsionen ergänzt, welcher durch eine erhöhten Anteil 
von stabilisierenden glatten Muskelzellen und einer erniedrigten Anzahl von 
entzündungsfördernder Immunzellen wie Makrophagen und T Zellen begleitet wurde.  
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Multiple Mechanismen tragen zu der verringerten Atheroprogression in T Zell-CD40L- sowie DC-
CD40-defizienten Mäusen bei. So zeigen T Zell-CD40L-defiziente und auch DC-CD40-defiziente 
hyperlipidemische Mäuse eine systemisch erniedrigte Expression von entzündungsfördernden 
Zytokinen wie z.B. Inteleukin(IL)-1b, IL-2, IL-12 und Interferon-gamma. Gleichzeitig ist eine 
gesteigerte Expression von entzündungshemmenden Zytokinen wie IL-10 und Transforming 
growth factor beta zu beobachten. Das entzündungshemmende Milieu sorgt für eine reduzierte 
Rekrutierung von Immunzellen in die atherosklerotische Läsion und trägt somit einen Teil zu der 
verminderten Pathogenese der Atherosklerose bei.  
Zusätzlich finden sich in beiden Mäuselinien Hinweise auf einen veränderten Entwicklungs- und 
Aktivierungsstatus der T-Zellen, DCs und ihrer jeweiligen Subpopulationen. Mäuse mit einer 
Defizienz von CD40L auf T Zellen oder einer Defizienz von CD40 auf DCs weisen eine 
systemisch verminderte Expression von Genen auf, welche mit der Aktivierung von T Zellen in 
Verbindung stehen (IL-2, CD69). Diese Veränderung spiegelt sich auch innerhalb der T Zell-
Populationen der beiden Mäuselinien wieder. So finden sich in jeweils beiden Mäuselinien ein 
erhöhter Anteil von naiven T Zellen, welche über geringe entzündungsfördernde Eigenschaften 
verfügen und ein reduzierten Anteil von aktivierten, entzündungsfördernden Effektor T Zellen. 
Um die Änderungen in der Beziehung zwischen T-Zellen und DCs weiter zu entschlüsseln, 
benutzten wir die Kontakt-Hypersensitivität (KHS) als in vivo –Model zur Überprüfung der 
Antigenpräsentation zwischen T Zellen und DCs. Dies ermöglichte uns die genauere Analyse 
der Antigenpräsentation zwischen T-Zellen und DCs. Da das Model die Überprüfung der 
effizienten Antigen-Aufnahme, -Verarbeitung und -Präsentation durch DCs erlaubt. Dabei 
konnten wir zeigen, dass T Zell CD40L-defiziente und DC CD40-defiziente Mäusen über einen 
erhöhten Anteil an unreifer, nicht aktivierter DCs verfügen, welche eine geringere Kapazität zur 
Antigenpräsentation und T-Zellaktivierung aufweisen. 
Des weiteren weisen hyperlipidemische Mäuse mit einer T Zell-spezifischen CD40L Defizienz 
und auch Mäuse mit einer DC-spezifischen Defizienz von CD40 eine systemische Reduktion 
regulatorischen T Zellen (Treg) auf, welche von der IL-2 Produktion durch aktivierte T Zellen und 
DCs abhängig sind. Trotz einer reduzierten Anzahl verfügen diese jedoch über dieselbe 
suppressive Kapazität wie Tregs aus Kontrolltieren. 
Zusätzlich zur gestörten Aktivierung von T Zellen und DCs führt das Fehlen der 
kostimulatorischen CD40-CD40L Signalen, in beiden Mauslinien, zu einer nicht ausreichenden 
Aktivierung von B Zellen, sowie einer veränderten Sekretion von Antikörpern. B Zellen aus 
Mäusen mit einer Defizienz von CD40L auf T Zellen und auch aus Mäusen mit einer Defizienz 
von CD40 auf DCs produzieren insgesamt weniger Antikörper mit einem geringeren Anteil von 
entzündungsfördernden Antikörpern und einem gesteigerten Anteil von 
entzündungshemmenden Antikörpern. 
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Zusammenfassend scheint die reduzierte Atheroskleroseentwicklung durch T Zell-spezifische 
CD40L und DC-spezifische CD40 Defizienz daher in der systemischen Reduktion der adaptiven 
Immunantwort begründet zu sein. Fehlende Interaktion von CD40-CD40L zwischen T Zellen. 
DCs und B Zellen führen zu einer limitierten Antige-Erkennung sowie -Präsentation und somit zu 
einer verminderten Immunreaktion.  
Im Gegensatz zu Tieren mit einer Defizienz von CD40L auf T Zellen weisen Mäuse mit einer 
Defizienz von CD40 oder CD40L auf Plättchen keine Veränderung der Läsionsgrößen oder des 
Läsionsphänotypes auf. Das Fehlen der Plättchen-spezifischen CD40 oder CD40L Expression 
scheint sich nicht auf deren Beitrag zur Atheroskleroseentwicklung auszuwirken.  
Zusammenfassend unterstreichen diese Ergebnisse die Notwendigkeit, die unterschiedlichen 
pro- sowie anti-atherosklerotischen Auswirkungen von CD40-CD40L Interaktionen in einem 
zellspezifischen Kontext zu betrachten und das CD40-CD40L Interaktionen zwischen T Zellen 
und DCs als besonders wichtige Einflussfaktoren innerhalb der Atherosklerose zu sehen sind.  
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